DOWN-REGULATING GENE EXPRESSION IN INSECT PLANTS

Abstract

The present invention relates to the prevention and/or control of infestation by insect pest species. In particular, the invention relates to down-regulation of expression of target genes in insect pests using interfering ribonucleic acid (RNA) molecules. Also described are transgenic plants that (i) express or are capable of expressing interfering RNAs of the invention and (ii) are resistant to infestation by insect pest species. Compositions containing the interfering RNAs of the invention are also provided.

Description

RELATED APPLICATIONS

[0001] This application is a continuation of U.S. application Ser. No. 15/869,336, filed Jan. 12, 2018, which is a divisional of U.S. application Ser. No. 13/811,792, filed on Jul. 15, 2013, which is a National Stage Entry of PCT/EP11/68910, filed Oct. 27, 2011, and which further claims priority to U.S. Provisional Application No. 61/407,212, filed Oct. 27, 2010. The disclosures at these applications are incorporated by reference herein in their entirety.

FIELD OF THE INVENTION

[0002] The present invention relates generally to genetic control of infestation by insect pest species, particularly prevention and/or control of pest infestation of plants. More specifically, the invention relates to down-regulation of expression of target genes in insect pest species by interlacing ribonucleic acid (RNA) molecules. Also provided are transgenic plants that (i) express or are capable of expressing interfering RNAs of the invention and (ii) are resistant to infestation by insect pest species. Compositions containing the interfering RNA molecules of the invention for use in topical application onto plants or into the environment surrounding plants are also described.

BACKGROUND TO THE INVENTION

[0003] There exists an abundance of insect pest species that can infect or infest a wide variety of environments and host organisms. Insect pests include a variety of species from the insect Orders Hemiptera (true bugs), Coleoptera (beetles), Siphoroptere (fleas), Dichyoptera (cockroaches and mantids), Lepidoptera (moths and butterflies), Orthoptera (e.g. grasshoppers) and Diptera (true flies). Pest infestation can lead to significant damage. Insect pests that infest plant species are particularly problematic in agriculture as they can cause serious damage to crops and significantly reduce plant yields. A wide variety of different types of plant are susceptible to pest infestation including commercial crops such as rice, cotton, soybean, potato and corn.

[0004] Traditionally, infestation with insect pests has been prevented or controlled through the use of chemical pesticides. However, these chemicals are not always suitable for use in the treatment of crops as they can be toxic to other species and can cause significant environmental damage. Over more recent decades, researchers have developed more environmentally-friendly methods of controlling pest infestation. For example, microorganisms such as Bacillus thuringiensis bacteria that naturally express proteins toxic to insect pests have been used. Scientists have also isolated the genes encoding these insecticidal proteins and used them to generate transgenic crops resistant to insect pests e.g. corn and cotton plants genetically engineered to produce proteins of the Cry family.

[0005] Although bacterial toxins have been highly successful in controlling certain types of pest they are not effective against all pest species. Researchers have therefore looked for other more targeted approaches to pest control and in particular to RNA interference or `gene silencing` as a means to control pests at the genetic level.

[0006] RNA interference or `RNAi` is a process whereby the expression of genes in the context of a cell or whole organism is down-regulated in a sequence-specific manner. RNAi is now a well-established technique in the art for inhibiting or down-regulating gene expression in a wide variety of organisms including pest organisms such as fungi, nematodes and insects. Furthermore, previous studies have shown that down-regulation of target genes in insect pest species can be used as a means to control pest infestation.

[0007] WO2007/074405 describes methods of inhibiting expression of target genes in invertebrate pests including Colorado potato beetle. WO2005/110068 describes methods of inhibiting expression of target genes in invertebrate pests including in particular Western corn rootworm as a means to control insect infestation. Furthermore, WO2009/091864 describes compositions and methods for the suppression of target genes from insect pest species including pests from the Lygus genus.

[0008] Although the use of RNAi for down-regulating gene expression in pest species is known in the art, the success of this technique for use as a pest control measure depends on selection of the most appropriate target genes, namely those wherein loss of function results in significant disruption of an essential biological process and/or death of the organism. The present invention is thus directed towards the down-regulation of particular target genes in insect pests as a means to achieve more effective prevention and/or control of insect pest infestation, particularly of plants.

SUMMARY OF THE INVENTION

[0009] The current inventors sought to identify improved means for preventing and/or controlling insect pest infestation using genetic approaches. In particular, they investigated the use of RNAi to down-regulate genes in such a way as to impair the ability of the insect pest to survive, grow, colonize specific environments and/or infest host organisms and thus limit the damage caused by the pest.

[0010] It has now been found by the inventors that RNAi-mediated down-regulation of specific target genes singly or in combination within insect pest species can be used as an effective means to control pest infestation.

[0011] In one embodiment, the present invention relates to an interfering ribonucleic acid (RNA or double stranded RNA) that inhibits or downregulates the expression of a target gene that encodes an insect ribosomal protein such as the ribosomal protein L19 (e.g. an insect orthologue of the CG2746 Dm protein), the ribosomal protein L40 (e.g. an insect orthologue of the CG2960 Dm protein) or the ribosomal protein S27A (e.g. an insect orthologue of the CG5271 Dm protein).

[0012] According to another embodiment the present invention relates to an interfering ribonucleic acid (RNA or double stranded RNA) that inhibits or downregulates the expression of a target gene that encodes an insect proteasome subunit such as the Rena protein (e.g. an insect orthologue of the CG10149 Dm protein), the Pros 25 protein (e.g. an insect orthologue of the CG5266 Dm protein), the Rpn2 protein (e.g. an insect orthologue of the CG118158 Dm protein), the proteasome beta 1 subunit protein (e.g. an insect orthologue of the CG8392 Dm protein) or the Pros beta 2 protein [e.g. an insect orthologue of the CG3329 Dm protein).

[0013] According to still another embodiment the present invention relates to an interfering ribonucleic acid (RNA or double stranded RNA) that inhibits or downregulates the expression of a target gene that encodes an insect .beta.-coatomer of the COPI vesicle (e.g. an insect orthologue of the CG6223 Dm protein), the .gamma.-coatomer of the COPI vesicle (e.g. an insect orthologue of the 1528 Dm protein), the .beta.'-coatomer protein (e.g. an insect orthologue of the CG6699 Dm protein) or the .zeta.-coatomer of the COPI vesicle (e.g. an insect orthologue of the CG3948 Dm protein).

[0014] According to still another embodiment the present invention relates to an interfering ribonucleic acid (RNA or double stranded RNA) that inhibits or downregulates the expression of a target gene that encodes an insect Tetraspanine 2 A protein which is a putative transmembrane domain protein (e.g. an insect orthologue of the CG11415 Dm protein).

[0015] According to still another embodiment the present invention relates to an interfering ribonucleic acid (RNA or double stranded RNA) that inhibits or downregulates the expression of a target gene that encodes an insect protein belonging to the actin family (e.g. an insect orthologue of the CG5409 Dm protein) such as Actin 5C (e.g. an insect orthologue of the CG4027 Dm protein).

[0016] According to still another embodiment the present invention relates to an interfering ribonucleic acid (RNA or double stranded RNA) that inhibits or downregulates the expression of a target gene that encodes an insect ubiquitin-5E protein (e.g. an insect orthologue of the CG32744 Dm protein).

[0017] According to still another embodiment the present invention relates to an interfering ribonucleic acid (RNA or double stranded RNA) that inhibits or downregulates the expression of a target gene that encodes an insect Sec23 protein which is a GTPase activator involved in intracellular protein transport (e.g. an insect orthologue of the CG1250 Dm protein).

[0018] According to still another embodiment the present invention relates to an interfering ribonucleic acid (RNA or double stranded RNA) that inhibits or downregulates the expression of a target gene that encodes an insect crinkled protein which is an unconventional myosin which is involved in motor activity (e.g. an insect orthologue of the CG7595 Dm protein).

[0019] According to still another embodiment the present invention relates to an interfering ribonucleic acid (RNA or double stranded RNA) that inhibits or downregulates the expression of a target gene that encodes an insect crooked neck protein which is involved in the regulation of nuclear alternative mRNA splicing (e.g. an insect orthologue of the CG3193 Dm protein).

[0020] According to still another embodiment the present invention relates to an interfering ribonucleic acid (RNA or double stranded RNA) that inhibits or downregulates the expression of a target gene that encodes an insect vacuolar H+-ATPase G-subunit protein (e.g. an insect orthologue of the CG6213 Dm protein).

[0021] According to still another embodiment the present invention relates to an interfering ribonucleic acid (RNA or double stranded RNA) that inhibits or downregulates the expression of a target gene that encodes an insect Tbp-1; Tat-binding protein (e.g. an insect orthologue of the CG10370 Dm protein).

[0022] Therefore, in accordance with a first aspect of the invention, there is provided an interfering ribonucleic acid (RNA or double stranded RNA) that functions upon uptake by an insect pest species to down-regulate expression of a target gene in said insect pest, wherein the target gene.

(i) is selected from the group of genes having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when the two sequences are optimally aligned and compared, is at least 75%, preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (ii) is selected from the group of genes having a nucleotide sequence consisting of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15.35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (iii) is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60.70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when said gene comprising said fragment is optimally aligned and compared with any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence is al least 75% preferably al least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5.25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (iv) is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21.22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3.23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, and wherein when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence of said fragment is at least 75% preferably al least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (v) is an insect pest orthologue of a gene having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, wherein the two orthologous genes are similar in sequence to such a degree that when the two genes are optimally aligned and compared, the orthologue has a sequence that is al least 75% preferably al least 80%, 85%, 90%, 95%, 98% or 99% identical to any of the sequences represented by SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or (vi) is selected from the group of genes having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence encoded by the nucleotide sequence represented in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14.34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or (vii) is selected from the group of genes having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence represented in any of SEQ ID NOs 285, 242, 271, 226, 227, 281, 228, 282, 229, 230 to 233, 234, 283, 235, 236, 237, 238, 239, 240, 284, 241, 243, 244, 286, 269, 270, 287, 288, 206 to 225.

[0023] In a particular aspect of the invention, interfering RNA molecules of the current invention comprise at least one double-stranded region, typically the silencing element of the interfering RNA, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of nucleotides complementary to a sequence of nucleotides located within the RNA transcript of the target gene.

[0024] In one embodiment, the present invention relates to an interfering RNA molecule which comprises at least one double-stranded region, typically the silencing element of the interfering RNA molecule, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides, that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a sequence of nucleotides located within the RNA transcript of a target gene that encodes an insect ribosomal protein such as the ribosomal protein L19 (e.g. an insect orthologue of the CG2746 m protein), the ribosomal protein L40 (e.g. an insect orthologue of the CG2960 Dm protein) or the ribosomal protein S27A (e.g. an insect orthologue of the CG5271 Dm protein).

[0025] According to another embodiment the present invention relates to an interfering RNA molecule which comprises at least one double-stranded region, typically the silencing element of the interfering RNA molecule, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides, that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a sequence of nucleotides located within the RNA transcript of a target gene that encodes an insect proteasome subunit such as the Rpn6 protein (e.g. an insect orthologue of the CG10149 Dm protein), the Pros 25 protein (e.g. an insect orthologue of the CG5266 Dm protein), the Rpn2 protein (e.g. an insect orthologue of the CG11888 Dm protein), the proteasome beta 1 subunit protein (e.g. an insect orthologue of the CG8392 Dm protein) or the Pros beta 2 protein (e.g. an insect orthologue of the CG3329 Cm protein).

[0026] According to still another embodiment the present invention relates to an interfering RNA molecule which comprises at least one double-stranded region, typically the silencing element of the interfering RNA molecule, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 50, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides, that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a sequence of nucleotides located within the RNA transcript of a target gene that encodes an insect .beta.-coatomer of the COPI vesicle (e.g. an insect orthologue of the CG6223 Dm protein), the .gamma.-coatomer of the COPI vesicle (e.g. an insect orthologue of the 1528 Dm protein), the .beta.'-coatomer protein (e.g. an insect orthologue of the CG6699 Dm protein) or the .zeta.-coatomer of the COPI vesicle (e.g. an insect orthologue of the 003948 Dm protein).

[0027] According to still another embodiment the present invention relates to an interfering RNA molecule which comprises at least one double-stranded region, typically the silencing element of the interfering RNA molecule, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides, that is al least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a sequence of nucleotides located within the RNA transcript of a target gene that encodes an insect Tetraspanine 2 A protein which is a putative transmembrane domain protein (e.g. an insect orthologue of the CG11415 Dm protein).

[0028] According to still another embodiment the present invention relates to an interfering RNA molecule which comprises at least one double-stranded region, typically the silencing element of the interfering RNA molecule, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80.90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800.900 1000, 1100 or 1115 contiguous nucleotides, that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a sequence of nucleotides located within the RNA transcript of a target gene that encodes an insect protein belonging to the actin family (e.g. an insect orthologue of the CG5409 Om protein) such as Actin 5C (e.g. an insect orthologue of the CG4027 Dm protein).

[0029] According to still another embodiment the present invention relates to an interfering RNA molecule which comprises at least one double-stranded region, typically the silencing element of the interfering RNA molecule, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of at least 17, 18, 19, 20, 21.22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides, that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a sequence of nucleotides located within the RNA transcript of a target gene that encodes an insect ubiquitin-5E protein (e.g. an insect orthologue of the CG32744 Dm protein).

[0030] According to still another embodiment the present invention relates to an interfering RNA molecule which comprises at least one double-stranded region, typically the silencing element of the interfering RNA molecule, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides, that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a sequence of nucleotides located within the RNA transcript of a target gene that encodes an insect Sec23 protein which is a GTPase activator involved in intracellular protein transport (e.g. an insect orthologue of the CG1250 Dm protein).

[0031] According to still another embodiment the present invention relates to an interfering RNA molecule which comprises at least one double-stranded region, typically the silencing element of the interfering RNA molecule, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides, that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a sequence of nucleotides located within the RNA transcript of a target gene that encodes an insect crinkled protein which is an unconventional myosin which is involved in motor activity (e.g. an insect orthologue of the CG7595 Dm protein).

[0032] According to still another embodiment the present invention relates to an interfering RNA molecule which comprises at least one double-stranded region, typically the silencing element of the interfering RNA molecule, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides, that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a sequence of nucleotides located within the RNA transcript of a target gene that encodes an insect crooked neck protein which is involved in the regulation at nuclear alternative mRNA splicing (e.g. an insect orthologue of the CG3193 Dm protein).

[0033] According to still another embodiment the present invention relates to an interfering RNA molecule which comprises at least one double-stranded region, typically the silencing element of the interfering RNA molecule, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides, that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a sequence of nucleotides located within the RNA transcript of a target gene that encodes an insect vacuolar H+-ATPase G-subunit protein (e.g. an insect orthologue of the CG6213 Dm protein).

[0034] According to still another embodiment the present invention relates to an interfering RNA molecule which comprises at least one double-stranded region, typically the silencing element of the interfering RNA molecule, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45.50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides, that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a sequence of nucleotides located within the RNA transcript of a target gene that encodes an insect Tbp-1; Tat-binding protein (e.g. an insect orthologue of the CG10370 Dm protein).

[0035] In accordance with a second aspect of the invention, there is provided an isolated polynucleotide selected from the group consisting of:

(i) a polynucleotide which comprises at least 21, preferably at least 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide sequence as represented by any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 262, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, or (ii) a polynucleotide which consists of at least 21, preferably at least 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80.90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide sequence as represented by any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93, to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19.39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, or (iii) a polynucleotide which comprises at least 21, preferably at least 22, 23 or 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide sequence as represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, that, when the two sequences are optimally aligned and compared, said polynucleotide is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 337, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256.261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, or (iv) a polynucleotide which comprises a fragment of at least 21, preferably at least 22, 23 or 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide as represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, and wherein said fragment or said complement has a nucleotide sequence that, when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, said nucleotide sequence is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, to 104, 17, 37, 105 to 108, 18, 38, to 9 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120 or the complement thereof, or (v) a polynucleotide which consists of a fragment of at least 21, preferably at least 22, 23 or 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide as represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40.117 to 120, or the complement thereat, and wherein said fragment or said complement has a nucleotide sequence that, when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 65 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, said nucleotide sequence is at least 75% preferably al least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120 or the complement thereof, or (vi) a polynucleotide encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence encoded by the nucleotide sequence represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25.57 to 60, 6, 26, 61 to 64, 7.27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or (vii) a polynucleotide encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably al least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence represented in any of SEQ ID NOs 285, 242, 271, 226, 227, 281, 228, 282, 229, 230 to 233, 234, 283, 235, 236, 237, 238, 239, 240, 284, 241, 243, 244, 288, 269, 270, 287, 288, 206 to 225, and wherein said polynucleotide is no longer than 10000, 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000 or 1500 nucleotides.

[0036] In a particular aspect of the invention, the isolated polynucleotide is part of an interfering RNA molecule, typically part of the silencing element, comprising at least one double-stranded region comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of nucleotides complementary to a sequence of nucleotides located within the RNA transcript of the target gene. More particularly, the isolated polynucleotide is cloned in a DNA construct in a sense and antisense orientation so that upon transcription of the sense and antisense polynucleotide a dsRNA molecule is formed, which functions upon uptake by a pest to inhibit or down-regulate the expression of a target gene within said pest.

[0037] In one embodiment, the present invention relates to an isolated polynucleotide that is cloned in a DNA construct in a sense and antisense orientation so that upon transcription of the sense and antisense polynucleotide a dsRNA molecule is formed, which functions upon uptake by an insect to inhibit or down-regulate the expression of a target gene that encodes an insect ribosomal protein such as the ribosomal protein L19 (e.g. an insect orthologue of the CG2746 Dm protein), the ribosomal protein L40 (e.g. an insect orthologue of the CG2960 Dm protein) or the ribosomal protein S27A (e.g. an insect orthologue of the CG5271 Dm protein).

[0038] According to another embodiment the present invention relates to an isolated polynucleotide that is cloned in a DNA construct in a sense and antisense orientation so that upon transcription of the sense and antisense polynucleotide a dsRNA molecule is formed, which functions upon uptake by an insect to inhibit or down-regulate the expression of a target gene that encodes an insect proteasome subunit such as the Rpn6 protein (e.g. an insect orthologue of the CG10149 Dm protein), the Pros 25 protein (e.g. an insect orthologue of the CG5266 Dm protein), the Rpn2 protein (e.g. an insect orthologue of the CG11888 Dm protein), the proteasome beta 1 subunit protein (e.g. an insect orthologue of the CG8392 Dm protein) or the Pros beta 2 protein (e.g. an insect orthologue of the CG3329 Dm protein).

[0039] According to still another embodiment the present invention relates to an isolated polynucleotide that is cloned in a DNA construct in a sense and antisense orientation so that upon transcription of the sense and antisense polynucleotide a dsRNA molecule is formed, which functions upon uptake by an insect to inhibit or down-regulate the expression of a target gene that encodes an insect .beta.-coatomer of the COPI vesicle (e.g. an insect orthologue of the CG6223 Dm protein), the .gamma.-coatomer of the COPI vesicle (e.g. an insect orthologue of the 1528 Dm protein), the .beta.'-coatomer protein (e.g. an insect orthologue of the CG6699 Dm protein) or the .zeta.-coatomer of the COPT vesicle (e.g. an insect orthologue of the CG3948 Dm protein).

[0040] According to still another embodiment the present invention relates to an isolated polynucleotide that is cloned in a DNA construct in a sense and antisense orientation so that upon transcription of the sense and antisense polynucleotide a dsRNA molecule is formed, which functions upon uptake by an insect to inhibit or down-regulate the expression of a target gene that encodes an insect Tetraspanine 2 A protein which is a putative transmembrane domain protein (e.g. an insect orthologue of the CG11415 Dm protein).

[0041] According to still another embodiment the present invention relates to an isolated polynucleotide that is cloned in a DNA construct in a sense and antisense orientation so that upon transcription of the sense and antisense polynucleotide a dsRNA molecule is formed, which functions upon uptake by an insect to inhibit or down-regulate the expression of a target gene that encodes an insect protein belonging to the actin family (e.g. an insect orthologue of the CG5409 Dm protein) such as Actin 5C (e.g. an insect orthologue of the CG4027 Dm protein).

[0042] According to still another embodiment the present invention relates to an isolated polynucleotide that is cloned in a DNA construct in a sense and antisense orientation so that upon transcription of the sense and antisense polynucleotide a dsRNA molecule is formed, which functions upon uptake by an insect to inhibit or down-regulate the expression of a target gene that encodes an insect ubiquitin-5E protein (e.g. an insect orthologue of the CG32744 Dm protein).

[0043] According to still another embodiment the present invention relates to an isolated polynucleotide that is cloned in a DNA construct in a sense and antisense orientation so that upon transcription of the sense and antisense polynucleotide a dsRNA molecule is formed, which functions upon uptake by an insect to inhibit or down-regulate the expression of a target gene that encodes an insect Sec23 protein which is a GTPase activator involved in intracellular protein transport (e.g. an insect orthologue of the CG1250 Dm protein).

[0044] According to still another embodiment the present invention relates to an isolated polynucleotide that is cloned in a DNA construct in a sense and antisense orientation so that upon transcription of the sense and antisense polynucleotide a dsRNA molecule is formed, which functions upon uptake by an insect to inhibit or down-regulate the expression of a target gene that encodes an insect crinkled protein which is an unconventional myosin which is involved in motor activity (e.g. an insect orthologue of the CG7595 Dm protein).

[0045] According to still another embodiment the present invention relates to an isolated polynucleotide that is cloned in a DNA construct in a sense and antisense orientation so that upon transcription of the sense and antisense polynucleotide a dsRNA molecule is formed, which functions upon uptake by an insect to inhibit or down-regulate the expression of a target gene that encodes an insect crooked neck protein which is involved in the regulation of nuclear alternative mRNA splicing (e.g. an insect orthologue of the CG3193 Dm protein).

[0046] According to still another embodiment the present invention relates to an isolated polynucleotide that is cloned in a DNA construct in a sense and antisense orientation so that upon transcription of the sense and antisense polynucleotide a dsRNA molecule is formed, which functions upon uptake by an insect to inhibit or down-regulate the expression of a target gene that encodes an insect vacuolar ATPase G-subunit protein (e.g. an insect orthologue of the CG6213 Dm protein).

[0047] According to still another embodiment the present invention relates to an isolated polynucleotide that is cloned in a DNA construct in a sense and antisense orientation so that upon transcription of the sense and antisense polynucleotide a dsRNA molecule is formed, which functions upon uptake by an insect to inhibit or down-regulate the expression of a target gene that encodes an insect Tbp-1; Tat-binding protein (e.g. an insect orthologue of the CG10370 Dm protein).

[0048] In accordance with a third aspect of the invention there is provided a composition for preventing and/or controlling insect pest infestation comprising at least one interfering ribonucleic acid (ANA) and at least one suitable carrier, excipient or diluent, wherein the interfering RNA functions upon uptake by the pest to down-regulate the expression of a target gene within said pest, wherein the target gene.

(i) is selected from the group of genes having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when the two sequences are optimally aligned and compared, is at least 75%, preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (ii) is selected from the group of genes having a nucleotide sequence consisting of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (iii) is selected from the group of genes having a nucleotide sequence comprising a fragment of al least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when said gene comprising said fragment is optimally aligned and compared with any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence is al least 75% preferably al least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (iv) is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, and wherein when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence of said fragment is al least 75% preferably at least 80%, 85%, 90%, 95%, 98% Of 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (v) is an insect pest orthologue of a gene having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, wherein the two orthologous genes are similar in sequence to such a degree that when the two genes are optimally aligned and compared, the orthologue has a sequence that is al least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of the sequences represented by SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or (vi) is selected from the group of genes having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is al least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence encoded by the nucleotide sequence represented in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or (vii) is selected from the group of genes having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 96% or 99% identical to the amino acid sequence represented in any of SEQ ID NOs 285, 242, 271, 226, 227, 281, 228, 282, 229, 230 to 233, 234, 283, 235, 236, 237, 238, 239, 240, 284, 241, 243, 244, 286, 269, 270, 287, 288, 206 to 225.

[0049] In accordance with a fourth aspect of the invention, there is provided a method for down-regulating expression of a target gene in an insect pest species comprising contacting said insect pest species with an effective amount of at least one interfering ribonucleic acid (RNA) or an effective amount of a composition comprising at least one interfering ribonucleic acid (RNA) and al least one suitable carrier, excipient or diluent, wherein the interfering RNA functions upon uptake by the pest to down-regulate the expression of a target gene within said pest, and wherein the target gene

(i) is selected from the group of genes having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when the two sequences are optimally aligned and compared, is at least 75%, preferably at least 80%, 85%, 90%, 05%, 98% or 99% identical any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (ii) is selected from the group of genes having a nucleotide sequence consisting of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4.24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (iii) is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when said gene comprising said fragment is optimally aligned and compared with any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (iv) is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21.22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, and wherein when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence of said fragment is al least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (v) is an insect pest orthologue of a gene having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, wherein the two orthologous genes are similar in sequence to such a degree that when the two genes are optimally aligned and compared, the orthologue has a sequence that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of the sequences represented by SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or (vi) is selected from the group of genes having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence encoded by the nucleotide sequence represented in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 8, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or (vii) is selected from the group of genes having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence represented in any of SEQ ID NOs 285, 242, 271, 226, 227, 281, 228, 282, 229, 230 to 233, 234, 283, 235, 236, 237, 238, 239, 240, 284, 241, 243, 244, 286, 269, 270, 287, 288, 206 to 225.

[0050] Preferably, the method of the invention finds practical application in the prevention and/or control of insect pest infestation, in particular, control of pest infestation of crop plants such as but not limited to rice, cotton, strawberries, seed crops such as alfalfa, soy, potato, tomato, canola, sunflower, sorghum, pearl millet, corn, eggplant, pepper and tobacco. In addition, the interfering RNA of the invention may be introduced into the plants to be protected by routine genetic engineering techniques.

[0051] Therefore, in accordance with a fifth aspect of the invention, there is provided a method for generating a transgenic plant resistant to infestation by an insect pest species comprising:

(a) transforming a plant cell with a DNA construct comprising a polynucleotide sequence encoding an interfering ribonucleic acid (RNA) that functions upon uptake by an insect pest species to down-regulate expression of a target gene in said insect pest species, wherein the target gene (i) is selected from the group of genes having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, in to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereat, or having a nucleotide sequence that, when the two sequences are optimally aligned and compared, is at least 75%, preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (ii) is selected from the group of genes having a nucleotide sequence consisting of arty of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21.2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (iii) is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when said gene comprising said fragment is optimally aligned and compared with any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (iv) is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25.26, 27, 28.29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6.26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, and wherein when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence of said fragment is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (v) is an insect pest orthologue of a gene having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, wherein the two orthologous genes are similar in sequence to such a degree that when the two genes are optimally aligned and compared, the orthologue has a sequence that is al least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of the sequences represented by SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or (vi) is selected from the group of genes having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence encoded by the nucleotide sequence represented in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or (vii) is selected from the group of genes having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is al least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence represented in any of SEQ ID NOs 285, 242, 271, 226, 227, 281, 228, 282, 229, 230 to 233, 234, 283, 235, 236, 237, 238, 239, 240, 284, 241, 243, 244, 286, 269, 270, 287, 288, 206 to 225: (b) regenerating a plant from the transformed plant cell; and (c) growing the transformed plant under conditions suitable for the expression of the interfering RNA from the recombinant DNA construct, said plant thus being resistant to said pest as compared with an untransformed plant.

[0052] In accordance with a sixth aspect of the invention, there is provided a transgenic plant, or reproductive or propagation material for a transgenic plant or a cultured transgenic plant cell, which expresses or is capable of expressing at least one interfering ribonucleic acid (RNA) that functions upon uptake by an insect pest species to down-regulate the expression of a target gene within said pest, wherein the target gene

(i) is selected from the group of genes having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when the two sequences are optimally aligned and compared, is at least 75%, preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (ii) is selected from the group of genes having a nucleotide sequence consisting of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (iii) is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when said gene comprising said fragment is optimally aligned and compared with any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence is al least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 138, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (iv) is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23.4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, and wherein when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 38, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence of said fragment is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (v) is an insect pest orthologue of a gene having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, wherein the two orthologous genes are similar in sequence to such a degree that when the two genes are optimally aligned and compared, the orthologue has a sequence that is al least 75% preferably al least 80%, 85%, 90%, 95%, 98% or 99% identical to any of the sequences represented by MO ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 28, 7, 27, 8, 28, 9.29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or (vi) is selected from the group of genes having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence encoded by the nucleotide sequence represented in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or (vii) is selected from the group of genes having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is al least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence represented in any of SEQ ID NOs 285, 242, 271, 226, 227, 281, 228, 282, 229, 230 to 233, 234, 283, 235, 236, 237, 238, 239, 240, 284, 241, 243, 244, 286, 269, 270, 287, 288, 206 to 225.

[0053] In one embodiment, the present invention relates to a transgenic plant or plant cell comprising an interfering nucleic acid (RNA or double stranded RNA) that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a part of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of or all of a mRNA encoding an insect ribosomal protein such as the ribosomal protein L19 (e.g. an insect orthologue of the CG2746 Dm protein), the ribosomal protein L40 (e.g. an insect orthologue of the CG2960 Dm protein) or the ribosomal protein S27A (e.g. an insect orthologue of the CG5271 Dm protein), and wherein the interfering nucleic acid inhibits or interferes with the translation of said mRNA and wherein the plant or plant cell is resistant to the insect as compared with an untransformed plant.

[0054] According to another embodiment the present invention relates to a transgenic plant or plant cell comprising an interfering nucleic acid (RNA or double stranded RNA) that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a part of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of or all of a mRNA encoding an insect proteasome subunit such as the Rpn6 protein (e.g. an insect orthologue of the CG10149 Dm protein), the Pros 25 protein (e.g. an insect orthologue of the CG5266 Dm protein), the Rpn2 protein (e.g. an insect orthologue of the CG11888 Dm protein), the proteasome beta 1 subunit protein (e.g. an insect orthologue of the CG8392 Dm protein) or the Pros beta 2 protein (e.g. an insect orthologue of the CG3329 Dm protein), and wherein the interfering nucleic acid inhibits or interferes with the translation of said mRNA and wherein the plant or plant cell is resistant to the insect as compared with an untransformed plant.

[0055] According to still another embodiment the present invention relates to a transgenic plant or plant cell comprising an interfering nucleic acid (RNA or double stranded RNA) that is at least 75% preferably al least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a part of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of or all of a mRNA encoding an insect .beta.-coatomer of the COPI vesicle (e.g. an insect orthologue of the CG6223 Dm protein), the .gamma.-coatomer of the COPI vesicle (e.g. an insect orthologue of the 1528 Dm protein), the .beta.'-coatomer protein (e.g. an insect orthologue of the CG6699 Dm protein) or the C-coatomer of the COPI vesicle (e.g. an insect orthologue of the CG3948 Dm protein), and wherein the interfering nucleic acid inhibits or interferes with the translation of said mRNA and wherein the plant or plant cell is resistant to the insect as compared with an untransformed plant.

[0056] According to still another embodiment the present invention relates to a transgenic plant or plant cell comprising an interfering nucleic acid (RNA or double stranded RNA) that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a part of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of or all of a mRNA encoding an insect Tetraspanine 2 A protein which is a putative transmembrane domain protein (e.g. an insect orthologue of the CG11415 Dm protein), and wherein the interfering nucleic acid inhibits or interferes with the translation of said mRNA and wherein the plant or plant cell is resistant to the insect as compared with an untransformed plant.

[0057] According to still another embodiment the present invention relates to a transgenic plant or plant cell comprising an interfering nucleic acid (RNA or double stranded RNA) that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a part of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of or all of a mRNA encoding an insect protein belonging to the actin family (e.g. an insect orthologue of the CG5409 Dm protein) such as Actin 5C (e.g. an insect orthologue of the CG4027 Dm protein), and wherein the interfering nucleic acid inhibits or interferes with the translation of said mRNA and wherein the plant or plant cell is resistant to the insect as compared with an untransformed plant.

[0058] According to still another embodiment the present invention relates to a transgenic plant or plant cell comprising an interfering nucleic acid (RNA or double stranded RNA) that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a part of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of or all of a mRNA encoding an insect ubiquitin-56 protein (e.g. an insect orthologue of the CG32744 Dm protein), and wherein the interfering nucleic acid inhibits or interferes with the translation of said mRNA and wherein the plant or plant cell is resistant to the insect as compared with an untransformed plant.

[0059] According to stilt another embodiment the present invention relates to a transgenic plant or plant cell comprising an interfering nucleic acid (RNA or double stranded RNA) that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a part of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of or all of a mRNA encoding an insect Sec23 protein which is a GTPase activator involved in intracellular protein transport (e.g. an insect orthologue of the CG1250 Dm protein), and wherein the interfering nucleic acid inhibits or interferes with the translation of said mRNA and wherein the plant or plant cell is resistant to the insect as compared with an untransformed plant.

[0060] According to still another embodiment the present invention relates to a transgenic plant or plant cell comprising an interfering nucleic acid (RNA or double stranded RNA) that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a part of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of or all of a mRNA encoding an insect crinkled protein which is an unconventional myosin which is involved in motor activity (e.g. an insect orthologue of the CG7595 Dm protein), and wherein the interfering nucleic acid inhibits or interferes with the translation of said mRNA and wherein the plant or plant cell is resistant to the insect as compared with an untransformed plant.

[0061] According to still another embodiment the present invention relates to a transgenic plant or plant cell comprising an interfering nucleic acid (RNA or double stranded RNA) that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a part of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of or all of a mRNA encoding an insect crooked neck protein which is involved in the regulation of nuclear alternative mRNA splicing (e.g. an insect orthologue of the CG3193 Dm protein), and wherein the interfering nucleic acid inhibits or interferes with the translation of said mRNA and wherein the plant or plant cell is resistant to the insect as compared with an untransformed plant.

[0062] According to still another embodiment the present invention relates to a transgenic plant or plant cell comprising an interfering nucleic acid (RNA or double stranded RNA) that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a part of al least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of or all of a mRNA encoding an insect vacuolar H+-ATPase G-subunit protein (e.g. an insect orthologue of the CG6213 Dm protein), and wherein the interfering nucleic acid inhibits or interferes with the translation of said mRNA and wherein the plant or plant cell is resistant to the insect as compared with an untransformed plant.

[0063] According to still another embodiment the present invention relates to a transgenic plant or plant cell comprising an interfering nucleic acid (RNA or double stranded RNA) that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98%, 99% or 100% complementary to a part of at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of or all of a mRNA encoding an insect Tbp-1; Tat-binding protein (e.g. an insect orthologue of the CG10370 Dm protein), and wherein the interfering nucleic acid inhibits or interferes with the translation of said mRNA and wherein the plant or plant cell is resistant to the insect as compared with an untransformed plant.

BRIEF DESCRIPTION OF THE TABLES AND FIGURES

[0064] Table 1 Polynucleotide sequences of target genes identified in Leptinotarsa decemlineata (Colorado potato beetle, CPB).

[0065] Table 2 Amino acid sequences of target genes identified in Leptinotarsa decemlineata (Colorado potato beetle, CPB).

[0066] Table 3 Polynucleotide sequences of target genes identified in Lygus hesperus.

[0067] Table 4 Amino acid sequences of target genes identified in Lygus hesperus.

[0068] Table 5 dsRNAs (sense strand represented by equivalent DNA sequence) corresponding to Leptinotarsa decemlineata target genes.

[0069] Table 6 dsRNAs (sense strand represented by equivalent DNA sequence) corresponding to Lygus hesperus target genes.

[0070] Table 7 Effects of dsRNAs derived from different target genes on time taken to kill 50% (LT.sub.50) of CPB larvae expressed as ratios versus the effect of a dsRNA derived from reference target gene Ld248 (SEQ ID NO 40).

[0071] Table 8 Effects of dsRNAs derived from different target genes on time taken to kill 50% (LT.sub.50) of CPB adults expressed as ratios versus the effect of a dsRNA derived from reference target gene Ld248 (SEQ ID NO 40).

[0072] Table 9 Effects of dsRNAs derived from different target genes on CPB egg production. Abbreviations: EM, normal egg masses; SE, single eggs; VS, yellow smear; none, no eggs.

[0073] Table 10 Survival analyses of target dsRNAs versus GFP dsRNA in the presence of tRNA in a Lygus hesperus nymph feeding assay. Log-rank test used to test the differences between the survival curves of the target dsRNA (or diet only) and GFP dsRNA generated using Kaplan-Meier estimates.

[0074] Table 11 Ranking of different target genes according to potency.

[0075] Table 12 Comparison of survival curves of test targets at 0.1, 0.05, or 0.025 .mu.g/.mu.L with GFP dsRNA at 0.1 .mu.g/.mu.L. Statistics were performed on data graphically represented in FIG. 5. ***: P-value 0.001; **: 0.001<P-value.ltoreq.0.01; *: 0.01<P-value.ltoreq.0.05; ns: not significant, P-value>0.05.

[0076] Table 13 Lygus targets for which full length cDNAs were cloned.

[0077] Table 14 Full length polynucleotide sequences of target genes identified in Lygus hesperus.

[0078] Table 15 Corresponding amino acid sequences to full length cDNAs of target genes identified in Lygus hesperus.

[0079] FIG. 1 Effects of dsRNAs derived from different target genes on survival and fitness of CPB adults. For each target gene investigated, 10 young adult beetles were individually led target dsRNA-treated potato leaf discs (total of 10 .mu.g dsRNA) for the first 24 hours and thereafter pined together on untreated potato foliage. The numbers of dead or moribund insects were assessed over a 14-day period. Data are presented as percentage mortality or moribundity. GFP dsRNA (SEQ ID NO 245) was used as a control. Ld105 dsRNA (SEQ ID NO 39), Ld248 dsRNA (SEQ ID NO 40), Ld516 dsRNA (SEQ ID NO 29), Ld511 dsRNA (SEQ ID NO 36), Ld512 dsRNA (SEQ ID NO 37), Ld513 dsRNA (SEQ ID NO 22), Ld520 dsRNA (SEQ ID NO 24), Ld537 dsRNA (SEQ ID NO 25), Ld563 dsRNA (SEQ ID NO 38), Ld579 dsRNA (SEQ ID NO 30).

[0080] FIG. 2 Survival curves for Lygus hesperus nymphs exposed to 0.5 .mu.g/.mu.L target dsRNA in the presence of 5 .mu.g/.mu.L yeast tRNA in a feeding assay. (a) Targets: Lh520 (SEQ ID NO 143), Lh423 (SEQ ID NO 152), Lh537 (SEQ ID NO 144), (b) Targets: Lh504.2 (SEQ ID NO 142), Lh512 (SEQ ID NO 153), Lh334 (SEQ ID NO 145), (c) Targets: Lh300.1 (SEQ ID NO 151), Lh327 (SEQ ID NO 146), Lh332 (SEQ ID NO 148), (d) Targets: Lh237 (SEQ ID NO 149), Lh579 (SEQ ID NO 147), Lh261 (SEQ ID NO 150), Lh513 (SEQ ID NO 141). GFP dsRNA plus yeast tRNA at the same concentrations, respectively, and diet-only treatments were used as controls. Young nymphs were each exposed to 25 .mu.L of 15% sucrose diet with or without incorporated test components for three days prior to transferring them on to 50 .mu.L Bioserv diet. Complex diet was refreshed on day 7. For all treatments, n=24.

[0081] FIG. 3 Survival curves for Lygus hesperus nymphs exposed to 0.5 .mu.g/.mu.L target dsRNA in the presence of 5 .mu.g/.mu.L yeast tRNA in a feeding assay, wherein the targets are grouped in A, B, C, D according to potency. Set-up described as in FIG. 2.

[0082] FIG. 4 Survival curves over time of Lygus hesperus nymphs exposed to lowering concentrations (from 0.5 to 0.1 .mu.g/.mu.L) of novel target dsRNA in the presence of yeast transfer RNA (5 .mu.g/.mu.l) in feeding bioassays. Each treatment in a bioassay consisted of 24 one-day-old nymphs placed individually in every welt of a 24-well plate. Each nymph was exposed to a parafilm sachet containing the ribonucleic acids in a solution of 15% sucrose for a duration of 3 days. On days 3 and 7, the diets were replaced with fresh rearing (Bioserv) diet. The following controls were included in the assays: GFP dsRNA and diet only.

[0083] FIG. 5 Survival curves over time of Lygus hesperus nymphs exposed to lowering concentrations (from 0.1 to 0.025 .mu.g/.mu.L) of novel target dsRNA in the presence of yeast transfer RNA (5 .mu.g/.mu.L) in feeding bioassays. Set-up described similarly as in FIG. 4.

[0084] FIG. 6 Survival curves over time of Lygus hesperus nymphs exposed to 0.5 .mu.g/.mu.L of target dsRNA in the presence of yeast transfer RNA (5 .mu.g/.mu.L) in feeding bioassays. Target dsRNA tested: Lh105.2 (SEQ ID NO 254), Lh248.2 (SEQ ID NO 255), Lh248.3 (SEQ ID NO 256), Lh327 (SEQ ID NO 146) and Lh300 (SEQ ID NO 151). Set-up described similarly as in FIG. 4.

[0085] FIG. 7 Schematic representation of the plant expression vector harbouring the Lygus hesperus hpRNA cassette. RB: right border; LB: left border; P35S: Cauliflower Mosaic Virus 35S promoter; 735S: Cauliflower Mosaic Virus 35S terminator; TNOS: nopatine synthase terminator; GFP: green Fluorescent reporter gene; NPT II: coding sequence of neomycin phosphotransferase II gene; KmR: Kanamycin resistance gene; pBR322 ori: pBR322 origin of replication; pBR322 born: pBR322 mobilization; pVS1 rep: pVS1 replicon; pVS1 sla: pVS1 stability element.

[0086] FIG. 8: Potato-Lygus in plank, assay set up. White arrows indicate insect damage.

[0087] FIG. 9 Lygus feeding assays on transgenic potatoes, expressing Lh423 hairpin. Survival rate of Lygus nymphs feeding on transgenic potatoes carrying Lh423 hairpin (P006/XX) or a GUS hairpin (P001/XX). Wild type (WT) potatoes were also used as control.

[0088] FIG. 10 Lygus feeding assays on positive transgenic potatoes, expressing Lh423 hairpin. Survival rate of Lygus nymphs feeding on transgenic potatoes carrying Lh423 hairpin (P006/59, P006129 and P006/22) or a GUS hairpin (P001/19, P001/28). Wild type (WT) potatoes were also used as control. Statistical analysis results, based on GraphPad survival curve analysis: ***=P<0.001: *=0.01<P<0.05.

DETAILED DESCRIPTION OF THE INVENTION

[0089] The present inventors have discovered that down-regulating the expression of particular target genes in insect pest species by RNAi can be used to effectively prevent and/or control infestation by said insect pest. As used herein, the term "control" of pest infestation refers to any effect on a pest that serves to limit and/or reduce either the numbers of pest organisms and/or the damage caused by the pest. Preferred target genes are therefore essential genes that control or regulate one or more essential biological functions within the insect pest, for example, cell division, reproduction, energy metabolism, digestion, neurological function and the like. Down-regulation of these essential genes by RNAi techniques can lead to death of the insect, or otherwise significantly retard growth and development or impair the ability of the pest to colonize an environment or infest host organisms.

[0090] Thus, in a first aspect, the invention provides an interfering ribonucleic acid (RNA) that functions upon uptake by an insect pest species to down-regulate expression of a target gene in said insect pest.

[0091] As used herein, a "target gene" comprises any gene in the insect pest which one intends to down-regulate. In a preferred embodiment, the target gene is down-regulated so as to control pest infestation, for example by disrupting an essential biological process occurring in the pest, or by decreasing the pathogenicity of the pest. Preferred target genes therefore include but are not limited to those that play key roles in regulating feeding, survival, growth, development, reproduction, infestation and infectivity. According to one embodiment, the target gene is such that when its expression is down-regulated or inhibited, the insect pest is killed. According to another embodiment, the target gene is such that when its expression is down-regulated or inhibited, growth of the pest is prevented or retarded or stunted or delayed or impeded or pest reproduction is prevented. According to yet another embodiment of the invention, the target gene is such that when its expression is down-regulated or inhibited, the damage caused by the pest and/or the ability of the pest to infect or infest environments, surfaces and/or plant or crop species is reduced; or the pest stops feeding from its natural food resources such as plants and plant products. The terms "infest" and "infect" or "infestation" and "infection" are generally used interchangeably throughout.

[0092] The target genes may be expressed in all or some of the cells of the insect pest. Furthermore, the target genes may only be expressed by the insect pest al a particular stage of its life-cycle, for example, the mature adult phase, immature nymph or larval phase or egg phase.

[0093] In specific embodiments, the present invention provides target genes which encode proteins involved in the function of a proteasome (subunit or regulatory particle), ribosomal protein, intracellular protein transport, COPI vesicle (coal protein complex), protein modification process, cytoskeleton, ATPase or GTPase activator activity (specified in Tables 7 and 8).

[0094] In preferred embodiments, the present invention provides target genes selected from the group of genes having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when the two sequences are optimally aligned and compared, is at least 75%, preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence consisting of any of SEQ ID NOs 277.138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1.21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7.27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that when said gene comprising said fragment is optimally aligned and compared with any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6.26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, and wherein when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence of said fragment is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or which gene is an insect pest orthologue of a gene having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, wherein the two orthologous genes are similar in sequence to such a degree that when the two genes are optimally aligned and compared, the orthologue has a sequence that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of the sequences represented by SEQ ID NOs 277, 138.253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145.275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or having a nucleotide sequence encoding an amino add sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to lie amino acid sequence encoded by the nucleotide sequence represented by any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40 or having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence represented in any of SEQ ID NOs 285, 242, 271, 226, 227, 281, 228, 282, 229, 230 to 233, 234, 283, 235, 236, 237, 238, 239, 240, 284, 241, 243, 244, 286, 269, 270, 287, 288, 206 to 225; and wherein the nucleotide sequence of said gene is no longer than 5000, 4000, 3000, 2000 or 1500 nucleotides.

[0095] As used herein, the term "sequence identity" is used to describe the sequence relationship between two or more nucleotide or amino acid sequences. The percentage of "sequence identity" between two sequences is determined by comparing two optimally aligned sequences over a comparison window (a defined number of positions), wherein the portion of the sequence in the comparison window may comprise additions or deletions (i.e. gaps) as compared to the reference sequence in order to achieve optimal alignment. The percentage sequence identity is calculated by determining the number of positions at which the identical nucleotide base or amino acid residue occurs in both sequences to yield the number of `matched` positions, dividing the number of matched positions by the total number of positions in the comparison window and multiplying the result by 100. For comparison of two optimally aligned sequences, the comparison window will be determined by the full length of the aligned regions. Methods and software for determining sequence identity are available in the art and include the Blast software and GAP analysis. For nucleic acids, the percent identity is calculated preferably by the BlastN alignment tool whereby the percent identity is calculated over the entire length of the query nucleotide sequence.

[0096] A person skilled in the art will recognise that homologues or orthologues (homologues existing in different species) of the target genes represented by any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25.6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40 can be identified. These pest homologues and/or orthologues are also within the scope of the current invention. Preferred homologues and/or orthologues are genes similar in sequence to such a degree that when the two genes are optimally aligned and compared, the homologue and/or orthologue has a sequence that is at least 75%, preferably at least 80% or 85%, more preferably at least 90% or 95%, and most preferably at least about 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40 or the complement thereof.

[0097] Other homologues are genes which are alleles of a gene comprising a sequence as represented by any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40. Further preferred homologues are genes comprising at least one single nucleotide polymorphism (SNP) compared to a gene comprising a sequence as represented by any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 146, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3.23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40.

[0098] The `interfering ribonucleic acid (RNA)` of the current invention encompasses any type of RNA molecule capable of down-regulating or `silencing` expression of a target gene, including but not limited to sense RNA, antisense RNA, short interfering RNA (siRNA), microRNA (miRNA), double stranded RNA (dsRNA), short hairpin RNA (shRNA) and the like. Methods to assay for functional interfering RNA molecules are well known in the art and are disclosed elsewhere herein.

[0099] The interfering RNA molecules of the current invention effect sequence-specific down-regulation of expression of a target gene by binding to a target nucleotide sequence within the target gene. Binding occurs as a result of base pairing between complementary regions of the interfering RNA and the target nucleotide sequence. As used herein, the term `silencing element` refers to the portion or region of the interfering RNA comprising or consisting of a sequence of nucleotides which is complementary, or at least partially complementary, to a target nucleotide sequence within the target gene, and which functions as the active portion of the interfering RNA to direct down-regulation of expression of said target gene. In one embodiment of the invention, the silencing element comprises or consists of a sequence of at least 17 contiguous nucleotides, preferably al least 18 or 19 contiguous nucleotides, more preferably al least 21 contiguous nucleotides, even more preferably at least 22, 23, 24 or 25 contiguous nucleotides complementary to a target nucleotide sequence within the target gene.

[0100] As used herein, "expression of a target gene" refers to the transcription and accumulation of the RNA transcript encoded by a target gene and/or translation of the mRNA into protein. The term `down-regulate` is intended to refer to any of the methods known in the art by which interfering RNA molecules reduce the level of primary RNA transcripts, mRNA or protein produced from a target gene. In certain embodiments, down-regulation refers to a situation whereby the level of RNA or protein produced from a gene is reduced by at least 10%, preferably by at least 33%, more preferably by al least 50%, yet more preferably by at least 80%. In particularly preferred embodiments, down-regulation refers to a reduction in the level of RNA or protein produced from a gene by at least 80%, preferably by at least 90%, more preferably by at least 95%, and most preferably by at least 99% within cells of the insect pest as compared with an appropriate control insect pest which has for example, not been exposed to an interfering RNA or has been exposed to a control interfering RNA molecule. Methods for detecting reductions in RNA or protein levels are well known in the art and include RNA solution hybridization, Northern hybridization, reverse transcription (e.g. quantitative RT-PCR analysis), microarray analysis, antibody binding, enzyme-linked immunosorbent assay (ELISA) and Western blotting. In another embodiment of the invention, down-regulation refers to a reduction in RNA or protein levels sufficient to result in a detectable change in a phenotype of the pest as compared with an appropriate pest control, for example, cell death, cessation of growth, or the like. Down-regulation can thus be measured by phenotypic analysis of the insect pest using techniques routine in the art.

[0101] In a preferred embodiment of the invention, the interfering RNA down-regulates gene expression by RNA interference or RNAi. RNAi is a process of sequence-specific gene regulation typically mediated by double-stranded RNA molecules such as short interfering RNAs (siRNAs), siRNAs comprise a sense RNA strand annealed by complementary basepairing to an antisense RNA strand. The sense strand or `guide strand` of the siRNA molecule comprises a sequence of nucleotides complementary to a sequence of nucleotides located within the RNA transcript of the target gene. The sense strand of the siRNA is therefore able to anneal to the RNA transcript via Watson-Crick-type basepairing and target the RNA for degradation within a cellular complex known as the RNAi-induced silencing complex or RISC. Thus, in the context of preferred interfering RNA molecules of the current invention, the silencing element as referred to herein may be a double-stranded region comprising annealed complementary strands, at least one strand of which comprises or consists of a sequence of nucleotides which is complementary or at least partially complementary to a target nucleotide sequence within a target gene. In one embodiment the double-stranded region has a length of at least 21, 22, 23, 24, 25, 30, 35, 40, 50, 55, 60, 70, 80, 90, 100, 125, 150, 175, 200 base pairs.

[0102] Longer double-stranded RNA (dsRNA) molecules comprising one or more functional double-stranded silencing elements as described elsewhere herein, and capable of RNAi-mediated gene silencing are also contemplated within the scope of the current invention. Such longer dsRNA molecules comprise at least 80, 200, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000 or 1100 base pairs. These dsRNA molecules may serve as precursors for the active siRNA molecules that direct the RNA transcript to the RISC complex for subsequent degradation. dsRNA molecules present in the environment surrounding an organism or the cells thereof may be taken up by the organism and processed by an enzyme called Dicer to yield siRNA molecules. Alternatively, the dsRNA may be produced in vivo i.e. transcribed from a polynucleotide or polynucleotides encoding the same present within a cell, for instance a bacterial cell or a plant cell, and subsequently processed by Dicer either within the host cell or preferably within the insect pest cells following uptake of the longer precursor dsRNA. The dsRNA may be formed from two separate (sense and antisense) RNA strands that anneal by virtue of complementary basepairing. Alternatively, the dsRNA may be a single strand that is capable of folding back on itself to form a short hairpin RNA (shRNA) or stem-loop structure. In the case of a shRNA, the double-stranded region or `stem` is formed from two regions or segments of the RNA that are essentially inverted repeats of one another and possess sufficient complementarily to allow the formation of a double-stranded region. One or more functional double-stranded silencing elements may be present in this `stem region` of the molecule. The inverted repeat regions are typically separated by a region or segment of the RNA known as the `loop` region. This region can comprise any nucleotide sequence conferring enough flexibility to allow self-pairing to occur between the flanking complementary regions at the RNA. In general, the loop region is substantially single-stranded and acts as a spacer element between the inverted repeats.

[0103] All the interfering RNA molecules of the invention effect sequence-specific down-regulation of expression of a target gene by binding to a target nucleotide sequence within the target gene. Binding occurs as a result of complementary base pairing between the silencing element of the interfering RNA and the target nucleotide sequence. In one embodiment of the current invention, the target nucleotide sequence comprises a sequence of nucleotides as represented by the RNA transcript of the target gene, or a fragment thereof wherein the fragment is preferably at least 17 nucleotides, more preferably at least 18, 19 or 20 nucleotides, or most preferably at least 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000 or 1100 nucleotides. In a preferred embodiment of the current invention, the target nucleotide sequence comprises a sequence of nucleotides equivalent to the RNA transcript encoded by any of the polynucleotides selected from the group consisting of (i) a polynucleotide which comprises at least 21, preferably at least 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80.90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide sequence as represented by any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, or (ii) a polynucleotide which consists of at least 21, preferably at least 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide sequence as represented by any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 1136 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof.

Or (iii) a polynucleotide which comprises at least 21, preferably at least 22, 23 or 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide sequence as represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, that, when the two sequences are optimally aligned and compared, said polynucleotide is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, or (iv) a polynucleotide which comprises a fragment of at least 21, preferably at least 22, 23 or 24, 25, 26, 27, 28, 29, 30, 35, 40.45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide as represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 106, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, and wherein said fragment or said complement has a nucleotide sequence that, when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, said nucleotide sequence is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120 or the complement thereof. or (v) a polynucleotide which consists of a fragment of at least 21, preferably at least 22, 23 or 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide as represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 148, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194, to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, and wherein said fragment or said complement has a nucleotide sequence that, when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, said nucleotide sequence is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120 or the complement thereof, or (vi) a polynucleotide encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence encoded by the nucleotide sequence represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or (vii) a polynucleotide encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence represented in any of SEQ ID NOs 285, 242, 271, 226, 227, 281, 228, 282, 229, 230 to 233, 234, 283, 235, 236, 237, 238, 239, 240, 284, 241, 243, 244, 286, 269, 270, 287, 288, 206 to 225. In a more preferred embodiment of the above, said polynucleotide is no longer than 10000, 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000 or 1500 nucleotides.

[0104] Preferably, the interfering RNA molecules of the current invention comprise at least one double-stranded region, typically the silencing element of the interfering RNA, comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of nucleotides complementary to a sequence of nucleotides located within the RNA transcript of the target gene.

[0105] The silencing element, or at least one strand thereof wherein the silencing element is double-stranded, may be fully complementary or partially complementary to the target nucleotide sequence of the target gene. As used herein, the term "fully complementary" means that all the bases of the nucleotide sequence of the silencing element are complementary to or `match` the bases of the target nucleotide sequence. The term "at least partially complementary" means that there is less than a 100% match between the bases of the silencing element and the bases of the target nucleotide sequence. The skilled person will understand that the silencing element need only be at least partially complementary to the target nucleotide sequence in order to mediate down-regulation of expression of the target gene. It is known in the art that RNA sequences with insertions, deletions and mismatches relative to the target sequence can still be effective at RNAi. According to the current invention, it is preferred that the silencing element and the target nucleotide sequence of the target gene share at least 80% or 85% sequence identity, preferably at least 90% or 95% sequence identity, or more preferably at least 97% or 98% sequence identity and still more preferably at least 99% sequence identity. Alternatively, the silencing element may comprise 1, 2 or 3 mismatches as compared with the target nucleotide sequence over every length of 24 partially complementary nucleotides.

[0106] It will be appreciated by the person skilled in the art that the degree of complementarity shared between the silencing element and the target nucleotide sequence may vary depending on the target gene to be down-regulated or depending on the insect pest species in which gene expression is to be controlled.

[0107] In another embodiment of the current invention, the silencing element comprises a sequence of nucleotides that is the RNA equivalent of any of the polynucleotides selected from the group consisting of a polynucleotide which comprises al least 21, preferably at least 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide sequence as represented by any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21.41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7.27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 so 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, or (II) a polynucleotide which comprises at least 21, preferably at least 22, 23 or 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide sequence as represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 69 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, that, when the two sequences are optimally aligned and compared, said polynucleotide is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 260, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 106, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, or (iii) a polynucleotide which comprises a fragment of at least 21, preferably at least 22, 23 or 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide as represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145.170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, and wherein said fragment or said complement has a nucleotide sequence that, when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 80, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, said nucleotide sequence is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120 or the complement thereof, wherein said polynucleotide is no longer than 10000, 9000, 8000, 7000, 6000, 5000, 4000, 3000, 2000 or 1500 nucleotides. It will be appreciated that in such embodiments the silencing element may comprise or consist of a region of double-stranded RNA comprising annealed complementary strands, one strand of which, the sense strand, comprises a sequence of nucleotides at least partially complementary to a target nucleotide sequence within a target gene.

[0108] The target nucleotide sequence may be selected from any suitable region or nucleotide sequence of the target gene or RNA transcript thereof. For example, the target nucleotide sequence may be located within the 5'UTR or 3'UTR of the target gene or RNA transcript or within exonic or intronic regions of the gene.

[0109] The skilled person will be aware of methods of identifying the most suitable target nucleotide sequences within the context of the lull-length target gene. For example, multiple silencing elements targeting different regions of the target gene can be synthesised and tested. Alternatively, digestion of the RNA transcript with enzymes such as RNAse H can be used to determine sites on the RNA that are in a conformation susceptible to gene silencing. Target sites may also be identified using in calico approaches, for example, the use of computer algorithms designed to predict the efficacy of gene silencing based on targeting different sites within the full-length gene.

[0110] The interfering RNAs of the current invention may comprise one silencing element or multiple silencing elements, wherein each silencing element comprises or consists of a sequence of nucleotides which is at least partially complementary to a target nucleotide sequence within a target gene and that functions upon uptake by an insect pest species to down-regulate expression of said target gene. Concatemeric RNA constructs of this type are described in WO2006/046148 as incorporated herein by reference. In the context of the present invention, the term `multiple` means at least two, at least three, al least four, etc and up to at least 10, 15, 20 or at least 30. In one embodiment, the interfering RNA comprises multiple copies of a single silencing element i.e. repeats of a silencing element that binds to a particular target nucleotide sequence within a specific target gene. In another embodiment, the silencing elements within the interfering RNA comprise or consist of different sequences of nucleotides complementary to different target nucleotide sequences. It should be clear that combinations of multiple copies of the same silencing element combined with silencing elements binding to different target nucleotide sequences are within the scope of the current invention.

[0111] The different target nucleotide sequences may originate from a single target gene in an insect pest species in order to achieve improved down-regulation of a specific target gene in an insect pest species. In this case, the silencing elements may be combined in the interfering RNA in the original order in which the target nucleotide sequences occur in the target gene, or the silencing elements may be scrambled and combined randomly in any rank order in the context of the interfering RNA as compared with the order of the target nucleotide sequences in the target gene.

[0112] Alternatively, the different target nucleotide sequences are representing a single target gene but originating from different insect pest species.

[0113] Alternatively, the different target nucleotide sequences may originate from different target genes. If the interfering RNA is for use in preventing and/or controlling pest infestation, it is preferred that the different target genes are chosen from the group of genes regulating essential biological functions of insect pest species, including but not limited to survival, growth, development, reproduction and pathogenicity. The target genes may regulate the same or different biological pathways or processes. In one embodiment, at least one of the silencing elements comprises or consists of a sequence of nucleotides which is at least partially complementary to a target nucleotide sequence within a target gene wherein the target gene is selected from the group of genes having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when the two sequences are optimally aligned and compared, is at least 75%, preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (ii) is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28.29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when said gene comprising said fragment is optimally aligned and compared with any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3.23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (iii) is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, and wherein when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence of said fragment is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 200, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or (iv) is an insect pest orthologue of a gene having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, wherein the two orthologous genes are similar in sequence to such a degree that when the two genes are optimally aligned and compared, the orthologue has a sequence that is al least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of the sequences represented by SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6.26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or (v) is selected from the group of genes having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence encoded by the nucleotide sequence represented in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1.21, 2, 22.3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11.31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or (vi) is selected from the group of genes having a nucleotide sequence encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence represented in any of SEQ ID NOs 285, 242, 271, 226, 227, 281, 228, 282, 229, 230 to 233, 234, 283, 235, 236, 237, 238, 239, 240, 284, 241, 243, 244, 286, 269, 270, 287, 288, 206 to 225. Preferably, the nucleotide sequence of the target gene is no longer than 5000, 4000, 3000, 2000 or 1500 nucleotides.

[0114] In a further embodiment of the invention, the different genes targeted by the different silencing elements originate from the same insect pest species. This approach is designed to achieve enhanced attack against a single insect pest species. In particular, the different target genes may be expressed differentially in the different stages of the insect's life cycle, for example, the mature adult, immature larval and egg stages. The interfering RNA of the invention may thus be used to prevent and/or control insect pest infestation at more than one stage of the insect's life cycle.

[0115] In an alternative embodiment of the invention, the different genes targeted by the different silencing elements originate from different insect pest species. The interfering RNA of the invention can thus be used to prevent and/or control infestation by more than one insect pest species simultaneously.

[0116] The silencing elements may be arranged as one contiguous region of the interfering RNA or may be separated by the presence of linker sequences. The linker sequence may comprise a short random nucleotide sequence that is not complementary to any target nucleotide sequences or target genes. In one embodiment, the tinker is a conditionally sell-cleaving RNA sequence, preferably a pH-sensitive linker or a hydrophobic-sensitive linker. In one embodiment, the linker comprises a sequence of nucleotides equivalent to an intronic sequence. Linker sequences of the current invention may range in length from about 1 base pair to about 10,000 base pairs, provided that the linker does not impair the ability of the interfering RNA to down-regulate the expression of target gene(s).

[0117] In addition to the silencing element(s) and any linker sequences, the interfering RNA of the invention may comprise at least one additional polynucleotide sequence. In different embodiments of the invention, the additional sequence is chosen from (i) a sequence capable of protecting the interfering RNA against RNA processing, (ii) a sequence affecting the stability of the interfering RNA, (iii) a sequence allowing protein binding, for example to facilitate uptake of the interfering RNA by cells of the insect pest species, (iv) a sequence facilitating large-scale production of the interfering RNA, (v) a sequence which is an aptamer that binds to a receptor or to a molecule on the surface of the insect pest cells to facilitate uptake, or (v) a sequence that catalyses processing of the interfering RNA within the insect pest cells and thereby enhances the efficacy of the interfering RNA. Structures for enhancing the stability of RNA molecules are well known in the art and are described further in WO2006/046148 as incorporated herein by reference.

[0118] The length of the interfering RNA of the invention needs to be sufficient for uptake by the cells of an insect pest species and down-regulation of target genes within the pest as described elsewhere herein. However, the upper limit on length may be dependent on (i) the requirement for the interfering RNA to be taken up by cells of the pest and (ii) the requirement for the interfering RNA to be processed in the cells of the pest to mediate gene silencing via the RNAi pathway. The length may also be dictated by the method of production and the formulation for delivery of the interfering RNA to cells. Preferably, the interfering RNA of the current invention will be between 21 and 10,000 nucleotides in length, preferably between 50 and 5000 nucleotides or between 100 and 2500 nucleotides, more preferably between 80 and 2000 nucleotides in length.

[0119] The interfering RNA may contain DNA bases, non-natural bases or non-natural backbone linkages or modifications of the sugar-phosphate backbone, for example to enhance stability during storage or enhance resistance to degradation by nucleases. Furthermore, the interfering RNA may be produced chemically or enzymatically by one skilled in the an through manual or automated reactions.

[0120] Alternatively, the interfering RNA may be transcribed from a polynucleotide encoding the same. Thus, provided herein is an isolated polynucleotide encoding any of the interfering RNAs of the current invention.

[0121] Also provided herein is an isolated polynucleotide selected from the group consisting of (i) a polynucleotide which comprises of least 21, preferably at least 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide sequence as represented by any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 13, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, or (ii) a polynucleotide which consists of at least 21, preferably at least 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide sequence as represented by any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25.57 to 60, 6.26, 61 to 64.7, 27, 65 to 68, 8, 28, 69 to 72.9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, to 1 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, or (iii) a polynucleotide which comprises al least 21, preferably at least 22, 23 or 24, 25, 26, 27, 28, 29, 30, 35.40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide sequence as represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, that, when the two sequences are optimally aligned and compared, said polynucleotide is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, or (iv; a polynucleotide which comprises a fragment of at least 21, preferably al least 22, 23 or 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide as represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, and wherein said fragment or said complement has a nucleotide sequence that, when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, said nucleotide sequence is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120 or the complement thereof, or (v) a polynucleotide which consists of a fragment of at least 21, preferably at least 22, 23 or 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900, 1000, 1100 or 1115 contiguous nucleotides of a nucleotide as represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, or the complement thereof, and wherein said fragment or said complement has a nucleotide sequence that, when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11.31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120, said nucleotide sequence is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22.45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25.57 to 60, 6.26, 61 to 64, 7, 27.65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11.31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19, 39, 113 to 116, 20, 40, 117 to 120 or, the complement thereof, or (vii a polynucleotide encoding an amino add sequence that, when the two amino acid sequences are optimally aligned and compared, is al least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence encoded by the nucleotide sequence represented in any of SEQ ID NOs 277, 138, 253, 152, 198 to 201, 121, 122, 141, 154 to 157, 273, 123, 142, 158 to 161, 274, 124, 143, 162 to 165, 125 to 129, 144, 166 to 169, 130, 145, 170 to 173, 275, 131, 146, 174 to 177, 132, 133, 147, 178 to 181, 134, 148, 182 to 185, 135, 149, 186 to 189, 136, 150, 190 to 193, 276, 137, 151, 194 to 197, 139, 140, 153, 202 to 205, 278, 251, 254, 257 to 260, 279, 252, 255, 256, 261 to 268, 280, 1, 21, 41 to 44, 2, 22, 45 to 48, 3, 23, 49 to 52, 4, 24, 53 to 56, 5, 25, 57 to 60, 6, 26, 61 to 64, 7, 27, 65 to 68, 8, 28, 69 to 72, 9, 29, 73 to 76, 10, 30, 77 to 80, 11, 31, 81 to 84, 12, 32, 85 to 88, 13, 33, 89 to 92, 14, 34, 93 to 96, 15, 35, 97 to 100, 16, 36, 101 to 104, 17, 37, 105 to 108, 18, 38, 109 to 112, 19.39, 113 to 116, 20, 40, 117 to 120, or (vii) a polynucleotide encoding an amino acid sequence that, when the two amino acid sequences are optimally aligned and compared, is at least 70% preferably at least 75%, 80%, 85%, 90%, 95%, 98% or 99% identical to the amino acid sequence represented in any of SEQ ID NOs 285, 242, 271, 226, 227, 281, 228, 282, 229, 230 to 233, 234, 283, 235, 236, 237, 238, 239, 240, 284, 241, 243, 244, 286, 269, 270, 287, 288, 206 to 225, and wherein said polynucleotide is no longer than 10000, 9000.8000, 7000, 6000, 5000, 4000, 3000, 2000 or 1500 nucleotides.

[0122] In preferred embodiments, the isolated polynucleotide is part of an interfering RNA molecule, typically part of the silencing element, comprising at least one double-stranded region comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of nucleotides complementary to a sequence of nucleotides located within the RNA transcript of the target gene. The sense strand of the dsRNA is therefore able to anneal to the RNA transcript and target the RNA for degradation within the RNAi-induced silencing complex or RISC.

[0123] The polynucleotides of the invention may be inserted via routine molecular cloning techniques into DNA constructs or vectors known in the art. Therefore, according to one embodiment, a DNA construct comprising any of the polynucleotides of the current invention is provided. Preferably, provided herein is a DNA construct comprising a polynucleotide encoding any of the interfering RNAs of the current invention. The DNA construct may be a recombinant DNA vector, for example a bacterial or yeast vector or plasmid. In a preferred embodiment of the invention, the DNA construct is an expression construct and the polynucleotide is operably linked to at least one regulatory sequence capable of driving expression of the polynucleotide sequence. The term `regulatory sequence` is to be taken in a broad context and is intended to rater to any nucleotide sequence capable of reflecting expression of polynucleotides to which it is operably linked including but not limited to promoters, enhancers and other naturally-occurring or synthetic transcriptional activator elements. The regulatory sequence may be located at the 5' or 3' end of the polynucleotide sequence. The term `operably linked` refers to a functional linkage between the regulatory sequence and the polynucleotide sequence such that the regulatory sequence drives expression of the polynucleotide. Operably linked elements may be contiguous or non-contiguous.

[0124] Preferably, the regulatory sequence is a promoter selected from the group comprising but not limited to constitutive promoters, inducible promoters, tissue-specific promoters and growth/developmental stage-specific promoters. In one embodiment, the polynucleotide is placed under the control of a strong constitutive promoter such as any selected from the group comprising the CaMV35S promoter, doubled CaMV35S promoter, ubiquitin promoter, actin promoter, rubisco promoter, GOS2 promoter, Figwort mosaic virus 34S promoter. In another embodiment, the regulatory sequence is a plant promoter for use in regulating expression of the polynucleotide in plants. Plant promoters, in particular, tissue-specific plant promoters encompassed within the scope of the current invention are described in more detail elsewhere herein.

[0125] Optionally, one or more transcription termination sequences may be incorporated in the expression construct of the invention. The term `transcription termination sequence` encompasses a control sequence at the end of a transcriptional unit, which signals termination of transcription, 3' processing and poly-adenylation of a primary transcript. Additional regulatory sequences including but not limited to transcriptional or translational enhancers may be incorporated in the expression construct, for instance as with the double enhanced CaMV35S promoter.

[0126] The present invention also encompasses a method for generating any of the interfering RNAs of the invention comprising the steps of (i) contacting a polynucleotide encoding said interfering RNA or a DNA construct comprising the same with cell-free components; or (ii) introducing (e.g. by transformation, transfection or injection) a polynucleotide encoding said interfering RNA or a DNA construct comprising the same into a cell. Accordingly, also provided herein is a host cell comprising any of the interfering RNAs of the current invention, any of the polynucleotides of the current invention or a DNA construct comprising the same. The host cell may be a prokaryotic cell including but not limited to gram-positive and gram-negative bacterial cells, or an eukaryotic cell including but not limited to yeast cells or plant cells. Preferably, said host cell is a bacterial cell or a plant cell. The bacterial cell can be chosen from the group comprising, but not limited to, Gram positive and Gram negative cells comprising Escherichia spp. (e.g. E. coli), Bacillus spp. (e.g. B. thuringiensis), Rhizobium spp., Lactobacillus spp., Lactococcus spp. Pseudomonas spp. and Agrobacterium spp. The polynucleotide or DNA construct of the invention may exist or be maintained in the host cell as an extra-chromosomal element or may be stably incorporated into the genome of the host cell. Characteristics of particular interest in selecting a host cell for the purposes of the current invention include the ease with which the polynucleotide or DNA construct encoding the interfering RNA can be introduced into the host, the availability of compatible expression systems, the efficiency of expression, and the stability of the interfering RNA in the host.

[0127] The DNA construct of the invention may further include an origin of replication which is required for maintenance and/or replication in a specific cell type or host cell. One example is when an expression construct is required to be maintained in a bacterial cell as an extra-chromosomal or episomal genetic element (e.g. a plasmid or cosmid molecule) in a cell. Preferred origins of replication include but are not limited to f1-ori, pBR322 ori (pMB1) and colE1 on.

[0128] The recombinant construct may optionally comprise a selectable marker gene. As used herein, the term `selectable marker gene` includes any gene, which confers a phenotype on a cell in which it is expressed to facilitate the identification and/or selection of cells, which are transfected or transformed with an expression construct of the invention. Examples of suitable selectable markers include resistance genes against ampicillin (Ampr), tetracycline (Tcr), kanamycin (Kanr), phosphinothricin, and chloramphenicol (CAT). Other suitable marker genes provide a metabolic trait, for example manA. Visual marker genes may also be used and include for example beta-glucuronidase (GUS), luciferase and Green Fluorescent Protein (GFP).

[0129] In situations wherein the interfering RNA is expressed within a host cell and/or is used to prevent and/or control pest infestation of a host organism, it is preferred that the interfering RNA does not exhibit significant "off-target" effects i.e. the interfering RNA does not affect expression of genes within the host. Preferably, the silencing element does not exhibit significant complementarity with nucleotide sequences other than the intended target nucleotide sequence of the target gene. In one embodiment of the invention, the silencing element shows less than 30%, more preferably less than 20%, more preferably less than 10% and even more preferably less than 5% sequence identity with any gene of the host cell or organism. If genomic sequence data is available for the host organism, one can cross-check identity with the silencing element using standard bioinformatics tools. In one embodiment, there is no sequence identity between the silencing element and a gene from the host cell or host organism over a region of 17, more preferably over a region of 18 or 19 and most preferably over a region of 20 or 21 contiguous nucleotides.

[0130] Any of the interfering RNA molecules or DNA constructs encoding the interfering RNA molecule or host cells comprising the interfering RNA molecule as herein described may be used for the prevention and/or control of insect pest infestation. As such, the interfering RNAs or DNA constructs or host cells comprising the same may be referred to as pesticides or insecticides. Preferably, the interfering RNA molecules and/or DNA constructs or host cells of the present invention are used to treat plants as a means to prevent and/or control pest infestation thereof. In particular, the interfering RNA molecules and/or DNA constructs or host cells may be provided as a kit for the purposes of preventing and/or controlling pest infestation, preferably pest infestation of plants.

[0131] Furthermore, in accordance with another aspect of the invention, there is provided herein a composition for preventing and/or controlling insect pest infestation comprising at least one interfering ribonucleic acid (RNA) and optionally at least one suitable carrier, excipient or diluent, wherein the interfering RNA functions upon uptake by the pest to down-regulate the expression of a target gene within said pest. The interfering RNA may be any of those as disclosed elsewhere herein. Preferably, the interfering RNA comprises or consists of at least one silencing element and said silencing element is a region of double-stranded RNA comprising annealed complementary strands, one strand of which (the sense strand) comprises a sequence of nucleotides which is at least partially complementary to a target nucleotide sequence within a target gene. The `target gene` may be any of the pest target genes as disclosed elsewhere herein including but not limited to genes involved in regulating pest survival, growth, development, reproduction and pathogenicity. Alternatively, the composition comprises at least one host cell comprising at least one interfering RNA molecule or DNA construct encoding the same and optionally at least one suitable carrier, excipient or diluent, wherein the interfering RNA functions upon uptake of the host cell by the insect pest to down-regulate the expression of a target gene within said pest.

[0132] In the practical application of the invention, the composition may be used for the prevention and/or control of any insect pest belonging to the Orders Coleoptera, Lepidoptera, Diptera, Dichyoptera, Orthoptera, Hemiptera and Siphonaptera. The composition may therefore be in any suitable form for application to insect pests or for application to substrates and/or organisms, in particular plants, susceptible to infestation by said insect pest, to one embodiment, the composition is for use in preventing and/or controlling pest infestation of plants or propagation or reproductive material of plants and is thus directed towards insect pest species that infest plants. The composition of the present invention is particularly effective when the insect pest belongs to the category of `chewing` insects that cause considerable damage to plants by eating plant tissues such as roots, leaves, flowers, buds, twigs and the like. Examples from this large insect category include beetles and their larvae. In a preferred embodiment of the invention, the insect pest is selected from the Leptinotarsa genus. More preferably, the target insect pest species is Leptinotarsa decemlineata.

[0133] The composition of the present invention is also effective against species of insects that pierce and/or suck the fluids from the cells and tissues of plants. Thus, in a further preferred embodiment of the invention, the insect pest is selected from the Lygus genus. Preferably, the target insect pest species is selected from the group comprising Lygus adspersus, Lygus alashanensis, Lygus borealis, Lygus elisus, Lygus gemellatus, Lygus hesperus, Lygus lineolaris or Lygus rugulipennis. More preferably, the target insect pest species is Lygus hesperus. The composition of the invention may be used to control insect pests at all stages of their life cycle, for example, the mature adult stage, the larval and egg stages.

[0134] In the context of the composition of the invention, the interfering RNA may be produced from a DNA construct. In particular an expression construct as described elsewhere herein, comprising a polynucleotide encoding the same. Furthermore, the interfering RNA may be produced inside a host cell or organism engineered to express said interfering RNA from a polynucleotide encoding the same. Suitable host organisms for use in the compositions of the current invention include but are not limited to microorganisms that are known to colonize the environment on and/or around plants or crops of interest i.e. plants or crops susceptible to infestation by insect pest species. Such microorganisms include but are not limited to those that occupy the phylloplane (the surface of plant leaves) and/or the rhizosphere (the soil surrounding plant roots). These microorganisms are selected so as to be capable of successfully competing with any wild-type organisms present in the plant environment. Suitable microorganisms for use as hosts include various species of bacteria, algae and fungi. It is clear that the chosen microorganisms must not be toxic to plants.

[0135] Host organisms that do not naturally colonize plants and/or their environment are also within the scope of the current invention. In one embodiment, the interfering RNA is fermented in a bacterial host, and the resulting dead bacteria are processed and used as an insecticidal spray in the same manner that Bacillus thuringiensis strains have been used as an insecticide for a spray application.

[0136] Wherein the composition of the invention is for use in preventing and/or controlling pest infestation of a plant, the composition can contain an agriculturally suitable carrier. Such a carrier may be any material that the plant to be treated can tolerate, which does not cause undue damage to the environment or other organisms therein and, which allows the interfering RNA to remain effective against the insect pest species. In particular, the compositions of the invention may be formulated for delivery to plants in accordance with routine agricultural practices used in the bioinsecticide industry. The composition may contain further components capable of performing other functions including but not limited to (i) enhancement or promotion of uptake of the interfering RNA by cells of the pest and (ii) stabilization of the active components of the composition. Specific examples of such further components contained in the composition comprising the interfering RNA, are yeast tRNA or yeast total RNA.

[0137] The compositions may be formulated for direct application or as a concentration of a primary composition that requires dilution prior to use. Alternatively, the composition may be supplied as kit comprising the interfering RNA or the host cell comprising or expressing the same in one container and the suitable diluent or carrier for the RNA or host cell in a separate container. In the practical application of the invention, the composition may be applied to a plant or any part of a plant at any stage of the plant's development. In one embodiment, the composition is applied to the aerial parts of a plant, for example during cultivation of plant crops in a field. In a further embodiment, the composition is applied to the seeds of a plant either while they are in storage or once they are planted in the soil. It is generally important to obtain good control of pests in the early stages of plant growth as this is the time when the plant can be most severely damaged by pest species.

[0138] The composition may be applied to the environment of an insect pest by various techniques including but not limited to spraying, atomizing, dusting, scattering, pouring, coating of seeds, seed treatment, introduction into the soil, and introduction into irrigation water. In the treatment of plants susceptible to pest infestation, the composition may be delivered to the plant or part of a plant before the appearance of the pest (for the purposes of prevention), or once signs of pest infestation begin to appear (for the purposes of pest control).

[0139] In a further embodiment of the invention, the composition is formulated so as to contain at least one further agronomical agent, for example a herbicide or an additional pesticide. As used herein, a `second pesticide` or `additional pesticide` refers to a pesticide other than the first or original interfering RNA molecule of the composition. Alternatively, the composition of the invention may be delivered in combination with at least one other agronomical agent, for a example a herbicide or a second pesticide. In one embodiment, the composition is provided in combination with a herbicide selected from any known in the art, for instance glyphosate, imidazolinone, sulphonylurea and bromoxynil. In a further embodiment, the composition is provided in combination with at least one additional pesticide. The additional pesticide may be selected from any pesticides known in the art and/or may comprise an interfering ribonucleic acid that functions upon uptake by a pest to down-regulate expression of a target gene in said pest species. In one embodiment, the target pest is an insect pest species and the interfering RNA is selected from any of the interfering RNAs as described herein. In a further embodiment, the additional pesticide comprises an interfering RNA that functions to down-regulate expression of a known gene in any target pest species, not limited to insect pests. The original interfering RNA molecule of the composition and the second or additional pesticide(s) may target the same insect pest species or may be intended to target different insect pest species. For example, the original interfering RNA and the second pesticide may target different species of insect pest or may target different families or classes of pest organisms, for example, fungi or nematodes or insects. It will be apparent to one skilled in the art how to test combinations of interfering RNA molecules and other agronomical agents for synergistic effects. In a preferred embodiment, the composition contains a first interfering RNA molecule described elsewhere herein and one or more additional pesticides, each toxic to the same insect pest, wherein the one or more additional pesticides are selected from a patatin, a Bacillus thuringiensis insecticidal protein, a Xenorhabdus insecticidal protein, a Photorhabdus insecticidal protein, a Bacillus laterosporous insecticidal protein, a Bacillus spaericus insecticidal protein, and a lignin, and wherein said Bacillus thuringiensis insecticidal protein is selected from the group consisting of a Cry1Ab, a Cry1C, a Cry2Aa, a Cry3, a TIC851, a CryET70, a Cry22, a VIP, a TIC901, a TIC1201, a TIC407, a TIC417, a binary insecticidal protein selected from CryET33 and CryET34, CryET80 and CryET76, TIC100 and TIC101, and PS149B1, and insecticidal chimeras of any of the preceding insecticidal proteins.

[0140] The different components of the combinations described herein may be administered, (or example to a host organism susceptible to infestation by pest, in any order. The components may be delivered simultaneously or sequentially to the area or organism to be treated.

[0141] According to a further aspect of the current invention, there is provided herein a method for down-regulating expression of a target gene in an insect pest species comprising contacting said pest with an effective amount of at least one interfering ribonucleic acid (RNA), wherein the interfering RNA functions upon uptake by the pest to down-regulate the expression of a target gene within said pest.

[0142] The target gene may be any of the pest genes as described elsewhere herein. In particular, the target gene may be selected from the group of genes having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when the two sequences are optimally aligned and compared, is at least 75%, preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or is selected from the group of genes having a nucleotide sequence consisting of any of SEQ) ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when said gene comprising said fragment is optimally aligned and compared with any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, and wherein when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence of said fragment is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 312, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof.

[0143] The target gene may also be an insect pest orthologue of a gene having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, wherein the two orthologous genes are similar in sequence to such a degree that when the two genes are optimally aligned and compared, the orthologue has a sequence that is al least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of the sequences represented by SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13.33, 14, 34, 15, 35, 16.36, 17, 37, 18, 38, 19, 39, 20 or 40. Preferably the nucleotide sequence of said target gene is no longer than 5000, 4000, 3000, 2000 or 1500 nucleotides.

[0144] The interfering RNA for use in the present method may be any of the interfering RNA molecules as described elsewhere herein. In one embodiment, the interfering RNA mediates down-regulation of gene expression by the process of RNA interference or RNA', and the interfering RNA is selected from the group of regulatory RNA molecules capable of effecting RNAi or `gene silencing` Including but not limited to short interfering RNAs (siRNA), microRNAs (miRNA), double-stranded RNAs (dsRNA) and hairpin RNAs (shRNA).

[0145] In preferred embodiments, the interfering RNA molecules for use in the present method comprise at least one silencing element wherein the silencing element is a region of double-stranded RNA comprising a sense RNA strand annealed by complementary basepairing to an antisense RNA strand wherein the sense strand of the dsRNA molecule comprises a sequence of nucleotides complementary to a sequence of nucleotides located within the RNA transcript of the target gene. The sense strand of the dsRNA is therefore able to anneal to the RNA transcript and target the RNA for degradation within the RNAi-induced silencing complex or RISC.

[0146] In the present method, the insect pest is treated with at least one interfering RNA. In one embodiment of the method, the insect pest species may be contacted with multiple interfering RNA molecules. Wherein the pest is contacted with multiple interfering RNAs, the different RNAs may function to down-regulate the same target gene or different target genes.

[0147] The interfering RNA to be delivered to the insect pest species may be formulated as a composition comprising at least one suitable carrier, excipient or diluent. Furthermore, the interfering RNA may be transcribed from a polynucleotide encoding the same or a DNA construct comprising said polynucleotide. In one embodiment, the interfering RNA is expressed inside a host cell or organism including a prokaryotic or eukaryotic host. The host cell or organism may be a host susceptible to infestation by an insect pest wherein the interfering RNA functions to down-regulate expression of a target gene in said pest. In a preferred embodiment, the host organism is a plant susceptible to infestation by the targeted insect pest species.

[0148] As used in the context of the present method, the term `contacting` refers to any means by which the insect pest species or a cell thereof is exposed to the interfering RNA and which allows for uptake of the interfering RNA by cells of the pest. Thus, `contacting` encompasses for example, the processes of cell transformation, microinjection and feeding. These techniques may be carried out in respect of isolated cells grown in vitro or cells within the intact body of the insect pest species. Wherein the intact insect pest is contacted with the interfering RNA of the method, the RNA may be microinjected into an extracellular space and subsequently taken up by cells of the body by natural processes such as endocytosis or transcytosis. In a preferred embodiment of the invention, the interfering RNA is provided to the pest in the form of or included in foodstuff to be ingested by the pest. Once ingested, the interfering RNA may pass from the insect's digestive tract into the cells of the body by natural processes such as endocytosis or transcytosis. In one embodiment, the insect pest is exposed to a plant that has been treated with an interfering RNA or a composition comprising the same, and the interfering RNA is taken up as the pest feeds on the plant tissue. The interfering RNA may be present on the surface of a plant or a part thereof or may be present intracellularly in the plant or the plant tissue eaten by the insect pest.

[0149] In the context of a method for down-regulating expression of a target gene in an insect pest species, the phrase `effective amount` should be taken to mean the quantity or concentration of interfering RNA required to down-regulate expression of the target gene by at least 10% or 20%, preferably by at least 33%, more preferably by at least 50%, yet more preferably by at least 80% or 90%. In particularly preferred embodiments, an `effective amount` is the quantity or concentration required to down-regulate expression of the target gene by al least 60%, 70% or 80%, preferably by at least 90%, more preferably by at least 95%, and most preferably by al least 99% relative to expression in the absence of an interfering RNA or in the presence of a control RNA. As described elsewhere herein, down-regulation of gene expression can be measured by a reduction in the levels of either the RNA transcript or the protein ultimately produced from the target gene. Levels of RNA and/or protein can be measured using techniques routine in the art.

[0150] Also provided herein is a method for preventing and/or controlling pest infestation, comprising contacting an insect pest species with an effective amount of at least one interfering RNA wherein the RNA functions upon uptake by said pest to down-regulate expression of an essential pest target gene. The essential target gene may be any pest gene involved in the regulation of an essential biological process required by the pest to initiate or maintain infestation including but not limited to survival, growth, development, reproduction and pathogenicity. In particular, the target gene may be any of the pest genes as described elsewhere herein. Furthermore, there is provided herein a method for preventing and/or controlling insect pest infestation in a field of crop plants, said method comprising expressing in said plants an effective amount of an interfering RNA as described herein.

[0151] Wherein the method is for the control of pest infestation, the phrase `effective amount` extends to the quantity or concentration of interfering RNA required to produce a phenotypic effect on the pest such that the numbers of pest organisms infesting a host organism are reduced and/or the amount of damage caused by the pest is reduced. In one embodiment, the phenotypic effect is death of the pest and the interfering RNA is used to achieve at least 20%, 30%, 40%, preferably at least 50%, 60%, 70%, more preferably at least 80% or 90% pest mortality as compared to control insect pests. In a further embodiment, the phenotypic effects include but are not limited to stunting of pest growth, cessation of feeding and reduced egg-laying. The total numbers of pest organisms infesting a host organism may thus be reduced by at least 20%, 30%, 40%, preferably at least 50%, 60%, 70%, more preferably at least 80% or 90% as compared with control pests. Alternatively, the damage caused by the insect pest may be reduced by at least 20%, 30%, 40%, preferably at least 50%, 60%, 70%, more preferably at least 60% or 90% as compared with control insect pests. Hence, the method of the invention can be used to achieve at least 20%, 30%, 40%, preferably at least 50%, 60%, 70%, more preferably at least 80% or 90% pest control. As used herein `control pests` are pests not contacted with any pesticidal agent, or pests contacted with an interfering RNA targeting a non-essential gene i.e. a gene not required for the initiation or maintenance of pest infestation or pests contacted with an interfering RNA targeting a gene not found and/or not expressed in said pest.

[0152] Methods for down-regulating expression of a target gene in an insect pest species may be used to prevent and/or control pest infestation on a particular substrate or material susceptible to infestation by said insect pest. In one embodiment, the method is used to treat any plant susceptible to infestation by said pest. Plants of interest for use according to the methods of the current invention include but are not limited to rice, potato, cotton, tomato, canola, soy, sunflower, sorghum, pearl millet, corn, seed crops such as alfalfa, strawberries, eggplant, pepper and tobacco.

[0153] Furthermore, there is provided herein a method for increasing the yield of a plant crop comprising contacting said plants with an effective amount of an interfering RNA that functions upon uptake by an insect pest species to down-regulate expression of a target gene in said pest, wherein down-regulation of the target gene affects an essential biological function of the pest required for initiation and/or maintenance of infestation, such that the damage caused to the plant crop is reduced as compared with untreated crops.

[0154] Plants or plant crops to be treated according to the methods of the current invention may be treated externally with an interfering RNA or composition comprising the same. For example, the interfering RNA or host cells comprising or expressing the same may be applied to the surface of the plant or to the plant's environment by processes including but not limited to spraying, atomizing, dusting, scattering, pouring, coaling of seeds, seed treatment, introduction into the soil and introduction into irrigation water. In one embodiment, the plant to be treated is engineered to express the interfering RNA intracellularly via transcription from a polynucleotide incorporated therein. As the pest feeds on tissues of the plant, the cells containing the interfering RNA will be broken down inside the insect's digestive tract and the interfering RNA will thus be distributed within the insect's body resulting in down-regulation of target genes.

[0155] Thus, in accordance with another aspect of the present invention is provided a method for generating a transgenic plant resistant to infestation by an insect pest species comprising the steps of (a) transforming a plant cell with a DNA construct comprising a polynucleotide sequence encoding an interfering ribonucleic acid (RNA) that functions upon uptake by an insect pest species to down-regulate expression of a target gene in said insect pest species, (b) regenerating a plant tram the transformed plant cell; and (c) growing the transformed plant under conditions suitable for the expression of the interfering RNA from the recombinant DNA construct, said plant thus being resistant to said pest as compared with an untransformed plant.

[0156] The interfering RNA expressed by the plant or part thereof may be any of those as disclosed elsewhere herein. Preferably, the interfering RNA comprises or consists alai least one silencing element and said silencing element is a region of double-stranded RNA comprises annealed complementary strands, one strand of which (the sense strand) comprises a sequence of nucleotides which is at least partially complementary to a target nucleotide sequence within a target gene. Wherein part of the interfering RNA is double-stranded, the two strands of the molecule may be expressed from at least two separate polynucleotides or may be encoded by a single polynucleotide encoding an interfering RNA with for example, a stem-loop structure as described elsewhere herein.

[0157] The interfering RNA expressed by the plant or part thereof may target any of the pest genes as described elsewhere herein. In particular, the target gene may be selected from the group of genes having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when the two sequences are optimally aligned and compared, is at least 75%, preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6.26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or is selected from the group of genes having a nucleotide sequence consisting of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 900 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or having a nucleotide sequence that, when said gene comprising said fragment is optimally aligned and compared with any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, or is selected from the group of genes having a nucleotide sequence comprising a fragment of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 125, 150, 175, 200, 225, 250, 300, 350, 400, 450, 500, 550, 600, 700, 800, 000 1000, 1100 or 1115 contiguous nucleotides of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, and wherein when said fragment is optimally aligned and compared with the corresponding fragment in any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, said nucleotide sequence of said fragment is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to said corresponding fragment of any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23.4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof. The target gene may also be an insect pest orthologue of a gene having a nucleotide sequence comprising any of SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40, or the complement thereof, wherein the two orthologous genes are similar in sequence to such a degree that when the two genes are optimally aligned and compared, the orthologue has a sequence that is at least 75% preferably at least 80%, 85%, 90%, 95%, 98% or 99% identical to any of the sequences represented by SEQ ID NOs 277, 138, 253, 152, 121, 122, 141, 273, 123, 142, 274, 124, 143, 125 to 129, 144, 130, 145, 275, 131, 146, 132, 133, 147, 134, 148, 135, 149, 136, 150, 276, 137, 151, 139, 140, 153, 278, 251, 254, 279, 252, 255, 256, 280, 1, 21, 2, 22, 3, 23, 4, 24, 5, 25, 6, 26, 7, 27, 8, 28, 9, 29, 10, 30, 11, 31, 12, 32, 13, 33, 14, 34, 15, 35, 16, 36, 17, 37, 18, 38, 19, 39, 20 or 40. Preferably the nucleotide sequence of said target gene is no longer than 5000, 4000, 3000, 2000 or 1500 nucleotides. Furthermore, it is important that the interfering RNA does not disrupt expression of any genes of the plant host.

[0158] As used herein, the term `transgenic plant` or `transgenic plant cell` refers to any plant or plant cell that has been genetically engineered or is descended from a plant that has been genetically engineered so as to carry an exogenous polynucleotide sequence. "Exogenous" refers to the tact that the polynucleotide originates from outside the plant cell. Typically, the exogenous polynucleotide is non-native to the transgenic plant i.e. it is not found naturally within the genome of the plant.

[0159] As used herein, the term `transformation` refers to the introduction of exogenous polynucleotide molecules into a plant or a cell thereof. Techniques for introducing polynucleotides into plants are known in the art. In one embodiment of the current invention, the plants are `stably transformed` with a polynucleotide or DNA construct comprising the same, i.e. the polynucleotide or DNA construct introduced into the plant cell integrates into the genome of the plant and is capable of being inherited by the progeny thereof. Transformation protocols for introducing polynucleotides or DNA constructs into the cells of plants may vary depending on the type of plant concerned. Suitable transformation methods include but are not limited to microinjection, electroporation, Agrobacterium-mediated transformation, and ballistic particle acceleration. Methods are also known in the art for the targeted insertion of a polynucleotide or DNA construct at a specific location in the plant genome using site-specific recombination systems.

[0160] The DNA construct comprising the polynucleotide encoding the active interfering RNA molecule may be any vector suitable for transformation of plant cells. Suitable vectors include but are not limited to bacterial plasmids, for example the 11 plasmid of Agrobacterium tumefaciens, and viral vector systems. The DNA construct introduced into the cells of a plant must not be harmful or toxic to the plant and/or must not be harmful or toxic to any organisms higher up the food chain that feed on said plants.

[0161] In one embodiment, the DNA construct is an expression construct comprising a polynucleotide encoding an interfering RNA operably linked to a regulatory sequence capable of driving expression of the polynucleotide sequence in plants such as any selected from the group comprising the CaMV35S promoter, doubled CaMV35S promoter, ubiquitin promoter, actin promoter, rubisco promoter, GOS2 promoter, Figwort mosaic virus 34S promoter and the double enhanced CaMV35S promoter. Preferably, the regulatory sequence is a plant promoter selected from those known in the art. In some embodiments, it may be preferred that the plant produces interfering RNA molecules only in the parts of the plant which will come into contact with and/or are damaged by the insect pest species, for example, the aerial parts of the plant, the roots etc. This effect can be achieved through the use of tissue-specific plant promoters including but not limited to leaf-specific promoters, root-specific promoters, stem-specific promoters, flower-specific promoters and fruit-specific promoters known in the art. Suitable examples of a root specific promoter are PsMTA and the Class III Chitinase promoter. Examples of leaf- and stem-specific or photosynthetic tissue-specific promoters that are also photoactivated are promoters of two chlorophyll binding proteins (cab1 and cab2) from sugar beet, ribulose-bisphosphate carboxylase (Rubisco), encoded by rbcS, A (gapA) and B (gapB) subunits of chloroplast glyceraldehyde-3-phosphate dehydrogenase, promoter of the Solanum tuberosum gene encoding the leaf and stem specific (ST-LS1) protein, stem-regulated, defense-inducible genes, such as JAS promoters, flower-specific promoters such as chalcone synthase promoter and fruit-specific promoters such as that of RJ39 from strawberry.

[0162] In other embodiments, it may be preferred that the plant produces interfering RNA molecules only at a particular stage of its growth. This effect can be achieved through the use of development-specific plant promoters that drive expression only during certain periods of plant development. In particular, it is important to protect plants from pest infestation during the early stages of plant growth or during flowering (for instance in case of rice) or during fructification or fruit maturation or seed-filling, as this is the time when the plant can be most severely damaged.

[0163] The DNA construct for use in transformation of a plant according to the present method may comprise more than one polynucleotide encoding an interfering RNA molecule of the current invention. In one embodiment, the different polynucleotides may encode interfering RNA molecules targeting different nucleotide sequences within the same target gene. In a further embodiment, the different polynucleotides may encode interfering RNA molecules targeting different nucleotide sequences within different target genes, wherein the different target genes originate from the same or different insect pest species. Wherein the DNA construct encodes more than one interfering RNA, these RNAs may be expressed differentially within different tissues of the plant by virtue of being under the control of different tissue-specific promoter sequences as described elsewhere herein. In one embodiment, the plant is engineered to express an interfering RNA in the leaves which down-regulates expression of a target gene in an insect that feeds on the leaves, and to additionally express an interfering RNA in the roots which down-regulates expression of a target gene in an insect that colonizes the soil and feeds on the plant roots.

[0164] The DNA construct may also comprise at least one other polynucleotide of interest, for example a polynucleotide encoding an additional regulatory RNA molecule, a polynucleotide encoding a protein toxic to insect pest species and/or a polynucleotide encoding a protein conferring herbicide resistance.

[0165] In accordance with the present method, a plant is regenerated from a transformed plant cell using techniques known in the art. One such technique comprises enzymatic digestion of the plant cell wall to produce a plant protoplast, which can subsequently undergo multiple rounds of cell division and differentiation to produce an adult plant. Adult plants generated in such a way can be subsequently tested for resistance to pest infestation. `Resistant` as used herein should be interpreted broadly and relates to the ability of the plant to defend against attack from a pest that is typically capable of inflicting damage or loss to the plant. Resistant may either be taken to mean that the plant is no longer susceptible to pest infestation or that any disease symptoms resulting from pest infestation are reduced by at least about 20%, preferably al least 30%, 40% or 50%, more preferably at least 60%, 70% or 80% and most preferably by at least 90%. Techniques to measure the resistance of a plant to insect pest species are commonly known in the art and include but are not limited to measuring over time the average lesion diameter, the pest biomass, and/or the overall percentage of decayed plant tissues.

[0166] In one embodiment, the present method of producing a transgenic plant also includes the step of generating offspring or progeny from the transgenic plant and testing the progeny for resistance to the insect pest. Two or more generations may be produced to ensure that expression of the resistance trait is stably maintained and inherited. Seeds may also be harvested from the parent transgenic plant and/or its progeny to test for resistance to an insect pest.

[0167] Also encompassed within the present invention is a method for generating transgenic plants resistant to infestation by an insect pest species comprising the steps of crossing a first transgenic plant carrying a DNA construct encoding an interfering RNA that functions to down-regulate expression of a pest target gene, with a second plant lacking said DNA construct, and selecting progeny resistant to said pest. Crossing may be carried out by any methods routinely used in the context of plant breeding. The progeny selected for pest resistance may additionally be self-pollinated or `selfed` to produce a subsequent generation of pest resistant progeny. In one embodiment, multiple rounds of self pollination or selling may be carried out to generate 2, 3, 4, 5 or more generations of progeny. The resultant progeny may be tested for pest resistance to ensure that expression of the resistance trait is stably maintained and inherited.

[0168] In a further embodiment, any pest resistant progeny plants derived from a cross between a first transgenic parent plant carrying a DNA construct of interest and a second parent plant lacking said DNA construct may be back-crossed to the second parent plant and subsequent progeny tested for resistance to pest infestation. Plants or their progeny may be tested for resistance to pest infestation either by phenotypic analysis as described elsewhere herein or by standard molecular techniques. For example, the pest resistant plants may be identified by the detection of the presence of a DNA construct comprising a polynucleotide sequence encoding an interfering RNA that functions upon uptake by an insect pest species to down-regulate expression of a target gene. Techniques for detecting the presence of specific polynucleotide sequences within cells are known in the art and include PCR, enzymatic digestion and SNP analysis.

[0169] The methods of the invention can be used to generate `stacked transgenic` plants that are resistant to insect pest species and that optionally possess at least one other desirable trait. As used herein, a `stacked` transgenic plant refers to a plant carrying more than one exogenous polynucleotide sequence. The phrase `more than one` refers to the possibility of a plant carrying al least 2, at least 3, at least 4 exogenous polynucleotides. In one embodiment, the plant cell transformed with the DNA construct encoding the interfering RNA targeting a pest gene may have previously been engineered to carry a separate exogenous polynucleotide. Alternatively, the method for generating a transgenic plant from a plant cell as described herein may comprise a cotransformation protocol wherein the DNA construct encoding an interfering RNA of the invention is delivered to a plant cell simultaneously or sequentially with a separate exogenous polynucleotide.

[0170] Stacked transgenic plants demonstrating pest resistance may also be generated by standard plant breeding techniques. In one embodiment, a first pest-resistant transgenic plant is crossed with a second plant engineered to express an exogenous polynucleotide or heterologous gene conferring a desirable plant trait. Any progeny produced can be tested for pest resistance and acquisition of the additional desirable trait. Alternatively or in addition, any pest-resistant progeny produced from the cross may be back-crossed to the second parent in order to generate further progeny that can be selected for inheritance of the heterologous gene carried by the second parent and thus the additional desirable plant trail. The exogenous polynucleotides carried by a stacked transgenic plant of the invention may be expressed in the same parts of the plant or may be expressed differentially by virtue of the tact that expression of each is controlled by a different tissue-specific promoter.

[0171] In one embodiment, the exogenous polynucleotide or heterologous gene conferring a further desirable trait encodes another interfering RNA targeting the same or different insect pest species. In a further embodiment, the heterologous gene encodes a protein harmful or toxic to a plant insect pest species, for example an insecticidal protein selected from the group including but not limited to Cry1Ab, Cry1C, Cry2Aa, Cry3, CryET70, Cry22, CryET33, CryET34, CryET80, CryET78, TIC100, TIC101, TIC851, TIC900, TIC901, TIC1201, TIC407, TIC417, PS149B1 and VIP insecticidal proteins. In a yet further embodiment, the heterologous gene encodes a protein conferring herbicide resistance. Examples of genes conferring herbicide resistance include Bar, EPSPS which confers glyphosate resistance, ALS which confers imidazolinone and sulphonylurea resistance and tort which confers bromoxynil resistance.

[0172] Also provided herein is a method for producing hybrid seed from any of the transgenic plants generated by the methods of the current invention, said method comprising the steps of (i) planting the seed obtained from a first inbred plant and the seed obtained from a second inbred plant, wherein at least one of the inbred plants is a transgenic plant resistant to pest infestation (ii) cultivating the seeds into plants that bear flowers, (iii) preventing sell-pollination of at least one of the first or second adult plants, (iv) allowing cross-pollination to occur between the first and second plants; and (v) harvesting the seeds resulting from the cross-pollination. Hybrid seed produced by this method and hybrid plants produced by cultivating said seed are within the scope of the current invention. Hybrid plants produced by this method will typically be genetically uniform and are likely to exhibit heterosis or hybrid vigour. Thus, crops with the potential for increased yield may be generated by such a method.

[0173] According to another aspect of the current invention are provided transgenic plants resistant to infestation by insect pest species. In particular, provided herein are transgenic plants which express or are capable of expressing at least one interfering ribonucleic acid (RNA) that functions upon uptake by an insect pest species to down-regulate the expression of a target gene as described elsewhere herein within said pest. The interfering RNA may be any of those as disclosed elsewhere herein. Preferably, the interfering RNA comprises or consists of at least one silencing element and said silencing element is a region of double-stranded RNA comprises annealed complementary strands, one strand of which (the sense strand) comprises a sequence of nucleotides which is at least partially complementary to a target nucleotide sequence within a target gene. Damn-regulation of a pest target gene can be used to disrupt an essential biological process or function in the pest, wherein `essential` refers to the fact that the process or function is required for initiation or maintenance of pest infestation.

[0174] As used herein, the term `plant` may include any reproductive or propagation material for a plant. Reference to a plant may also include plant cells, plant protoplasts, plant tissue cultures, plant calli, plant clumps and plant cells that are intact in plants or parts of plants such as embryos, pollen, ovules, seeds, leaves, flowers, branches, fruit, kernels, ears, cobs, husks, stalks, roots, root tips and the lice. Progeny, variants and mutants of any of the transgenic plants described herein are within the scope of the current invention. Also included is seed produced from any of said transgenic plants.

[0175] Included within the group of transgenic plants of the current invention are transgenic plants produced by any of the methods described herein. Thus in one embodiment of the invention the transgenic plants comprise stacked transgenic traits carrying a first exogenous polynucleotide conferring pest resistance and al least one other exogenous polynucleotide or heterologous gene conferring an additional desirable plant trait. The additional heterologous genes may comprise genes encoding additional pesticidal agents, genes encoding proteins toxic or harmful to insect pest species and/or genes encoding proteins conferring herbicide resistance as described elsewhere herein.

[0176] Also provided herein is the use of the interfering ribonucleic acid (RNA) as described herein or the DNA construct as described herein for preventing and/or controlling insect pest infestation, preferably insect pest infestation of plants.

[0177] The invention will be further understood with reference to the following non-limiting examples.

Examples

Example 1 Identification of Tartlet Genes in Insect Pest Species

[0178] 1.1 Cloning of partial sequences of the Leptinotarsa decemlineata genes Nucleic acids were isolated from the gut cells of Colorado potato beetle, CPB, (Leptinotarsa decemlineata) larvae and a cDNA library was prepared. The gut cDNAs were cloned into the pGN49A vector (as described in WO01/88121) such that they were flanked by chemically-inducible T7 promoters, oppositely oriented at each end of the cDNA duplex. The recombinant vector constructs were transformed into cells of Escherichia coli strain AB301-105 (DE3). The transformed cells were subsequently diluted and plated so as to obtain single colonies or clones. The clones were checked to ensure that clone redundancy for the library did not exceed 5%, Between 3000 and 4000 clones were generated.

1.2 Testing the Effect of Bacterially-Expressed dsRNA Molecules on the Survival of Leptinotarsa Decemlineata Larvae

[0179] Multiwell plates were pre-filled with LB (Luria-broth) medium and each well was inoculated with a separate clone of transformed bacterial cells taken from the CPB cDNA library. The bacteria were grown at 28.degree. C. with shaking at 280 rpm, followed by a chemical induction step at 37.degree. C. After centrifugation, the resulting bacterial pellet was washed with water and subjected to a heat treatment to inactivate the bacteria.

[0180] The bacterial suspensions were tested for their effects on CPB larvae survival using an artificial diet, based feeding assay. A bacterial suspension produced from a single bacterial clone was topically applied to solid artificial diet in the wells of a multiwell plate and the diet was dried in a laminar flow cabinet. The effects of each clone were tested in triplicate. A single 2nd stage CPB larva was subsequently added to each well. The plates were stored in an insect rearing chamber at 25.+-.2.degree. C., 60.+-.5% relative humidity, with a 16:8 hours light:dark photoperiod. Bacterial cells transformed with an empty vector, pGN29 (WO01/88121), were used as controls. The survival of CPB larvae in each of the wells was assessed on day 14.

[0181] A number of bacterial clones exhibited high potency against CPB larvae indicating that the cDNAs encoding double-stranded RNAs contained therein are essential for pest survival and thus represent target genes of interest for the purposes of pest control. The DNA sequences and corresponding amino acid sequences of these target genes were therefore determined and are provided in Tables 1 and 2 respectively.

TABLE-US-00001 TABLE 1 Target cDNA Sequence (sense strand) ID 5' .fwdarw. 3' Ld556 SEQ ID NO 1 Ld513 SEQ ID NO 2 Ld504.2 SEQ ID NO 3 Ld520 SEQ ID NO 4 Ld537 SEQ ID NO 5 Ld334 SEQ ID NO 6 Ld327 SEQ ID NO 7 Ld502 SEQ ID NO 8 Ld516 SEQ ID NO 9 Ld579 SEQ ID NO 10 Ld332 SEQ ID NO 11 Ld237 SEQ ID NO 12 Ld261 SEQ ID NO 13 Ld300.1 SEQ ID NO 14 Ld423 SEQ ID NO 15 Ld511 SEQ ID NO 16 Ld512 SEQ ID NO 17 Ld563 SEQ ID NO 18 Ld105 SEQ ID NO 19 Ld248 SEQ ID NO 20

TABLE-US-00002 TABLE 2 Target Corresponding amino acid sequence of ID cDNA clone as represented in Table 1 Ld556 SEQ ID NO 206 (frame + 2) Ld513 SEQ ID NO 207 (frame + 3) Ld504.2 SEQ ID NO 208 (frame + 2) Ld520 SEQ ID NO 209 (frame + 3) Ld537 SEQ ID NO 210 (frame + 1) Ld334 SEQ ID NO 211 (frame + 1) Ld327 SEQ ID NO 212 (frame + 3) Ld502 SEQ ID NO 213 (frame + 2) Ld516 SEQ ID NO 214 (frame + 3) Ld579 SEQ ID NO 215 (frame + 1) Ld332 SEQ ID NO 216 (frame + 3) Ld237 SEQ ID NO 217 (frame + 2) Ld261 SEQ ID NO 218 (frame + 3) Ld300.1 SEQ ID NO 219 (frame + 3) Ld423 SEQ ID NO 220 (frame + 1) Ld511 SEQ ID NO 221 (frame + 3) Ld512 SEQ ID NO 222 (frame + 3) Ld563 SEQ ID NO 223 (frame + 1) Ld105 SEQ ID NO 224 (frame + 1) Ld248 SEQ ID NO 225 (frame + 1)

1.3 Design of Degenerate Primers for Cloning Lygus hesperus Orthologous Sequences

[0182] A protein (blastp) search was performed for each target gene of Interest by searching non-redundant protein databases of Arthropods using the protein sequence corresponding to each of the Leptinotarsa decemlineata targets. A selection of up to twenty protein sequences was made from the best hits which represented a diversity of insect species.

[0183] These sequences were first processed into blocks using the "Blockmaker" program (http://bioinfo.weizmann.ac.ll/blockmkr-binimakeblocits.pl) which generated multiple sequence alignments and analyses of the protein sequences for regions of conservation.

[0184] Blocks of conserved amino acid sequences were submitted to CodeHop (http://blocks.fhcrc.org/codehop.html). From the output of degenerate primers a selection of up to ten forward and ten reverse primers for each target was produced.

1.4 Cloning of Partial Sequences of the Lygus hesperus Genes by Family PCR

[0185] High quality, intact RNA was isolated from 1st instar nymphs of Lygus hesperus. Any genomic DNA present in the RNA preparation was removed by RNase treatment. cDNA was generated using Reverse Transcriptase. To isolate cDNA sequences comprising a segment of the Lh513, Lh504.2, Lh520, Lh537, Lh334, Lh327, Lh579, Lh332, Lh237, Lh261, Lh300.1, Lh423, Lh512, Lh105 and Lh248 genes, a series of PCR reactions with degenerate primers was performed.

[0186] The resulting PCR fragments were analyzed on agarose gel, purified and sequenced. The sequences of the resulting PCR products are represented by the respective SEQ ID NOs as provided in Table 3 and are referred to as the partial sequences. The corresponding partial amino acid sequences are represented by the respective SKI ID NOs as provided in Table 4.

TABLE-US-00003 TABLE 3 Target cDNA Sequence (sense strand) ID 5' .fwdarw. 3' Lh513.1 SEQ ID NO 121 Lh513.2 SEQ ID NO 122 Lh564.2 SEQ ID NO 123 Lh520 SEQ ID NO 124 Lh537.1 SEQ ID NO 125 Lh537.2 SEQ ID NO 126 Lh537.3 SEQ ID NO 127 Lh537.4 SEQ ID NO 128 Lh537.5 SEQ ID NO 129 Lh334 SEQ ID NO 130 Lh327 SEQ ID NO 131 Lh579.1 SEQ ID NO 132 Lh579.2 SEQ ID NO 133 Lh332 SEQ ID NO 134 Lh237 SEQ ID NO 135 Lh261 SEQ ID NO 136 Lh300.1 SEQ ID NO 137 Lh423 SEQ ID NO 138 Lh423.2 SEQ ID NO 253 Lh512.1 SEQ ID NO 139 Lh512.2 SEQ ID NO 140 Lh105 SEQ ID NO 251 Lh248 SEQ ID NO 252

TABLE-US-00004 TABLE 4 corresponding amino acid sequence of cDNA clone Target ID as represented in Table 3 Lh513.1 SEQ ID NO 226 Lh513.2 SEQ ID NO 227 Lh504.2 SEQ ID NO 228 Lh520 SEQ ID NO 229 Lh537.1 SEQ ID NO 230 Lh537.2 and SEQ ID NO 231 Lh537.3 Lh537.4 SEQ ID NO 232 Lh537.5 SEQ ID NO 233 Lh334 SEQ ID NO 234 Lh327 SEQ ID NO 235 Lh579.1 SEQ ID NO 236 Lh579.2 SEQ ID NO 237 Lh332 SEQ ID NO 238 Lh237 SEQ ID NO 239 Lh261 SEQ ID NO 240 Lh300.1 SEQ ID NO 241 Lh423 SEQ ID NO 242 Lh423.2 SEQ ID NO 271 Lh512.1 SEQ ID NO 243 Lh512.2 SEQ ID NO 244 Lh105 SEQ ID NO 269 Lh248 SEQ ID NO 270

1.5 Full Length cDNA Cloning by RACE (Rapid Amplification of cDNA Ends)

[0187] In order to clone full length cDNA, starting from a known clone of internal fragment from the most potent targets, the 5'/3' RACE kit was used (Roche, Cat. No. 1 734 792; based on Sambrook, J. & Russell, D. M). The standard protocol, described in the instruction Manual, was followed. Briefly, for a 5' RACE, a target sequence specific antisense primer was designed on the known sequence and used for a first strand cDNA synthesis, using Lygus RNA as template. A tail was added to the first strand cDNA and used as an anchor for the second strand synthesis and amplification of an unknown end portion of the transcript. For a 3' RACE, an oligo dT anchor primer was used for the first strand cDNA synthesis. For the 5' and 3' RACES, nested primers, specific to the target sequence were used in a second PCR reaction. The PCR fragments were analysed on agarose gel, purified, cloned and sequenced for confirmation.

[0188] Full length cDNA sequences corresponding to the Lygus targets listed in Table 13 were assembled in VectorNTI, a fully integrated sequence analysis software package for DNA sequence analysis (Invitrogen). The nucleotide sequences resulting from the assemblies are provided in Table 14 and the corresponding amino acid sequences are provided in Table 15.

TABLE-US-00005 TABLE 13 Target Dm ID orthologue NAME SYMBOL Lh049 CG8055 shrub-snf7 (vesicle trafficking) shrb Lh248 CG6699 beta'-coatomer protein beta'Cop Lh105 CG1250 sec23 sec23 Lh300 CG6213 vacuolar H[+] ATPase G-subunit Vha13 Lh327 CG6223 beta-coatomer protein betaCop Lh423 CG2746 ribosomal protein L19 RpL19 Lh504 CG5271 ribosomal protein S27A RpS27A Lh520 CG2960 ribosomal protein L40 RpL40

TABLE-US-00006 TABLE 14 Target cDNA Sequence (sense strand) ID 5' .fwdarw. 3' Lh049 SEQ ID NO 280 Lh248 SEQ ID NO 279 Lh105 SEQ ID NO 278 Lh300 SEQ ID NO 276 Lh327 SEQ ID NO 275 Lh423 SEQ ID NO 277 Lh504 SEQ ID NO 273 Lh520 SEQ ID NO 274

TABLE-US-00007 TABLE 15 Target Corresponding amino acid sequence to ID cDNA, as respresented in Table 14 Lh049 SEQ ID NO 288 Lh248 SEQ ID NO 287 Lh105 SEQ ID NO 286 Lh300 SEQ ID NO 284 Lh327 SEQ ID NO 283 Lh423 SEQ ID NO 285 Lh504 SEQ ID NO 281 Lh520 SEQ ID NO 282

Example 2 In Vitro Production of Double-Stranded RNAs for Gene Silencing

[0189] 2.1 Production of dsRNAs Corresponding to the Partial Sequences of the Leptinotarsa decemlineata and Lygus hesperus Target Genes

[0190] Double-stranded RNA was synthesized in milligram quantities. First, two separate 5' T7 RNA polymerase promoter templates (a sense template and an antisense template) were generated by PCR. PCRs were designed and carried out so as to produce sense and antisense template polynucleotides, each having the T7 promoter in a different orientation relative to the target sequence to be transcribed.

[0191] For each of the target genes, the sense template was generated using a target-specific T7 forward primer and a target-specific reverse primer. The antisense templates were generated using target-specific forward primers and target-specific T7 reverse primers. The sequences of the respective primers for amplifying the sense and antisense templates via PCR for each of the target genes are provided in Table 5 (for Leptinotarsa decemlineata cDNAs) and in Table 6 (for Lygus hesperus cDNAs). The PCR products were analysed by agarose gel electrophoresis and purified. The resultant T7 sense and antisense templates were mixed and transcribed by the addition of T7 RNA polymerase. The single-stranded RNAs produced by transcription from the templates were allowed to anneal, were treated with DNase and RNase, and were purified by precipitation. The sense strand of the resulting dsRNA produced from each of the target genes is provided in Table 5 (tor Leptinotarsa decemlineata) and in Table 6 (for Lygus hesperus).

TABLE-US-00008 TABLE 5 dsRNA: sense strand represented Primers Primers by equivalent Target Forward Reverse DNA Sequence ID 5' .fwdarw. 3' 5' .fwdarw. 3' 5' .fwdarw. 3' Ld556 SEQ ID NO 41 SEQ ID NO 42 SEQ ID NO 21 SEQ ID NO 43 SEQ ID NO 44 Ld513 SEQ ID NO 45 SEQ ID NO 46 SEQ ID NO 22 SEQ ID NO 47 SEQ ID NO 48 Ld504.2 SEQ ID NO 49 SEQ ID NO 50 SEQ ID NO 23 SEQ ID NO 51 SEQ ID NO 52 Ld520 SEQ ID NO 53 SEQ ID NO 54 SEQ ID NO 24 SEQ ID NO 55 SEQ ID NO 56 Ld537 SEQ ID NO 57 SEQ ID NO 58 SEQ ID NO 25 SEQ ID NO 59 SEQ ID NO 60 Ld334 SEQ ID NO 61 SEQ ID NO 62 SEQ ID NO 26 SEQ ID NO 63 SEQ ID NO 64 Ld327 SEQ ID NO 65 SEQ ID NO 66 SEQ ID NO 27 SEQ ID NO 67 SEQ ID NO 68 Ld502 SEQ ID NO 69 SEQ ID NO 70 SEQ ID NO 28 SEQ ID NO 71 SEQ ID NO 72 Ld516 SEQ ID NO 73 SEQ ID NO 74 SEQ ID NO 29 SEQ ID NO 75 SEQ ID NO 76 Ld579 SEQ ID NO 77 SEQ ID NO 78 SEQ ID NO 30 SEQ ID NO 79 SEQ ID NO 80 Ld332 SEQ ID NO 81 SEQ ID NO 82 SEQ ID NO 31 SEQ ID NO 83 SEQ ID NO 84 Ld237 SEQ ID NO 85 SEQ ID NO 86 SEQ ID NO 32 SEQ ID NO 87 SEQ ID NO 88 Ld261 SEQ ID NO 89 SEQ ID NO 90 SEQ ID NO 33 SEQ ID NO 91 SEQ ID NO 92 Ld300.1 SEQ ID NO 93 SEQ ID NO 94 SEQ ID NO 34 SEQ ID NO 95 SEQ ID NO 96 Ld423 SEQ ID NO 97 SEQ ID NO 98 SEQ ID NO 35 SEQ ID NO 99 SEQ ID NO 100 Ld511 SEQ ID NO 101 SEQ ID NO 102 SEQ ID NO 36 SEQ ID NO 103 SEQ 10 NO 104 Ld512 SEQ ID NO 105 SEQ ID NO 106 SEQ ID NO 37 SEQ ID NO 107 SEQ ID NO 108 Ld563 SEQ ID NO 109 SEQ ID NO 110 SEQ ID NO 38 SEQ ID NO 111 SEQ ID NO 112 Ld105 SEQ ID NO 113 SEQ ID NO 114 SEQ ID NO 39 SEQ ID NO 115 SEQ ID NO 116 Ld248 SEQ ID NO 117 SEQ ID NO 118 SEQ ID NO 40 SEQ ID NO 119 SEQ ID NO 120

TABLE-US-00009 TABLE 6 dsRNA: sense strand represented Primers Primers by equivalent Target Forward Reverse DNA Sequence ID 5' .fwdarw. 3' 5' .fwdarw. 3' 5' .fwdarw. 3' Lh513 SEQ ID NO 154 SEQ ID NO 155 SEQ ID NO 141 SEQ ID NO 156 SEQ ID NO 157 Lh504.2 SEQ ID NO 158 SEQ ID NO 159 SEQ ID NO 142 SEQ ID NO 160 SEQ ID NO161 Lh520 SEQ ID NO 162 SEQ ID NO 163 SEQ ID NO 143 SEQ ID NO 164 SEQ ID NO 165 Lh537 SEQ ID NO 166 SEQ ID NO 167 SEQ ID NO 144 SEQ ID NO 168 SEQ ID NO 169 Lh334 SEQ ID NO 170 SEQ ID NO 171 SEQ ID NO 145 SEQ ID NO 172 SEQ ID NO 173 Lh327 SEQ ID NO 174 SEQ ID NO 175 SEQ ID NO 146 SEQ ID NO 176 SEQ ID NO 177 Lh579 SEQ ID NO 178 SEQ ID NO 179 SEQ ID NO 147 SEQ ID NO 180 SEQ ID NO 181 Lh332 SEQ ID NO 182 SEQ ID NO 183 SEQ ID NO 148 SEQ ID NO 184 SEQ ID NO 185 Lh237 SEQ ID NO 186 SEQ ID NO 187 SEQ ID NO 149 SEQ ID NO 188 SEQ ID NO 189 Lh261 SEQ ID NO 190 SEQ ID NO 191 SEQ ID NO 150 SEQ ID NO 192 SEQ ID NO 193 Lh300.1 SEQ ID NO 194 SEQ ID NO 195 SEQ ID NO 151 SEQ ID NO 196 SEQ ID NO 197 Lh423 SEQ ID NO 198 SEQ ID NO 199 SEQ ID NO 152 SEQ ID NO 200 SEQ ID NO 201 Lh512 SEQ ID NO 202 SEQ ID NO 203 SEQ ID NO 153 SEQ ID NO 204 SEQ ID NO 205 Lh105.2 SEQ ID NO 257 SEQ ID NO 258 SEQ ID NO 254 SEQ ID NO 259 SEQ ID NO 260 Lh248.2 SEQ ID NO 261 SEQ ID NO 262 SEQ ID NO 255 SEQ ID NO 263 SEQ ID NO 264 Lh248.3 SEQ ID NO 265 SEQ ID NO 266 SEQ ID NO 256 SEQ ID NO 267 SEQ ID NO 268 GFP SEQ ID NO 246 SEQ ID NO 247 SEQ ID NO 245 SEQ ID NO 248 SEQ ID NO 249

Example 3 Down-Regulating Expression of Target Aeries in Leptinotarsa decemlineata as a Means to Achieve Nest Control

[0192] 3.1 Testing of in Vitro-Synthesized dsRNA Molecules for Activity Against Leptinotarsa decemlineata Larvae

[0193] In vitro-synthesized dsRNAs transcribed from template polynucleotides derived from target genes identified according to the methods of Example 1 were tested for effects on the survival of CPB larvae using feeding assays. Briefly, artificial diet-based assays were carried out as follow. To each well of a 48-well plate was added 0.5 ml artificial diet pre-treated by topical application of 1000 ng/cm.sup.2 synthetic dsRNA in 25 .mu.L. A single L2 larva was added to each well. dsRNAs derived from a variety of target genes were tested using this method and 24 larvae were tested for each dsRNA. The total numbers of surviving larvae were counted at regular intervals up to 14 days alter the start of feeding. The time taken for each dsRNA to kill 50% of treated larvae (LT.sub.50) was calculated for each target gene investigated and compared to the LT.sub.50 for a reference target gene (Ld248) previously described in WO2007/074405. The results are presented in Table 7.

TABLE-US-00010 TABLE 7 LT.sub.50 target X/ dsRNA Dm.sup.1 LT.sub.50 target length Rank Target orthologue Name/Description (FlyBase) Ld248 (bp) 1 Ld556 CG11415 Tsp2A; Tetraspanin 2A, putative 0.60 558 transmembrane domain protein 2 Ld513 CG5409 & Protein belonging to the actin 0.67 320 others family; structural constituent of cytoskeleton 3 Ld504.2 CG5271 Ribosomal protein S27A; 0.70 490 structural constituent of rbosome 4 Ld520 CG2960 Ribosomal protein L40; structural 0.70 231 constituent of ribosome 5 Ld537 CG32744 Ubiquitin-5E; protein modification 0.77 571 process 6 Ld334 CG3948 .zeta.-coatomer of COPI vesicle 0.80 542 7 Ld327 CG6223 .beta.-coatomer of COPI vesicle 0.83 747 8 Ld105 CG1250 Sec23; GTPase activator involved 0.85 1504 in intracellular protein transport 9 Ld502 CG7595 Crinkled protein; unconventional 0.90 393 myosin involved in motor activity 10 Ld516 CG118138 Rpn2; proteasome regulatory 0.90 779 particle 11 Ld579 CG8392 Proteasome .beta.1 subunit 0.90 392 12 Ld332 CG1528 .gamma.-coatomer of COPI vesicle 0.90 178 13 Ld237 CG10149 Rpn6; proteasome p44.5 subunit 0.90 559 14 Ld261 CG5266 Pros25; proteasome 25kD subunit 0.90 586 15 Ld300.1 CG6213 Vacuolar H--ATPase G-subunit 1.00 267 16 Ld248 CG6699 .beta.'-coatomer protein 1.00 967 17 Ld423 CG2746 Ribosomal protein L19 1.00 603 18 Ld511 CG3329 Pros.beta.2; proteasome .beta.2 subunit 1.02 273 .sup.1Drosophila melanogasler

[0194] From these results, it can be concluded that dsRNAs targeting the CPB genes identified in Example 1 are more potent or at least as potent as reference CPB target genes that have been previously reported in WO2007/074405 i.e. in the majority of cases, the `time-to-kill` CPB larvae was shorter than for the reference targets Ld105 and Ld248 (as previously described in WO2007/074405: Ld105=[Target ID NO LD010], Ld248=[Target ID NO LD027]). The efficacy against CPB larvae alter dsRNA consumption differed depending on the nature of the gene targeted.

3.2 Testing of in Vitro-Synthesized dsRNA Molecules for Activity Against Leptinotarsa decemlineata Adults

[0195] The data provided below exemplify the findings that ingested dsRNAs produced from template polynucleotides derived from a variety of CPB target genes adversely affected the survival, fitness, feeding behaviour, mating behaviour, egg production and offspring generation of CPB adults.

[0196] Various gene targets selected from the larvae gut cDNA expression library and as shown above in Example 3.1 to be effective for the purposes of killing CPB larvae, were tested in order to assess the effects of gene down-regulation in adult beetles. Gene targets identified as important in both CPB larvae and adult beetles are of particular interest since they may be used to control and/or prevent insect pest infestation at different stages of an insect's life-cycle.

[0197] Briefly, a leaf disc assay to test the effects of dsRNA molecules derived from various target genes, against adult beetles was set up as follows. A potato leaf disc, diameter 1.5 cm, treated with 5 .mu.g of in vitro-synthesized target dsRNA provided in 20 .mu.L, was placed in a well of a 6-well plate together with a week-old CPB adult. After a few hours, once the leaf disc had been entirely consumed by the insect, another leaf disc treated with 5 .mu.g of in vitro-synthesized target dsRNA was presented to the adult. For each dsRNA to be tested, a total of ten young adult beetles (a mix of males and females) were exposed to treated leaf discs. The following day, after the second treated leaf disc had been entirely consumed, the ten adults in each treatment group were pooled in the same box and fed abundant untreated potato foliage. Adult beetles fed dsRNA derived from the GFP gene were used as controls in this assay.

[0198] The numbers of surviving and/or moribund adult insects were counted at regular intervals from day 4 up to 14 days after the start of the feeding assay. CPB adults were classified as moribund if they appeared sick and less mobile than healthy adults and were not able to right themselves when placed on their backs for longer than one minute. Effects on feeding, mating, egg production and hatching were also assessed at regular intervals from day 4,

Mortality and Moribundity

[0199] The percentage of moribund and/or dead CPB adults assessed over a 14-day period for each target gene tested are shown in FIG. 1. In addition, the lime taken to achieve 50% mortality of adult beetles (LT.sub.50) in each treatment group was calculated and the results shown in Table 8 are presented as a ratio based on the LT.sub.50 calculated for a reference target gene previously described in WO2007/074405.

TABLE-US-00011 TABLE 8 LT.sub.50 target X/ dsRNA Dm LT.sub.50 target length Rank Target orthologue Name/Description (FlyBase) Ld248 (bp) 1 Ld537 CG32744 Ubiquitin-5E: protein modification 0.63 571 process 2 Ld520 CG2960 Ribosomal protein L40; structural 0.70 231 constituent of ribosome 3 Ld516 CG11888 Rpn2; eproteasome regulatory 0.74 779 particle 4 Ld512 CG10370 Tbp-1; Tat-binding protein 0.74 310 5 Ld511 CG3329 Pros.beta.2; proteasome .beta.2 subunit 0.77 273 6 Ld579 CG8392 Proteasome .beta.1 subunit 0.87 392 7 Ld513 CG5409 & Protein belonging to the actin family; 0.88 320 others structural constituent of cytoskelelon 8 Ld248 CG6699 .beta.'-coatomer protein 1.00 967 9 Ld563 CG3193 Crooked neck protein; involved in 1.05 388 regulation of nuclear alternative mRNA splicing 10 Ld105 CG1250 Sec23; GTPase activator involved in 1.06 1504 intracellular protein transport

[0200] From these results, it can be concluded that dsRNAs targeting a variety of CPB genes identified in Example 1 are more potent or at least as potent as reference CPB target genes that have been previously reported in the WO2007/074405 i.e. in the majority of cases, the `lime-to-kill` CPB adults was shorter than for the reference targets Ld105 and Ld248 (as previously described in WO2007/074405: Ld105=[Target ID NO LD010], Ld248=[Target ID NO L0027]). The efficacy against CPB adults after dsRNA consumption differed depending on the nature of the gene targeted.

Feeding Inhibition

[0201] For all target genes of interest, complete cessation of feeding by CPB adults was observed from day 5 onwards of the assay (4 days after the treated potato foliage was replaced by untreated potato foliage). Control CPB adults ted as normal throughout the assay.

Mating, Egg Production, and Egg Hatching,

[0202] Mating, egg production, and egg hatching were assessed throughout the 14-day time-course of the assay. The results are shown in Table 9.

TABLE-US-00012 TABLE 9 Target Day 4 Day 5 Day 6 Day 7 Day 8 Day 14 Ld105 EM SE none none none none Ld248 EM YS YS none none none Ld516 EM SE none none none none Ld511 EM & SE YS none none none none Ld512 EM & SE SE SE none none none Ld513 EM & SE none none none none none Ld520 SE none none none none none Ld537 EM & SE SE none none none none Ld563 none SE none none none none Ld579 EM SE SE none none none GFP EM EM EM EM EM EM

[0203] From day 5 onwards, no mating was observed in CPB adults in the treated groups, however, mating of CPB adults in the GFP control group was as normal.

[0204] On day 4, normal egg masses (with 20-30 eggs per egg mass) were observed in groups treated with dsRNAs targeting Ld105, Ld248, Ld516. Ld579, and GFP. (These egg masses were laid between days 1 and 3 of the assay.) However, for the groups treated with dsRNAs targeting Ld511, Ld512, Ld513, and Ld537, a mixture of normal egg masses and single eggs were found. No normal egg masses were observed in the CPB group treated with dsRNA targeting Ld520; only individual single eggs were observed.

[0205] Eggs identified on day 4 were harvested and both hatching frequency and larval survival were assessed. In all treatment groups for which normal egg masses were harvested, hatching was 100% except for the Ld537 group in which only 50% of eggs in the single egg mass harvested went on to hatch. All larvae from these egg masses developed normally.

[0206] For groups in which Ld511 and Ld537 were the target genes of interest, less than 10% of the single eggs hatched and these larvae died within 7 days after hatching. For the groups in which the target genes were Ld512, Ld520 and Ld513, the hatching frequency was 30%, 70% and 100% respectively.

[0207] On day 5, no egg masses were observed in any of the treatment groups except for the GFP control. However, single eggs were present in the groups wherein the target genes were Ld105, Ld516, Ld512, Ld537, Ld563, and Ld579. A yellow smear (indicative of no intact eggs) was visible in the leading chambers of insects in the groups treated with dsRNAs targeting Ld248 and Ld511. In the groups for whet Ld513 and Ld520 were the target genes, no eggs were discovered.

[0208] Eggs identified on day 5 were harvested and both hatching frequency and larval survival were assessed. For groups with target genes Ld512, Ld516, and Ld563, hatching was between 20 and 50%, but all larvae in group Ld563 died within 7 days of hatching. For the group with Ld579 as the gene target, all eggs hatched and larvae developed as normal.

[0209] On day 6, only single eggs were identified in the treatment groups wherein the target genes were Ld512 and Ld579. A yellow smear was noted in the Ld248 target group. No eggs were present in any of the other treatment groups. From day 7 onwards, no eggs were laid by any of the treated adult beetles. However, GFP dsRNA-treated control females continued to lay normal egg masses throughout the assay.

Example 4 Down-Regulating Expression of Tweet Aeries in Lygus hesperus by Ingestion of dsRNA as a Means to Achieve Pest Control

[0210] 4.1 Modification of the Lygus hesperus Feeding Assay to Allow for More Effective Uptake of dsRNA Molecules

[0211] Although the rearing diet from BioServ used in maintaining the Lygus cultures over many generations is effective, this diet may not be appropriate for testing candidate dsRNA molecules in a feeding assay. The oligidic diet includes ingredients which are not chemically defined and therefore some components may possibly interact with the molecules to be delivered to the nymphs. Therefore, the Lygus feeding assay has been modified such that it consists of two phases: an initial exposure of early instar nymphs to dsRNA molecules in a simplified diet (15% sucrose only) for three days followed by transfer of the nymphs to a normal oligidic Lygus diet for the remainder of the assay.

4.2 Effects of Various Target dsRNAs Plus Yeast tRNA on Lygus hesperus Survival

[0212] Lygus hesperus nymphs were exposed to 0.5 .mu.g/.mu.L dsRNA derived a number of Lygus hesperus target genes as described herein in the presence of 5 .mu.g/.mu.L yeast tRNA (Sigma) in a feeding assay (FIG. 2). Controls are GFP dsRNA plus yeast tRNA at the same concentrations, respectively, and diet only treatments. Young nymphs were each exposed to 25 .mu.L of 15% sucrose diet with or without incorporated test components for three days prior to transferring them on to 50 .mu.L complex (Bioserv) diet. Complex diet was refreshed on day 7.

[0213] In this assay, ingested dsRNA from all tested targets in combination with tRNA led to high mortalities of L. hesperus nymphs when compared to the GFP dsRNA or diet only control treatments (Table 10).

TABLE-US-00013 TABLE 10 DsRNA Log-rank test (versus GFP) Target length Chi P- significant ID (bp) square value difference?.sup..dagger. Lh520 231 18.04 <0.0001 *** Lh423 511 17.11 <0.0001 *** Lh537 300 14.63 0.0001 *** Lh504.2 168 12.99 0.0003 *** Lh512 495 11.86 0.0006 *** Lh334 172 10.39 0.0013 ** Lh300.1 235 10.22 0.0014 ** Lh327 408 9.153 0.0025 ** Lh332 1041 7.972 0.0047 ** Lh237 710 5.793 0.0161 * Lh579 273 5.336 0.0209 * Lh261 368 3.928 0.0475 * Lh513 625 2.144 0.1432 ns diet / 1.483 0.2233 ns only .sup..dagger.survival curves significantly different? *** = extremely significant, ** = very significant, * = significant, ns = not significant

[0214] A table which ranks the targets according to potency is made based upon the results of this RNAi-by-assay (Table 11 and FIG. 3).

TABLE-US-00014 TABLE 11 % dsRNA D. Survival length melanogaster range at Target (bp) orthologue Description (Flyease) day 10 Figure Lh423 511 CG2746 Ribosomal protein L19 0-15 3 A Lh520 231 CG2960 Ribosomal protein L40 Lh504.2 168 CG5271 Ribosomal proteinS27A 16-30 3 B Lh537 300 CG32744 Ubiquitin-5E Lh512 495 CG10370 Tbp-1, Tat-binding protein Lh300.1 235 CG6213 Vacuolar H.sup.+-ATPase G subunit Lh327 408 CG6223 .beta.-coatomer of COPI 3 C vesicle Lh334 172 CG3948 .zeta.-coatomer of COPI vesicle Lh332 1041 CG1528 .gamma.-coatomer of COPI vesicle Lh579 273 CG8392 Proteasome .beta.1 subunit 31-45 3 D Lh237 710 CG10149 Rpn6, proteasome p44.5 subunit Lh261 368 CG5266 Pros25, proteasome >45 3 D 25 kD subunit Lh513 625 CG4027 Actin 5C

[0215] In another RNAi-by-feeding assay under the same conditions as described hereabove, we tested the effects of Lh105 and Lh248 target dsRNA on Lygus hesperus nymphal survival. Double-Stranded RNA from targets Lh105 and Lh248 at 0.5 .mu.g/.mu.L in the presence of 5 .mu.g/.mu.l of tRNA fed to significant L. hesperus nymphal lethality at day 10 in a feeding assay (83% for Lh105.2 dsRNA and 58% for Lh248.2 dsRNA and 71% for 0248.3 dsRNA) (FIG. 6). In the same assay, Lh327 and 0300 dsRNA showed only 4% and 13% survivors, respectively, at the end of the bioassay (FIG. 6).

4.3 Dose-Response Relationship Over Time of Target dsRNA Against Lygus Hesperus Nymphs in RNAI-by-Feeding Assays

[0216] The dose-response relationship was studied to determine the L. hesperus nymphs' susceptibility to lowering dsRNA concentrations of test targets in RNAI-by-feeding assays. The data are graphically represented in FIGS. 4 and 5. The Kaplan-Meier estimated survival curves of the test targets at the low concentrations of 0.1, 0.05 and 0.025 .mu.g/.mu.L were compared with those of GFP dsRNA control at 0.1 .mu.g/.mu.l, using the log rank test (Table 12).

TABLE-US-00015 TABLE 12 Target Dose dsRNA.sup.1 (.mu.g/.mu.L) X.sup.2 P-value Significance Lh423 0.1 30.36 <0.0001 *** 0.05 6.759 0.0093 ** 0.025 6.239 0.0125 * Lh504.2 0.1 5.828 0.0158 * 0.05 0.7283 0.3934 ns 0.025 0.4834 0.4869 ns Lh537 0.1 2.150 0.1426 ns 0.05 2.150 0.1426 ns 0.025 0.007874 0.9293 ns Lh327 0.1 13.80 0.0002 *** 0.05 6.176 0.0129 * 0.025 3.000 0.0833 ns Lh520 0.1 12.65 0.0004 *** 0.05 2.944 0.0862 ns 0.025 1.893 0.1689 ns Lh300.1 0.1 12.24 0.0005 *** 0.05 10.81 0.0010 ** 0.025 1.615 0.2038 ns .sup.1in the presence of 5 .mu.g/.mu.L of yeast transfer RNA

[0217] All targets tested were toxic towards L. hesperus nymphs at concentrations as low as 0.1 .mu.g/.mu.L. Target Lh423 dsRNA at this concentration yielded under 10% nymphal survival towards the end of the bioassays. At the lowest concentration tested, i.e. 0.025 .mu.g/.mu.L, target Lh423 still showed a significant drop in survival when compared to GFP. Double-stranded RNAs from targets Lh300.1 and Lh327 also demonstrated high potency at low concentrations with significant drops in survival at 0.05 .mu.g/.mu.L.

Example 5 Generation of Plants Resistant to Insect Pest Suedes

[0218] 5.1 Assembly of Plant Expression Vectors Comprising a Lygus hesperus Hairpin Sequence or Leptinotarsa decemlineata Hairpin Sequence for Transformation of Potato or Cotton

[0219] Since the mechanism of RNA interference operates through dsRNA fragments, the target polynucleotide sequences were cloned in anti-sense and sense orientation, separated by an intron (SEQ ID NO 250), to form a dsRNA hairpin construct. The dsRNA hairpin constructs encoding the L. hesperus dsRNA molecule derived from the target genes as mentioned herein were subcloned into a plant expression vector. Similarly a GUS dsRNA hairpin control construct, wherein the sense polynucleotide sequence encoding GUS (SEQ ID NO 272) was cloned in anti-sense and sense orientation, separated by the same intron (SEQ ID NO 250), was subcloned into a plant expression vector.

[0220] The plant expression vector comprises as well elements necessary for the maintenance of the plasmid in a bacterial cell. The dsRNA hairpin construct is located between the tell border (LB) and right border (RB), 3' downstream from the Cauliflower Mosaic Virus 35S promoter (P35S) and 5' upstream from the TNOS terminator. A GFP reporter expression cassette comprising the GFP sequence flanked by the P35S promoter and terminator was subcloned into the plant transformation vector harbouring the L. hesperus hairpin cassette. The NPT II expression cassette comprising the NPT II sequence flanked by the P35S promoter and terminator is used for selecting plants that have been effectively transformed. Correct assembly of the genetic fragments in the plant expression vector was confirmed by sequencing (FIG. 7).

[0221] The plant expression vectors comprising the individual L. hesperus target hairpins were subsequently transformed into Agrobacterium tumefaciens. For all L. hesperus target genes mentioned herein, fragments can be selected and cloned as hairpins in a similar manner.

5.2 Transformation of Potato with a Plant Expression Vector Comprising a Lygus hesperus Hairpin Sequence or Leptinotarsa decemlineata Hairpin Sequence and Testing of the Transformed Potato Plants for Resistance Towards L. hesperus or Leptinotarsa decemlineata

[0222] The example provided below is an exemplification of the finding that transgenic potato plants expressing target gene-specific hairpin RNAs adversely affect survival and/or development of insect pest species.

Lygus hesperus RNAi-by-Feeding in Planta

Potato Transformation

[0223] Stably transformed potato plants were obtained using an adapted protocol received through Julie Gilbert at the NSF Potato Genome Project (http://www.potatogenome.org/nsl5). Stem internode explants of potato `Line V` (originally obtained from the Laboratory of Plant Breeding al PRI Wageningen, the Netherlands) which was derived from the susceptible diploid Solanum tuberosum 6487-9 was used as starting material for transformation, to vitro-derived explants were inoculated with Agrobacterium tumelaciens C58C.sub.1Ril.RTM. containing the hairpin constructs. After three days co-cultivation, the explants were put onto a selective medium containing 100 mg/L Kanamycin and 300 mg/L Timentin. After 6 weeks post-transformation, the first putative shoots were removed and rooted on selective medium. Shoots originating tram different explants were treated as independent events, shoots originating from the same callus were termed `siblings` until their clonal status could be verified by Southern blotting, and nodal cuttings of a shoot were referred to as `clones`.

[0224] The transgenic status of the rooting shoots was checked either by GFP fluorescence and by plus/minus PCR for the inserted target sequence. Positive shoots were then clonally propagated in tissue culture to ensure enough replicates were available for the Lygus hesperus or Leptinotarsa decemlineata assays. These shoots were kept in tissue culture medium for greater flexibility to test for resistance towards Lygus nymphs/adults or L. decemlineata larvae/adults. The first plants were available to test fourteen weeks post transformation.

Bioassay

[0225] Following the positive results obtained in the dsRNA feeding experiments proof-of-principle in planta experiments were initiated.

[0226] The plantlets were analysed by PCR to confirm the integration of the T-DNA and the presence of the hairpin, before being propagated. Excess explants were produced with the aim of obtaining al least 30 independent events for each construct.

[0227] The in planta assay lar Lygus hesperus was developed with in vitro potato plantlets which sustained insect survival al least 8 days, keeping background mortality low. L. hesperus nymphs survived and fed on wild type potato plantlets. This was supported by the visual damage caused by insects which was observed on the leaves and buds (FIG. 8).

[0228] In the assay, L. hesperus was fed with transgenic potato, expressing hairpin dsRNA targeting the L. hesperus targets identified herein. Plasmids carrying hairpin constructs and a GUS control were generated.

[0229] Young transgenic potato plants were kept in tissue culture medium in a plant growth room chamber with the following conditions: 25.+-.1.degree. C., 50.+-.5% relative humidity, 16:8 hour light:dark photoperiod. Per construct, a number of events, in this case 30 (P008/XX), were generated with a suitable number of clones (more than 20) per event. A number of young Lygus nymphs/adults were placed on the individually caged young (for example, at the 4-5 unfolded leaf stage) potato plants and tell for at least seven days. The resistance towards Lygus hesperus was assessed regularly over the period of the assay in terms of reduced nymph/adult survival, delayed development and stunted growth, and/or decreased plant feeding damage. FIG. 9 specifically shows L. hesperus nymph survival. The transgenic events were compared to the control GUS hairpin transformed events (P001/XX) and the wild type potatoes (FIG. 9 and FIG. 10).

[0230] A bioassay for testing transgenic plants, transformed with L. decemlineata specific hairpin constructs, for resistance against L. decemlineata larvae or adults is done in the same way as described for L. hesperus.

5.3 Transformation of Cotton with a Plant Expression Vector Comprising a Lygus hesperus Hairpin Sequence and Testing of the Transformed Cotton Callus Material or Plants for Resistance Towards L. hesperus

[0231] The example provided below is an exemplification of the finding that transgenic cotton plants or callus expressing target gene-specific hairpin RNAs adversely affect survival and/or development of Insect pest species.

Cotton Transformation

[0232] Coker 312 seed is surface sterilized using first, a 5 minute wash in 70% ethanol and then shaking in a 20% bleach (Chlorox Co. USA, 1% available chlorine) solution plus 10 drops of the non-ionic detergent. Tween.RTM. 20, per litre. The seed is then rinsed 3 times in sterile distilled water before blotting dry on sterile filter papers. The sterile seed is germinated on Seed Germination (SG) medium for 4-6 days, and at this point the hypocotyls are harvested and cut into 0.5 cm lengths ready for Agrobacterium inoculation. The cut sections are placed on sterile filler papers overlaying a Murashige and Skoog based medium containing no phytohormones. The explants are incubated on a 16:8 hours day:night cycle at 28.degree. C.+/-2.degree. C. for 3 days prior to inoculation.

[0233] For the inoculation, an Agrobacterium tumefaciens liquid LB culture (10 ml), strain GV3101 (pMP90) Genl.RTM. or strain LBA4404 containing the RNA hairpin target of choice and a hygromycin resistance encoding plant selection cassette, is grown up overnight and 5 ml used to inoculate a 100 ml culture the evening prior to the inoculation. The culture is spun down, resuspended and diluted to an OD600 of 0.15 in the bacterial dilution medium.

[0234] The hypocotyl segments are inoculated with the Agrobacterium suspension for 5 minutes. After this the explants are blotted onto sterile filter paper to remove the excess bacterial suspension. The explants are incubated in the dark on Cotton Co-cultivation Medium (CCM) for 48 hours. The explants are then placed on Selective Callus Induction Medium (SCIM) containing 10 mg/l Hygromycin and 500 mg/l Cefotaxime and including the phytohormones 2, 4-dichlorophenoxyacetic acid (0.1 .mu.g/ml) and kinetin (0.1 .mu.g/ml). After 4-6 weeks the first resistant calli are observed, and these can be removed to fresh SCIM and further amplified for molecular assessment and insect bioassays. Plates are refreshed every 4-6 weeks to maintain nutrients and antibiotic selection.

[0235] Celli that are shown to give a positive result in the insect feeding bioassay are chosen for regeneration and callus is transferred to non-selective medium for the maturation of the somatic embryos, the recipe is based on the publication of Trolinder and Goodin, 1986. Once the embryos have reached 4 mm in length and have differentiated cotyledons and radicles (2-3 months after transfer to maturation medium), they can be transferred Elongation Rooting Medium. This consists of sterilized vermiculite in large test tubes soaked with a Stewart & Hsu (1977) based liquid medium supplemented with kinetin, giberellic acid both added at the final concentration of 0.1 mg/l. The embryos are incubated at 28.degree. C. in a 16:8 day/night cycle, and once they reach the 2-3 leaf stage the plantlets can be hardened off in pots of vermiculite enclosed in a propagator to maintain humidity. Once the plants are fully hardened (4-6 true leaf stage) they can be potted into a 50:50 peal:loam mix and grown in a 14:10 light cycle at 30/20.degree. C. day/night.

Bioassay

[0236] Lygus nymphs are placed in a Petri dish containing undifferentiated cotton callus tissue expressing target hairpin RNA. Per construct, a number of transformed cotton calli are generated and tested in a feeding bioassay for reduced nymph/adult survival and/or delayed development and stunted growth. Transgenic calli not expressing Lygus target hairpin RNA gene fragment serve as a negative control. Furthermore, young regenerated cotton plants from transgenic calli are grown in soil in a plant growth room chamber with the following conditions: 30/20.degree. C. day/night, 50.+-.5% relative humidity, 14:10 hour light:dark photoperiod. Per construct, a number of events (for example, twenty) are generated. A number of young Lygus nymphs/adults are placed on the individually caged young (for example, al the 4-5 unfolded leaf stage) plants and left for at least seven days before assessing resistance towards Lygus hesperus in terms of reduced nymph/adult survival, delayed development and stunted growth, and/or decreased plant feeding damage. Cotton plants not transformed with the Lygus target hairpin RNA gene fragment serve as a negative control.

[0237] It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the above mentioned assays without departing from the spirit or scope of this assay as generically described. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific examples, and such equivalents are intended to be encompassed by the present invention. The present example, therefore, is to be considered in all respects as illustrative and not restrictive.

Sequence CWU 1

1

28811217DNALeptinotarsa decemlineata 1agtacgcggg gagtgttctc aatattacaa caaagtgcgg tttcgggtgg ctttaacacg 60ttcagacggt tcagtgattg aggatattct tgtttgcttt gtcgtggaag atagcaggaa 120agggagacgg agaaggtgag ggaaacatcc tcaagttgga gaatcaaatt gccgtcatca 180agtatgtgct gatatttacg aatatcttgt catggtacat cggaactcaa gttgccggct 240ttatattcgg tctgtctgga gcgtctgtac tgctggataa cagcgctaga gattcccatt 300tccagcccag gatccgagaa agtatgcgac gacttatcat gaatgcccat cacgaggaat 360ccagacaaac actcgccatg attcaggaga atattgcttg ctgtggagct gatggtgcac 420atgattacct gtctttgcag caaccgctac caagcacttg cagagataca gttactggaa 480atccctttta tcatggatgc gttgatgagc tgacttggtt tttcgaggag aaatgcggct 540gggtggccgg acttgtcatg atactttgct tgatccaagt aataaacaca gtcctgtcaa 600ttatattcct tcaagctctc aagaaagaag agggacaagc tgatacatac agaaaatgaa 660gtgcacattc gcttttacga tttttgttgt ttcatttttg catacttgca tattcaccat 720agtcgtattt caaactgatt aatgtttgag tttgtagcgt aggtaatagt ttacttaaga 780gtttcattca catttgttag caattccgtt agccgaagaa gaaatattct cgagttttgg 840tgggtagtta ctgaaaagtt cattttatgt tcagcccgag ctaacgacat atatatatat 900tatataaccc aacttatttt tttatcgaat cattcgcagt tgcagaactt gaaagcattt 960ccagatatgc cgtaaatttc gattaacatt ataaaatcac tagtctgcat aatacataaa 1020cattatattt cacctaatga tgtttgtcta tgatcatgtt atgcgcagaa taaatcgttt 1080atcatatatg tatagcactg agtcaatccc atgatgaatg gtatgtggta tcatgattcc 1140atgatcacaa tgtcatctag ctggatcatg caatttctag aattcactcg aatatattag 1200ttgggcgtgt tccccag 12172750DNALeptinotarsa decemlineata 2cgcccagcag tggtatcaac gcagagtacg cgggagacat tcaagtcttg tgatagtgca 60ggcacggcag ttcaaataaa ctggtgcctt caatttattt atatatttat acttttttac 120tagaaaccaa atactaacca atcaacatgt gtgacgaaga ggttgccgca ttagtcgtag 180acaatggatc tggtatgtgc aaagctggat ttgctgggga tgatgccccc cgtgcagttt 240tcccatccat tgttggtcgt ccaagacatc aaggagttat ggtaggaatg ggccaaaagg 300actcgtatgt aggagatgaa gcccaaagca aaagaggtat ccttaccttg aaatacccca 360ttgaacacgg tattgtcaca aactgggatg atatggagaa aatctggcac cataccttct 420acaatgaact tcgagttgcc cccgaagagc accctgtttt gttgacagag gcaccattga 480accccaaagc caacagggag aagatgaccc agatcatgtt tgaaaccttc aatacccccg 540ccatgtacgt cgccatccaa gctgtattgt ctctgtatgc ttctggtcgt acaactggta 600ttgtgctgga ttctggagat ggtgtttctc acacagtacc aatctatgaa ggttatgccc 660ttcctcatgc catccttcgt ttggacttgg ctggtagaga cttgactgat taccttatga 720aaattctgac tgaacgtggt tactctttca 7503706DNALeptinotarsa decemlineata 3agtggggcgg aaacttggta agaatcgtct tttcgtcata tccactgtca aaaagtttct 60ttttatgagc agcgtgtaat ggtggagtag aagttgtttc aactaacttc ccaagatgca 120gatctttgtt aaaactttga ctggtaagac catcactctt gaggtcgaac cttcggatac 180catcgaaaat gttaaggcta agattcaaga caaggaggga attccaccag accaactgcg 240tttaattttt gctggtaaac aattggaaga tggacgtact ttgtcggact acaatataca 300aaaggaatct actcttcacc ttgtattgcg attgagggga ggtgcaaaga aacgtaagaa 360gaagaattac tccaccccaa aaaaaaatca agcataagaa gaagaaggtc aagctggctg 420tattgaaatt ttataaagtc gaagacaatg gtaaaatcca caggttgagg cgtgagtgtc 480ctgctgaaca atgcggagct ggtgtcttca tggcagccat ggaagacaga cattactgtg 540gaaagtgtgg atacacactt gtcttctcta aaccagatga taagtaaact ccaaaccaga 600tgagaactag tttagggttt aaaagtttat aaaaacttgt attatttcta aataaagtaa 660tacaaggatt agacttgaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 7064313DNALeptinotarsa decemlineata 4gatgtaagta gatttcaccg ttgtattatt cactaatttt cttactgtaa tttaaccaaa 60caagaaacgc cacgatgcaa attttcgtaa aaacactcac gggtaagacc atcaccctcg 120aggtcgaacc ctctgacacc atcgaaaacg tcaaggctaa gatccaagac aaggaaggga 180tccccccaga tcagcaaagg ttggtcttcg ctggaaaaca gctcgaagat ggtcgaactc 240tttccgacta caatattcag aaggagtcca ccctccatct cgtcctcaga ttgaggggag 300gtattatcga gcc 3135792DNALeptinotarsa decemlineata 5agtacgcggg gaccaacaaa ggcttatctt cgctggaaaa caactggaag atggccgaac 60cttatcagat tataacattc agaaagaatc tacacttcac ttggttcttc gtctccgtgg 120tggtatgcag atctttgtca aaactctaac tggaaagacc attaccttag aagtggaacc 180atccgatacc attgagaatg taaaagccaa aattcaggac aaggaaggaa ttcccccaga 240ccaacaaaga ttgatcttcg ctggaaaaca acttgaagat ggccgaacct tgtcagatta 300taacattcaa aaagaatcca cactccactt ggttcttcgt ctccgtggtg gtatgcagat 360ctttgtcaaa actctaactg gaaagacaat taccttggaa gttgaaccat ccgacaccat 420cgagaacgtg aaagctaaaa tccaagacaa agagggcatt cccccagacc aacaaagatt 480gatcttcgct ggaaaacgac tggaagatgg ccgaaccttg tcagattata acattcagaa 540agaatctacg cttcatttgg ttcttcgtct cagaggaggc aaatattgac tgattttttt 600cacttattta tttcattaaa ttgtactact ttgaagcaaa tattttattt taaaataaat 660attcctgttc tattatatta aggcttgaaa atgttttttt gatatgaaag gcttcgaatg 720aaattatatt tggctgtttt aagataaata aatgaaggtg tagtaaaaaa aaaaaaaaaa 780aaaaaaaaaa aa 7926719DNALeptinotarsa decemlineata 6agagtttaag ccgcgtctta taataggtta tagaaatatt tttaattaaa aaataaactt 60gtttgctcca gtctcgaaac tacgagaatt gaagccatgg aaggttcatt gttggaaccc 120actttataca ccataaaagg gattttgatc ctggataatg atggaaacag aatcctggca 180aaatattacg acaaaaccac attccccaca tcaaaagagc agaaggcatt tgagaaaaat 240ctatttaaca aaacacatag agcaaatgca gaaatcatca tgctggatgg attaacctgc 300ctctatagga gcaatgtgga tttatttttc tatgttatgg gcagctcaca cgaaaacgag 360cttattctta tgagtattct caattgtctt tatgactcag ttagccaaat actgaggaaa 420aatgtggaaa aacgagcagt actagagtcc ctggatatag ttatgttagc gctggatgag 480atatgtgatg gaggaattat ccttgatgct gattcgaatt ctgctgtgtc aagggtagct 540ttgaggaatg atgatatacc aattggagag cagaccgtag cccaggtctt tcaatctgca 600aaagaacagc tgaaatggtc attattaaag taggtgattt ttataaattt aatgaaatgt 660atgttctgaa actataagaa ttaaaatatt cgaaaaaaaa aaaaaaaaaa aaaaaaaaa 71971079DNALeptinotarsa decemlineata 7gtactccgca tcattcagat attcacagag cgctgcggta gtttcatgac atgcttgtcg 60ccatgagcag aagaggctcg atcgagacga aagagaaatt cgcatacgat caacagatga 120ccgatagctc tcagctggag gccgacaaga atggagactt gcgaaaacgt atttgagacc 180tcgctgtcgc aagccctcgt cggtggaaga ggcagcgcgg cagattctgc cacaggaaca 240aataagttga acaagataac gcagttgaca ggttttcgga tcccgtttat tcagaagctt 300atgtccacgt caaccagtat gatattgtgc tggacgtttt gatcgtcaat caaactaatg 360atactctgca aaattgtact ttggagctgg cgacgttggg agatctgaaa cttgtcgaaa 420aacctcagcc agtagttctt gctcccaaag acttctgtaa catcaaagcc cacgtaaagg 480ttgcttccac tgaaaacgga atcatctttg gaaacatcgt ttatgacgtg acgggcgcgg 540cctcagacag gaacgtagtc gtcctcaatg acatccacat cgacatcatg gactatattg 600ttccagcgtc ttgtaccgat tcagaattta tgaggatgtg ggctgaattt gaatgggaaa 660ataaggtgac tgtcaacaca cctttgacgg accttgcgga ctacttggag cacctcatta 720agagcaccaa catgaaatgc ttgacgccag aaaaggcgct cagcggtcag tgtggtttca 780tggcagccaa tatgtacgct aaatccatat ttggagaaga cgctttggcc aatttgagta 840tagagaaacc gtttaacaaa ccagaagcac ctgtagctgg acacatcaga atcagggcta 900agagtcaggg catggccttg agcttaggag acaaaataaa tatgactcaa aaaggcatac 960caagtaagat tgttgcatct tgatttgtat gttaactata tttgttattt cgccatttca 1020ttttataatc atgtctaata ttaaaatcta catagatttt gaataaaaag tatcgaatt 10798506DNALeptinotarsa decemlineata 8acgcggggga aaaaccagca aacgaagaca tcgaatcacc ccgagatatt ataaacaaag 60catttagaga aatttttgag gctgacgaaa acgggatcaa tgggtctctg gtggaaccac 120caactccaac gcagaaaacg tttgatagac ctttccaaga agatctaagc gagttcaact 180ttagaatata tgcagcaacg tattttacga acaatgccaa ctatcagttt tcaaagaaac 240ctcttaagga atccctacat tatcttccga ccccagatga cgtgatcgcc gcacaagcct 300tgtggataac catcctcagg ttcatgggag actatccgga gcccaaatac gacaattcga 360cgaaagaaaa cgttcccatc atgcaaatca tctcagagtc gatcggcaaa agtttcacga 420atcgtaaaga gtaccaggaa atactcaaag aagaaaaaaa tatgcctctg caacaaaatc 480aagcaaaaaa aaaaaaaaaa aaaaaa 5069959DNALeptinotarsa decemlineata 9tgtacggacg tttggaggaa gccgacgctc tcatccaaca gctctcttcc gacaaggatc 60ccatcctcag gcggtcgggc atgtacacta tcgccatggc ttactgcagc accggacaca 120accaggcgat caggaagctg cttcacgttg ctgtatccga cgtaaatgat gacgtccgac 180gagctgccgt cacggcgctg ggtttcctct tattcagaac tcctgaacaa tgcccaagcg 240tagtttctct gctggctgag agttacaacc ctcacgtacg ctacggagct gccatggcac 300tcggtatcgc ctgtgctggc accggactcc gcgaagctat tgctcttctg gaaccgatgg 360tgatgttcga tccagtcaat ttcgttcgtc aaggagctct catcgcttct gccatgatct 420tgatccagca gaccgaacag acctgtccta aagttagttt cttcagacag acttacgctc 480aggtcatcgc caacaaacat gaggatgtta tggccaaatt cggagctatt ttggctcaag 540gaattattga cgctggaggc aggaatgtta cattatcact ccagtcgaga acaggacaca 600ccaatatgtt ggcagtggtc ggaactttgg tgttcaccca gtattggtac tggttccctc 660tctcccattg tttggctctg gctttcaccc caacttgtgt tatcgccctc aatgaacaac 720tcaaaatgcc caagttggaa ctgaaatcga atgcaaaacc aagtctctac gcatatccag 780ctccaatgga agagaaaaag cgcgaagaga gagagaaagt aaccaccgct gttctgagta 840tcgctgcaag acaacgtggg aaggatcatg aaaagaagca tcgggatgaa aaaaatggat 900ggggacgaag acaagtctgc agagaaagat gaaaaaaaaa aaaaaaaaaa aaaaaaaaa 95910458DNALeptinotarsa decemlineata 10ttttttgact tattttttgt tagtgatttt gtattcagat tgtctccgtt cgtaaaaatg 60ctactgaatc aaatatccat agcaggtgcc gatgactgga gaaatgccgc tcatagcact 120gggacttcta ttatggcagc agaattcgat ggaggagtaa ttattggtgc tgattcccgt 180acaactacag gggcgtacat tgcaaatcgt gtaactgaca aactaactaa agtaactgac 240catatatatt gttgtcgatc tggatcagca gcagatactc aagccattgc tgatattgta 300tcgtaccatc tgaacttcca tggtatggaa ctaggagaag agccccttgt agaggtgggg 360gctgctatct tcagggagct ttgctacaac tatagggatt ctctcatggc gggaatccta 420gttgctggct gggacaaaaa aaaaaaaaaa aaaaaaaa 45811352DNALeptinotarsa decemlineata 11cagttaagaa tatcattcaa ttcctaggtc tccagccagc agaaagaacg gataaggttc 60ctgaggaaaa atcaactcat actcttttac tagcaggaat gcttcgaggg ggtattgaca 120ttttagttag ggcaaaacta gccctagctg atggtgtgac tatgcaactg accgtgaggt 180cacccgatgc tgatgttgct gaacttataa cctcgtctgt aggctaagag aaaagttagc 240ttggttagat gttcgaaatt atcaggtcat gtgtattata tttgatgtta ttccaatttt 300aataaatcct cctaatttaa gctaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 352121407DNALeptinotarsa decemlineata 12gagtgaaaat atggctggcg caatgttgtt tgaaagagct cagtcagtac cttctcaaca 60tgataaactg ttaaatttaa aaagaaatga agatgacgat gatcagaaca tcgttaataa 120agaacaggac atcctcaacc tcggcgaaaa gtacaagaaa gagggtaagg ctaaagaact 180ggcggaattg gtaaaggcta ctcgtccgtt tctcagcatt ataagcaagg cgaaagctgc 240gaaactggtc aggtctctgg tcgattattt cctagatttg gaagcaggta tcggaataga 300agtccaactg tgtaaagaat gtatagagtg ggcaaaagaa gagaaaagga cctttcttcg 360tcagtctttg gaagcgcgat tgatagcctt gtatttcgat actggtatgt atgccgaggc 420tctgattctg gaatccacct tgttgaaagg attgaagaag ttggatgaca aaaatttact 480ggtagaagta cagttgcttg aaagtaagac atatcacgcc ttgagtaacc tgcccaaggc 540tcgtgccgca ttaacttcag ctcgtacaac agccaattcc atctattgcc ctcctaagat 600gcaagctgcg cttgaccttc agtctggagt tctgcatgca gctgatgaaa aagacttcaa 660aactgcctat tcatactttt atgaggcatt tgaagggttt gacagcgtag aatcaccaaa 720agcgttgaca gctttgaaat atatgcttct ttcaaaaatt atgatcaaca gtccggaaga 780tgtacaacaa attgtaagcg ggaaattagc catcagatat gctggtcaag acatagaagc 840aatgaaagct gttgcacgag cttctcacaa gagatccttg gcagattttc agttagcagt 900gaagcagttc aaacatgaac tagaggatga tgttatcgtc agagcccatt taggaacttt 960gtatgataat atgttggagc aaaatctgtg caggattata gaaccatatt ccagagtaca 1020ggtggactat gttgcaaaaa caatcaaact tccaatgtta caagtggaaa agaagctctc 1080gcagatgatt cttgatgcta aatttcatgg gatattggat caaggagaag gtgttttaat 1140agtttttgaa gcaactccag tagacaaaac atatgaaatg gccctagaaa caatacaaag 1200catgagtaaa gtagtagata ccctatatca aaaagctaaa aagctgtcat aggtttgaca 1260caactaatat aaaactatta aaattattgt attttgatct ttcataaatt ttctctgttt 1320ggtaatatta cagtttaata taattataat gtttttttgg aatataaact aactaaattc 1380taaaaaaaaa aaaaaaaaaa aaaaaaa 140713821DNALeptinotarsa decemlineata 13ggttgcaagt aatcatggct tcggagcggt atagtttttc gctgacaact tccagtccat 60ctggaaaact agctcaaatt gaatatgccc tagctgctgt agccgctgga gctccttctg 120tgggcattaa agcttcaaat ggtgtagtta tcgccacaga aaacaaacat aagtcgatcc 180tctatgaaga acacagtgtt cataaagttg aaatgattac aaaacatata ggaatgatat 240attctggtat gggacctgat tatcgcttgt tggtgaaaca agctcgtaaa atggcccaac 300agtattatct agtttatcaa gagcctatac caacagttca actcgttcaa cgagttgcca 360ctgttatgca agaatatact cagtccggag gagttaggcc gtttggggtt tcattattga 420tatgtggttg ggacagtgaa cgaccatact tatttcaatg tgatccatca ggagcttatt 480ttgcctggaa agctactgcc atgggcaaga atttcatcaa tggaaaaaca tttttggaaa 540aaagatatag cgaggatttg gaacttgatg acgcagtaca cacagcaatt ctgacgttga 600aggagagttt tgaaggccaa atgacagcgg acaacattga agtgggaatt tgtgatgaag 660caggattcag gaggctagat ccctctcatg tgaaggatta cctagctaat attccataag 720gcatttaggt tatgtaacaa gatttctctt aattttttat gaaactcatg tttcacttga 780ataaaaccgg atttgaacga aaaaaaaaaa aaaaaaaaaa a 82114474DNALeptinotarsa decemlineata 14tgaagcaggc caaagaagaa gctcaagacg aaatcgaaaa ataccgtaaa gaacgcgaac 60gtcaattcag ggagttcgag gccaagcata tgggctccag agaggatgta ccgtccaaaa 120tcgaagtgga caccaaacgt agaatcgaag agatgaacaa ggctataatc agtcaaaaag 180aacctgttat ccaagaagtt ctcaacttag tgtacgacat caaacctgaa atccacaaga 240actaccgcca atagactgtg tgtggttgtt aaaaagtaat tgaattttcc tgtgggaaaa 300ctaggaatac ctttcaattg ttctgtatag atgttcattc catttattgt atatttaatc 360tcttaaggca gttcactctt aagttcacag ggtagtggaa tttgtgtact tgtatattgt 420aagtcaaaat agaaaaaata tattgtgaaa actaaaaaaa aaaaaaaaaa aaaa 47415692DNALeptinotarsa decemlineata 15gcatgtgaaa atgagttcct tgaagctaca gaagaggctc gccgcctcgg ttatgcgatg 60tggcaaaaaa aagtatggtt ggatcctaat gaaattaatg aaatcgctaa caccaactca 120aggcaaaaca tccgtaagtt gatcaaagat ggtctcataa tcaagaaacc agtagcagtg 180cattcccgtg ctcgagtacg caaaaacaca gaagcccgca ggaagggaag acattgcggt 240ttcggtaaaa ggaagggtac agcaaatgct cgaatgcccc agaaggaatt atggattcag 300cgcatgagag ttttgagacg tctcttgaaa aaataccgag aagccaaaaa gatcgacagg 360catctgtact atgcccttta catgaaagca aagggtaacg tattcaagaa caagagagtc 420ctcatggaat acatccataa gaagaaggca gagaaggccc gtgccaagat gttggcagac 480caagccaatg ccaggagatt gaaggtaaaa caagcacgtg aacgtcgtga agaacgtatc 540gctaccaaga aacaggaagt tctacagaat taccagcggg aagatgaagc ccaagctgct 600aagaaataag tttattttta tggtaatgac aaataaagtt tgaaattact taaaaaaaaa 660aataaaaaaa aaaaaaaaaa aaaaaaaaaa aa 69216750DNALeptinotarsa decemlineata 16aactttctgt accgaaacca aacagctaaa cttccaattg gtttatttag caaaaataga 60attttttttg aaattcataa ataaagatgt ctgttttgtg tcctgaaatt ccagcgccag 120gcttttcatt cgagaattgt aaaagaaatg cattgctgga aggcaaggga ttcgctctac 180caaaagctac taagactggt accaccatcg taggaattac ttataaagat ggagtcattc 240ttggggccga taccatagcc acagaagata ccacagttgc agacaagaac tctgagaaga 300ttcactatct tgctccaaat atgtattgtt gtggtgctgg tacagccgcg gatacagaga 360tgaccactca gatgatctcg tcccaattgg aactccacaa actgcacact aaccgcatcg 420ccagagtctg cacagctaac cagatgctga agcagtatct gttccgttac cagggctaca 480tcggtgctgc tcttatcctc ggaggagtcg atgtcgaagg tccccatctc tacatgattt 540acccccacgg ctctagtgac aacctcccat atggcacgat gggctcgggc tccccggccg 600ccatagcggt attcgagtcc cgctggagac ccaacttgga ggaggaggaa ggtgtacagc 660ttgtcagaga cgcgattgct gctggtatct tcaatgattt ggggtctgga tcgaatgttg 720atgtctgcat cattcggaag gggtctgttg 750171394DNALeptinotarsa decemlineata 17ttaaacagtg gctaaagcta aaactattat ttgaaatgtc gtctactcta gaagataaag 60ctatctggga agatggggaa gaatcattgg gggaggaagt tctgaggatg tcgactgatg 120aaatagtcag ccggacgcgt ttactcgata atgaaatcaa aataatgaag agcgaagtaa 180tgagaataaa ccatgaactc caagcccaaa acgaaaaaat caaagaaaac actgaaaaga 240taaaggtaaa taaaacgcta ccttacttgg tatctaatgt tatagaactg ctagatgtgg 300accctcaaga ggaagaagaa gacggggcag ttgtagactt ggattctcaa agaaagggaa 360aatgtgccgt tgtaaaaaca tctactcgtc aaacatattt tctaccagta atcgggctcg 420ttgatgaaga aaagctcaaa cctggagatt tagtgggtgt gaacaaagat tcttatctta 480tcctagaaac attaccagcg gagtatgatg caagagtaaa agctatggaa gttgatgaaa 540gaccaactga acaatactca gacattggtg ggctggacaa acaaatccag gaacttattg 600aagcagtcgt attgccaatg acccacaagg ataaatttgt taatcttggg attcatccac 660ctaaaggagt cttgttatat ggacccccag gaactggaaa aactttgttg gctagagcat 720gtgctgctca gacaaaatca acatttttga aactagctgg accccaatta gttcagatgt 780tcataggaga tggtgctaaa cttgtaagag atgcttttgc gttagccaag gaaaaggcac 840cagctataat tttcatcgat gaattggatg ctactggtac gaaacgtttt gattctgaga 900aggctgggga tcgtgaagta caacgtacaa tgttgggagc ttttgaatca gttggatggg 960tttagttcaa cagctgatat aaaagtaatt gcagctaccc atcgggttga ttttctagat 1020cctgctttac tttgatcagg tcggttagat tgtaaaaaag aatttcctcc tccaaaagaa 1080gaaggtaggg caagaataat gcaaattccc tcaagaaaaa agactgttaa ccccgaagta 1140aactttgaag aattgggtag atcccctggg ggctttaacg ggggtccggg taaagccgtt 1200tgttttgaag ccggtttgat agctttggga agaaaagccc ccgctgtttc ccctgaagat 1260tttttggatg tttttttgga agttcaagcc cagaaaaaag ggaattttaa tttttttttt 1320taatttcccg cctacagata ataaattttg tttttggtta aaaaaaaaaa aaaaaaaaaa 1380aaaaaaacaa aaaa 139418514DNALeptinotarsa decemlineata 18gacagatgtc gaacccttta tgaaaaattt ttggaatttg gaccagagaa ttgtgtgacc 60tggatgaaat ttgccgaact agaaacttta ttaggcgaca ttgatcgagc aagggctatt 120tacgaattgg ctataagtca gcctaggtta gatatgccag agttactttg gaaggcttat 180atagactttg aaatttctca ggaagaacct gaaaatgcta gacaaatcta tgaaaggctg 240ctagaaaaaa catcacatgt caaagtatgg ttgtcttatg ccaaatttga acttaacaca 300caatcagaac ccgacatgaa tgttctgtta tccaggagag tatttgaaag agccaacgag 360agcctaaaaa attcatctga aaaagaggca agagttctac ttcttgaaaa ctggagggag 420tttgagaaag cccatggaga tgaaactggt aatgctaaag ttaatagcag gatgcccaaa 480cgtataaaaa aaaaaaaaaa aaaaaaaaaa aaaa 514192328DNALeptinotarsa decemlineata 19atggctacat acgaagagta tatccagcaa aacgaagaca gagacgggat acggttcaca 60tggaacgttt ggccgtccag cagaatagaa gccacccgtt tggtggtgcc cttggcctgt 120ctttaccaac ccctgaaaga acgtcccgat

cttccaccaa ttcagtacga tccagtgctg 180tgcactagaa acaattgtcg tgcaatactg aacccactct gccaagtaga ttatcgtgcc 240aagctttggg tgtgcaactt ctgctttcag aggaacccgt ttccccctca atatgccgcc 300atttccgagc aacaccaacc agctgagctt atgccaatgt tttccaccat agagtacact 360attacaagag cacagtgttt acccccgata tatctctatg ttgtcgacac ttgcatggat 420gaggaagaat tgggttcact caaggactcc ttgcaaatgt ctttgagctt gttgcccccg 480aatgccttga tagggttgat tacctttggg aagatggtcc aagtgcacga actaggtacc 540gagggctgca gcaaatctta cgttttccga gggacgaaag acctcacagc taagcaagtt 600caagagatgt tggaagtggg cagagccgca gtaagtgctc aacctgctcc tcaacaacca 660ggacaaccca tgaggcctgg agcactccag caagctccta cgccaccagg aagcaggttc 720cttcaaccca tctcgaaatg cgacatgaac ctcactgatc ttattggaga gttgcaaaga 780gacccatggc ctgtccacca aggcaaatgc gcccttagat cgaccgggac agctttatcg 840atagccattg ggttgttgga gtgcacatac gccaatactg gtgccagggt catgctattc 900gttggaggac cttgctctca aggccctggt caagtcttga atgatgatct gaagcaacct 960atcagatctc accacgacat ccaaaaagac aatgccaaat acatgaagaa agcaatcaag 1020cactatgata atttagcgat gagagcagca acgaatggcc actgcgttga catatattca 1080tgcgctttgg atcagacagg attgatggag atgaaacagt gttgtaattc aacaggggga 1140catatggtca tgggcgactc gttcaattct tccctgttca agcaaacgtt ccagcgcata 1200ttttcgaaag atcagaaaaa cgagctgaag atggcattta atggtactct ggaggtcaag 1260tgttccaggg agttgaaaat tcaaggcggt attggatctt gtgtttcgtt gaatgtgaag 1320aatcctttgg tttccgacac cgaaatagga atgggtaaca cggtccagtg gaaaatgtgt 1380acggtaactc caagtactac catggccttg ttcttcgagg tcgtcaacca acattccgct 1440cccatacctc aagggggaag gggctgcata cagttcatca cgcaatatca gcatgctagt 1500ggccagaaga ggatccgagt aacgacagtt gctagaaact gggccgatgc ttccgctaat 1560atacatcatg tcagtgctgg attcgatcag gaggcagccg cagtgataat ggcgaggatg 1620gcagtttaca gagcggaatc agacgatagc cctgatgttt tgagatgggt cgataggatg 1680ttgatacgtc tgtgccagaa attcggcgaa tataacaagg acgacccgaa ttcgttccgc 1740ttgggcgaaa acttcagcct ctacccgcag ttcatgtacc atttgagaag gtcacagttc 1800ctgcaggtgt ttaacaattc tcccgacgaa acgtccttct acaggcacat gcttatgcgc 1860gaagacctca cgcagtcgct gatcatgatc cagccgatac tctacagcta cagtttcaat 1920ggaccaccag aacctgtgct tttggatacg agttccatcc aacccgatag aattctgctc 1980atggacacgt tcttccagat tctgatattc catggcgaga caatagccca atggcgtaac 2040ctcaaatatc aggacatgcc tgaatacgag aactttaggc agctgctgca agctccagtg 2100gacgatgccc aggaaattct tcaaaccagg tttcctatgc cgcgttacat cgatacggaa 2160caaggaggat cacaggctag attcttgctc tcgaaagtca acccgagtca gactcacaac 2220aatatgtacg cctacggagg ggacggaggt gctccagttc tcactgatga tgtatcgtta 2280caagtattca tggatcacct gaaaaaactg gcagtgtcct ctacggct 2328202697DNALeptinotarsa decemlineata 20atgcctcttc gtttagatat caaacgaaag ttaacagccc gttcagacag ggtaaaatgt 60gtagacctcc atccatctga accatggatg ttatgttctt tatatagtgg caatatcaat 120gtttggaatt atgaaaatca acaacaagta aaaagtttcg aagtatgtga cctgccagtg 180agagctgcaa aatttgtccc acgtaaaaac tggatagtca gtggatctga tgatatgcag 240ataagaatat tcaattacaa cactttagat agaattcatt cctttgaggc acattccgac 300tatgtgagat gtataatagt tcatccaacc caaccttata ttctgacaag tagcgatgac 360atgctcatca aattgtggaa ttgggataag gcttgggctt gtcagcaggt ctttgaaggc 420cactctcatt atatcatgca aatcgccatc aatccaaaag acaacaacac atttgcgagt 480gcttcactgg accgtacttt gaaagtgtgg caacttggag catcaacagc gaacttcacc 540cttgaagggc acgagaaagg tgtcaactgt gtggactact atcacggtgg agacaagcca 600tacttgatat cgggagcaga cgatcggttg gttaaaatct gggactatca aaacaaaacg 660tgtgtccaaa ccttggaagg acacgcccaa aacgtaaccg cggtttgttt ccaccctgaa 720ctacctgtgg ctctcacagg cagcgaagat ggtaccgtta gagtttggca tacgaataca 780cacagattag agaattgttt gaattatggg ttcgagagag tgtggaccat ttgttgcttg 840aagggttcga ataatgtttc tctggggtat gacgagggca gtatattagt gaaagttgga 900agagaagaac cggcagttag tatggatgcc agtggcggta aaataatttg ggcaaggcac 960tcggaattac aacaagctaa tttgaaggcg ctgccagaag gtggagaaat aagagatggg 1020gagcgtttac ctgtctctgt aaaagatatg ggagcatgtg aaatataccc tcaaacaatc 1080caacataatc cgaatggaag attcgttgta gtatgcggag acggcgaata tatcatttac 1140acagcgatgg ctctacggaa caaggctttt ggaagcgctc aagagtttgt ctgggctcag 1200gactccagcg agtatgccat tcgcgagtct ggttccacaa ttcggatatt caaaaacttc 1260aaagaaagga agaacttcaa gtcggatttc agcgcggaag gaatctacgg gggttttctc 1320ttggggatta aatcggtgtc cggtttaacg ttttacgatt gggaaacttt ggacttggtg 1380agacggattg aaatacaacc gagggcggtt tattggtctg acagtggaaa attagtctgt 1440ctcgcaacgg aggacagcta cttcatcctt tcttatgatt cggagcaagt tcagaaggcc 1500agggagaaca atcaagtcgc agaggatggc gtagaggccg ctttcgatgt gttgggggaa 1560atgaacgagt ctgtccgaac aggtctttgg gttggagact gtttcattta tacaaacgcc 1620gtcaatcgta taaattactt cgttggtggt gaacttgtca cgatagctca tctggaccgt 1680cctctgtatg tgctggggta tgttcctagg gacgatcgat tgtatctcgt agacaaagaa 1740ttaggagttg tcagttatca gttgttactg tctgttcttg aatatcaaac ggcagttatg 1800aggagggact ttcctacagc ggatcgtgtc ctgccttcga ttcccaaaga gcatagaaca 1860agagttgctc actttttaga aaaacaaggc ttcaagcagc aagccttagc agtgagcact 1920gatccagagc atcgattcga actcgctgta gccctggaag acctcgatac cgccaaagta 1980ttagcccagg aagccaacaa tcctcaaaag tggagccaac tagcagagct tgcggcgtca 2040acaaataatt tacagctagc aaaagagtgt atgcagaagg ctcaggatta tggaggactt 2100ctcctcctag ccaccagttc tggagatgaa caactagttc aaagcttggg agaactcacg 2160caagccgaag gaaagcataa cctctccttc ctttcttatt ttctggtggg agatctgccg 2220aaatgtttgg atatcttggt cagtacggga cgcctacccg aggctgcttt cttcgcacgc 2280tcgtatctgc cggacagaat atcggaaatt gttgaactgt ggaaggtgaa actgacgtca 2340attaatgaga aagctggtca gagtctggcg gatccgaaga gctacgagaa tctttttccg 2400ggtttgcaag aagcgattga aacgcaaaag tatttggagc agcaggatag ggggcttttc 2460ccggcttcag tatcaacaac gatcgttccc aaccatgaaa ggaatttggt ggcagaggca 2520cgggcccaga tgaagggtgg tgccgcggtt tttcagcaaa gcaggttact ttctggagaa 2580aaaacaatat cctttgaaca ggatgaagat gatctagact tagatttgga aggcgttaat 2640attgacgaca atatagacac aacggatatc aatatcgacg atgatttatt gagcgat 269721558DNALeptinotarsa decemlineata 21gtcgtggaag atagcaggaa agggagacgg agaaggtgag ggaaacatcc tcaagttgga 60gaatcaaatt gccgtcatca agtatgtgct gatatttacg aatatcttgt catggtacat 120cggaactcaa gttgccggct ttatattcgg tctgtctgga gcgtctgtac tgctggataa 180cagcgctaga gattcccatt tccagcccag gatccgagaa agtatgcgac gacttatcat 240gaatgcccat cacgaggaat ccagacaaac actcgccatg attcaggaga atattgcttg 300ctgtggagct gatggtgcac atgattacct gtctttgcag caaccgctac caagcacttg 360cagagataca gttactggaa atccctttta tcatggatgc gttgatgagc tgacttggtt 420tttcgaggag aaatgcggct gggtggccgg acttgtcatg atactttgct tgatccaagt 480aataaacaca gtcctgtcaa ttatattcct tcaagctctc aagaaagaag agggacaagc 540tgatacatac agaaaatg 55822320DNALeptinotarsa decemlineata 22atgtgtgacg aagaggttgc cgcattagtc gtagacaatg gatctggtat gtgcaaagct 60ggatttgctg gggatgatgc cccccgtgca gttttcccat ccattgttgg tcgtccaaga 120catcaaggag ttatggtagg aatgggccaa aaggactcgt atgtaggaga tgaagcccaa 180agcaaaagag gtatccttac cttgaaatac cccattgaac acggtattgt cacaaactgg 240gatgatatgg agaaaatctg gcaccatacc ttctacaatg aacttcgagt tgcccccgaa 300gagcaccctg ttttgttgac 32023490DNALeptinotarsa decemlineata 23ggtaagaatc gtcttttcgt catatccact gtcaaaaagt ttctttttat gagcagcgtg 60taatggtgga gtagaagttg tttcaactaa cttcccaaga tgcagatctt tgttaaaact 120ttgactggta agaccatcac tcttgaggtc gaaccttcgg ataccatcga aaatgttaag 180gctaagattc aagacaagga gggaattcca ccagaccaac tgcgtttaat ttttgctggt 240aaacaattgg aagatggacg tactttgtcg gactacaata tacaaaagga atctactctt 300caccttgtat tgcgattgag gggaggtgca aagaaacgta agaagaagaa ttactccacc 360ccaaaaaaaa atcaagcata agaagaagaa ggtcaagctg gctgtattga aattttataa 420agtcgaagac aatggtaaaa tccacaggtt gaggcgtgag tgtcctgctg aacaatgcgg 480agctggtgtc 49024231DNALeptinotarsa decemlineata 24ccaaacaaga aacgccacga tgcaaatttt cgtaaaaaca ctcacgggta agaccatcac 60cctcgaggtc gaaccctctg acaccatcga aaacgtcaag gctaagatcc aagacaagga 120agggatcccc ccagatcagc aaaggttggt cttcgctgga aaacagctcg aagatggtcg 180aactctttcc gactacaata ttcagaagga gtccaccctc catctcgtcc t 23125571DNALeptinotarsa decemlineata 25gggaccaaca aaggcttatc ttcgctggaa aacaactgga agatggccga accttatcag 60attataacat tcagaaagaa tctacacttc acttggttct tcgtctccgt ggtggtatgc 120agatctttgt caaaactcta actggaaaga ccattacctt agaagtggaa ccatccgata 180ccattgagaa tgtaaaagcc aaaattcagg acaaggaagg aattccccca gaccaacaaa 240gattgatctt cgctggaaaa caacttgaag atggccgaac cttgtcagat tataacattc 300aaaaagaatc cacactccac ttggttcttc gtctccgtgg tggtatgcag atctttgtca 360aaactctaac tggaaagaca attaccttgg aagttgaacc atccgacacc atcgagaacg 420tgaaagctaa aatccaagac aaagagggca ttcccccaga ccaacaaaga ttgatcttcg 480ctggaaaacg actggaagat ggccgaacct tgtcagatta taacattcag aaagaatcta 540cgcttcattt ggttcttcgt ctcagaggag g 57126542DNALeptinotarsa decemlineata 26cttgtttgct ccagtctcga aactacgaga attgaagcca tggaaggttc attgttggaa 60cccactttat acaccataaa agggattttg atcctggata atgatggaaa cagaatcctg 120gcaaaatatt acgacaaaac cacattcccc acatcaaaag agcagaaggc atttgagaaa 180aatctattta acaaaacaca tagagcaaat gcagaaatca tcatgctgga tggattaacc 240tgcctctata ggagcaatgt ggatttattt ttctatgtta tgggcagctc acacgaaaac 300gagcttattc ttatgagtat tctcaattgt ctttatgact cagttagcca aatactgagg 360aaaaatgtgg aaaaacgagc agtactagag tccctggata tagttatgtt agcgctggat 420gagatatgtg atggaggaat tatccttgat gctgattcga attctgctgt gtcaagggta 480gctttgagga atgatgatat accaattgga gagcagaccg tagcccaggt ctttcaatct 540gc 54227747DNALeptinotarsa decemlineata 27gtatttgaga cctcgctgtc gcaagccctc gtcggtggaa gaggcagcgc ggcagattct 60gccacaggaa caaataagtt gaacaagata acgcagttga caggttttcg gatcccgttt 120attcagaagc ttatgtccac gtcaaccagt atgatattgt gctggacgtt ttgatcgtca 180atcaaactaa tgatactctg caaaattgta ctttggagct ggcgacgttg ggagatctga 240aacttgtcga aaaacctcag ccagtagttc ttgctcccaa agacttctgt aacatcaaag 300cccacgtaaa ggttgcttcc actgaaaacg gaatcatctt tggaaacatc gtttatgacg 360tgacgggcgc ggcctcagac aggaacgtag tcgtcctcaa tgacatccac atcgacatca 420tggactatat tgttccagcg tcttgtaccg attcagaatt tatgaggatg tgggctgaat 480ttgaatggga aaataaggtg actgtcaaca cacctttgac ggaccttgcg gactacttgg 540agcacctcat taagagcacc aacatgaaat gcttgacgcc agaaaaggcg ctcagcggtc 600agtgtggttt catggcagcc aatatgtacg ctaaatccat atttggagaa gacgctttgg 660ccaatttgag tatagagaaa ccgtttaaca aaccagaagc acctgtagct ggacacatca 720gaatcagggc taagagtcag ggcatgg 74728393DNALeptinotarsa decemlineata 28ccagcaaacg aagacatcga atcaccccga gatattataa acaaagcatt tagagaaatt 60tttgaggctg acgaaaacgg gatcaatggg tctctggtgg aaccaccaac tccaacgcag 120aaaacgtttg atagaccttt ccaagaagat ctaagcgagt tcaactttag aatatatgca 180gcaacgtatt ttacgaacaa tgccaactat cagttttcaa agaaacctct taaggaatcc 240ctacattatc ttccgacccc agatgacgtg atcgccgcac aagccttgtg gataaccatc 300ctcaggttca tgggagacta tccggagccc aaatacgaca attcgacgaa agaaaacgtt 360cccatcatgc aaatcatctc agagtcgatc ggc 39329779DNALeptinotarsa decemlineata 29ggacgtttgg aggaagccga cgctctcatc caacagctct cttccgacaa ggatcccatc 60ctcaggcggt cgggcatgta cactatcgcc atggcttact gcagcaccgg acacaaccag 120gcgatcagga agctgcttca cgttgctgta tccgacgtaa atgatgacgt ccgacgagct 180gccgtcacgg cgctgggttt cctcttattc agaactcctg aacaatgccc aagcgtagtt 240tctctgctgg ctgagagtta caaccctcac gtacgctacg gagctgccat ggcactcggt 300atcgcctgtg ctggcaccgg actccgcgaa gctattgctc ttctggaacc gatggtgatg 360ttcgatccag tcaatttcgt tcgtcaagga gctctcatcg cttctgccat gatcttgatc 420cagcagaccg aacagacctg tcctaaagtt agtttcttca gacagactta cgctcaggtc 480atcgccaaca aacatgagga tgttatggcc aaattcggag ctattttggc tcaaggaatt 540attgacgctg gaggcaggaa tgttacatta tcactccagt cgagaacagg acacaccaat 600atgttggcag tggtcggaac tttggtgttc acccagtatt ggtactggtt ccctctctcc 660cattgtttgg ctctggcttt caccccaact tgtgttatcg ccctcaatga acaactcaaa 720atgcccaagt tggaactgaa atcgaatgca aaaccaagtc tctacgcata tccagctcc 77930392DNALeptinotarsa decemlineata 30gttagtgatt ttgtattcag attgtctccg ttcgtaaaaa tgctactgaa tcaaatatcc 60atagcaggtg ccgatgactg gagaaatgcc gctcatagca ctgggacttc tattatggca 120gcagaattcg atggaggagt aattattggt gctgattccc gtacaactac aggggcgtac 180attgcaaatc gtgtaactga caaactaact aaagtaactg accatatata ttgttgtcga 240tctggatcag cagcagatac tcaagccatt gctgatattg tatcgtacca tctgaacttc 300catggtatgg aactaggaga agagcccctt gtagaggtgg gggctgctat cttcagggag 360ctttgctaca actataggga ttctctcatg gc 39231178DNALeptinotarsa decemlineata 31ctaggtctcc agccagcaga aagaacggat aaggttcctg aggaaaaatc aactcatact 60cttttactag caggaatgct tcgagggggt attgacattt tagttagggc aaaactagcc 120ctagctgatg gtgtgactat gcaactgacc gtgaggtcac ccgatgctga tgttgctg 17832559DNALeptinotarsa decemlineata 32gtaaggctaa agaactggcg gaattggtaa aggctactcg tccgtttctc agcattataa 60gcaaggcgaa agctgcgaaa ctggtcaggt ctctggtcga ttatttccta gatttggaag 120caggtatcgg aatagaagtc caactgtgta aagaatgtat agagtgggca aaagaagaga 180aaaggacctt tcttcgtcag tctttggaag cgcgattgat agccttgtat ttcgatactg 240gtatgtatgc cgaggctctg attctggaat ccaccttgtt gaaaggattg aagaagttgg 300atgacaaaaa tttactggta gaagtacagt tgcttgaaag taagacatat cacgccttga 360gtaacctgcc caaggctcgt gccgcattaa cttcagctcg tacaacagcc aattccatct 420attgccctcc taagatgcaa gctgcgcttg accttcagtc tggagttctg catgcagctg 480atgaaaaaga cttcaaaact gcctattcat acttttatga ggcatttgaa gggtttgaca 540gcgtagaatc accaaaagc 55933586DNALeptinotarsa decemlineata 33gcttcggagc ggtatagttt ttcgctgaca acttccagtc catctggaaa actagctcaa 60attgaatatg ccctagctgc tgtagccgct ggagctcctt ctgtgggcat taaagcttca 120aatggtgtag ttatcgccac agaaaacaaa cataagtcga tcctctatga agaacacagt 180gttcataaag ttgaaatgat tacaaaacat ataggaatga tatattctgg tatgggacct 240gattatcgct tgttggtgaa acaagctcgt aaaatggccc aacagtatta tctagtttat 300caagagccta taccaacagt tcaactcgtt caacgagttg ccactgttat gcaagaatat 360actcagtccg gaggagttag gccgtttggg gtttcattat tgatatgtgg ttgggacagt 420gaacgaccat acttatttca atgtgatcca tcaggagctt attttgcctg gaaagctact 480gccatgggca agaatttcat caatggaaaa acatttttgg aaaaaagata tagcgaggat 540ttggaacttg atgacgcagt acacacagca attctgacgt tgaagg 58634267DNALeptinotarsa decemlineata 34gctgaagcag gccaaagaag aagctcaaga cgaaatcgaa aaataccgta aagaacgcga 60acgtcaattc agggagttcg aggccaagca tatgggctcc agagaggatg taccgtccaa 120aatcgaagtg gacaccaaac gtagaatcga agagatgaac aaggctataa tcagtcaaaa 180agaacctgtt atccaagaag ttctcaactt agtgtacgac atcaaacctg aaatccacaa 240gaactaccgc caatagactg tgtgtgg 26735603DNALeptinotarsa decemlineata 35gcatgtgaaa atgagttcct tgaagctaca gaagaggctc gccgcctcgg ttatgcgatg 60tggcaaaaaa aagtatggtt ggatcctaat gaaattaatg aaatcgctaa caccaactca 120aggcaaaaca tccgtaagtt gatcaaagat ggtctcataa tcaagaaacc agtagcagtg 180cattcccgtg ctcgagtacg caaaaacaca gaagcccgca ggaagggaag acattgcggt 240ttcggtaaaa ggaagggtac agcaaatgct cgaatgcccc agaaggaatt atggattcag 300cgcatgagag ttttgagacg tctcttgaaa aaataccgag aagccaaaaa gatcgacagg 360catctgtact atgcccttta catgaaagca aagggtaacg tattcaagaa caagagagtc 420ctcatggaat acatccataa gaagaaggca gagaaggccc gtgccaagat gttggcagac 480caagccaatg ccaggagatt gaaggtaaaa caagcacgtg aacgtcgtga agaacgtatc 540gctaccaaga aacaggaagt tctacagaat taccagcggg aagatgaagc ccaagctgct 600aag 60336273DNALeptinotarsa decemlineata 36gatgtctgtt ttgtgtcctg aaattccagc gccaggcttt tcattcgaga attgtaaaag 60aaatgcattg ctggaaggca agggattcgc tctaccaaaa gctactaaga ctggtaccac 120catcgtagga attacttata aagatggagt cattcttggg gccgatacca tagccacaga 180agataccaca gttgcagaca agaactctga gaagattcac tatcttgctc caaatatgta 240ttgttgtggt gctggtacag ccgcggatac aga 27337310DNALeptinotarsa decemlineata 37atgtcgtcta ctctagaaga taaagctatc tgggaagatg gggaagaatc attgggggag 60gaagttctga ggatgtcgac tgatgaaata gtcagccgga cgcgtttact cgataatgaa 120atcaaaataa tgaagagcga agtaatgaga ataaaccatg aactccaagc ccaaaacgaa 180aaaatcaaag aaaacactga aaagataaag gtaaataaaa cgctacctta cttggtatct 240aatgttatag aactgctaga tgtggaccct caagaggaag aagaagacgg ggcagttgta 300gacttggatt 31038388DNALeptinotarsa decemlineata 38ggaatttgga ccagagaatt gtgtgacctg gatgaaattt gccgaactag aaactttatt 60aggcgacatt gatcgagcaa gggctattta cgaattggct ataagtcagc ctaggttaga 120tatgccagag ttactttgga aggcttatat agactttgaa atttctcagg aagaacctga 180aaatgctaga caaatctatg aaaggctgct agaaaaaaca tcacatgtca aagtatggtt 240gtcttatgcc aaatttgaac ttaacacaca atcagaaccc gacatgaatg ttctgttatc 300caggagagta tttgaaagag ccaacgagag cctaaaaaat tcatctgaaa aagaggcaag 360agttctactt cttgaaaact ggagggag 388391504DNALeptinotarsa decemlineata 39gcttgttgcc cccgaatgcc ttgatagggt tgattacctt tgggaagatg gtccaagtgc 60acgaactagg taccgagggc tgcagcaaat cttacgtttt ccgagggacg aaagacctca 120cagctaagca agttcaagag atgttggaag tgggcagagc cgcagtaagt gctcaacctg 180ctcctcaaca accaggacaa cccatgaggc ctggagcact ccagcaagct cctacgccac 240caggaagcag gttccttcaa cccatctcga aatgcgacat gaacctcact gatcttattg 300gagagttgca aagagaccca tggcctgtcc accaaggcaa atgcgccctt agatcgaccg 360ggacagcttt atcgatagcc attgggttgt tggagtgcac atacgccaat actggtgcca 420gggtcatgct attcgttgga ggaccttgct ctcaaggccc tggtcaagtc ttgaatgatg 480atctgaagca acctatcaga tctcaccacg acatccaaaa agacaatgcc aaatacatga 540agaaagcaat caagcactat gataatttag cgatgagagc agcaacgaat ggccactgcg 600ttgacatata ttcatgcgct ttggatcaga caggattgat ggagatgaaa cagtgttgta 660attcaacagg gggacatatg gtcatgggcg actcgttcaa ttcttccctg ttcaagcaaa 720cgttccagcg catattttcg aaagatcaga aaaacgagct gaagatggca tttaatggta 780ctctggaggt caagtgttcc agggagttga

aaattcaagg cggtattgga tcttgtgttt 840cgttgaatgt gaagaatcct ttggtttccg acaccgaaat aggaatgggt aacacggtcc 900agtggaaaat gtgtacggta actccaagta ctaccatggc cttgttcttc gaggtcgtca 960accaacattc cgctcccata cctcaagggg gaaggggctg catacagttc atcacgcaat 1020atcagcatgc tagtggccag aagaggatcc gagtaacgac agttgctaga aactgggccg 1080atgcttccgc taatatacat catgtcagtg ctggattcga tcaggaggca gccgcagtga 1140taatggcgag gatggcagtt tacagagcgg aatcagacga tagccctgat gttttgagat 1200gggtcgatag gatgttgata cgtctgtgcc agaaattcgg cgaatataac aaggacgacc 1260cgaattcgtt ccgcttgggc gaaaacttca gcctctaccc gcagttcatg taccatttga 1320gaaggtcaca gttcctgcag gtgtttaaca attctcccga cgaaacgtcc ttctacaggc 1380acatgcttat gcgcgaagac ctcacgcagt cgctgatcat gatccagccg atactctaca 1440gctacagttt caatggacca ccagaacctg tgcttttgga tacgagttcc atccaacccg 1500atag 150440967DNALeptinotarsa decemlineata 40gggagcagac gatcggttgg ttaaaatctg ggactatcaa aacaaaacgt gtgtccaaac 60cttggaagga cacgcccaaa acgtaaccgc ggtttgtttc caccctgaac tacctgtggc 120tctcacaggc agcgaagatg gtaccgttag agtttggcat acgaatacac acagattaga 180gaattgtttg aattatgggt tcgagagagt gtggaccatt tgttgcttga agggttcgaa 240taatgtttct ctggggtatg acgagggcag tatattagtg aaagttggaa gagaagaacc 300ggcagttagt atggatgcca gtggcggtaa aataatttgg gcaaggcact cggaattaca 360acaagctaat ttgaaggcgc tgccagaagg tggagaaata agagatgggg agcgtttacc 420tgtctctgta aaagatatgg gagcatgtga aatataccct caaacaatcc aacataatcc 480gaatggaaga ttcgttgtag tatgcggaga cggcgaatat atcatttaca cagcgatggc 540tctacggaac aaggcttttg gaagcgctca agagtttgtc tgggctcagg actccagcga 600gtatgccatt cgcgagtctg gttccacaat tcggatattc aaaaacttca aagaaaggaa 660gaacttcaag tcggatttca gcgcggaagg aatctacggg ggttttctct tggggattaa 720atcggtgtcc ggtttaacgt tttacgattg ggaaactttg gacttggtga gacggattga 780aatacaaccg agggcggttt attggtctga cagtggaaaa ttagtctgtc tcgcaacgga 840ggacagctac ttcatccttt cttatgattc ggagcaagtt cagaaggcca gggagaacaa 900tcaagtcgca gaggatggcg tagaggccgc tttcgatgtg ttgggggaaa tgaacgagtc 960tgtccga 9674143DNAArtificialPrimer 41gcgtaatacg actcactata ggtcgtggaa gatagcagga aag 434231DNAArtificialPrimer 42cattttctgt atgtatcagc ttgtccctct t 314326DNAArtificialPrimer 43gtcgtggaag atagcaggaa agggag 264441DNAArtificialPrimer 44gcgtaatacg actcactata ggcattttct gtatgtatca g 414544DNAArtificialPrimer 45gcgtaatacg actcactata ggatgtgtga cgaagaggtt gccg 444624DNAArtificialPrimer 46gtcaacaaaa cagggtgctc ttcg 244722DNAArtificialPrimer 47atgtgtgacg aagaggttgc cg 224846DNAArtificialPrimer 48gcgtaatacg actcactata gggtcaacaa aacagggtgc tcttcg 464941DNAArtificialPrimer 49gcgtaatacg actcactata ggtaagaatc gtcttttcgt c 415022DNAArtificialPrimer 50gacaccagct ccgcattgtt ca 225129DNAArtificialPrimer 51ggtaagaatc gtcttttcgt catatccac 295242DNAArtificialPrimer 52gcgtaatacg actcactata ggacaccagc tccgcattgt tc 425344DNAArtificialPrimer 53gcgtaatacg actcactata ggccaaacaa gaaacgccac gatg 445420DNAArtificialPrimer 54aggacgagat ggagggtgga 205522DNALeptinotarsa decemlineata 55ccaaacaaga aacgccacga tg 225642DNAArtificialPrimer 56gcgtaatacg actcactata ggaggacgag atggagggtg ga 425743DNAArtificialPrimer 57gcgtaatacg actcactata gggaccaaca aaggcttatc ttc 435826DNAArtificialPrimer 58cctcctctga gacgaagaac caaatg 265924DNAArtificialPrimer 59gggaccaaca aaggcttatc ttcg 246042DNAArtificialPrimer 60gcgtaatacg actcactata ggcctcctct gagacgaaga ac 426141DNAArtificialPrimer 61gcgtaatacg actcactata ggcttgtttg ctccagtctc g 416224DNAArtificialPrimer 62gcagattgaa agacctgggc tacg 246327DNAArtificialPrimer 63cttgtttgct ccagtctcga aactacg 276440DNAArtificialPrimer 64gcgtaatacg actcactata gggcagattg aaagacctgg 406541DNAArtificialPrimer 65gcgtaatacg actcactata ggtatttgag acctcgctgt c 416623DNAArtificialPrimer 66ccatgccctg actcttagcc ctg 236725DNAArtificialPrimer 67gtatttgaga cctcgctgtc gcaag 256841DNAArtificialPrimer 68gcgtaatacg actcactata ggccatgccc tgactcttag c 416947DNAArtificialPrimer 69gcgtaatacg actcactata ggccagcaaa cgaagacatc gaatcac 477024DNAArtificialPrimer 70gccgatcgac tctgagatga tttg 247125DNAArtificialPrimer 71ccagcaaacg aagacatcga atcac 257246DNAArtificialPrimer 72gcgtaatacg actcactata gggccgatcg actctgagat gatttg 467341DNAArtificialPrimer 73gcgtaatacg actcactata ggacgtttgg aggaagccga c 417427DNAArtificialPrimer 74ggagctggat atgcgtagag acttggt 277521DNAArtificialPrimer 75ggacgtttgg aggaagccga c 217642DNAArtificialPrimer 76gcgtaatacg actcactata ggagctggat atgcgtagag ac 427741DNAArtificialPrimer 77gcgtaatacg actcactata ggttagtgat tttgtattca g 417828DNAArtificialPrimer 78gccatgagag aatccctata gttgtagc 287930DNAArtificialPrimer 79gttagtgatt ttgtattcag attgtctccg 308042DNAArtificialPrimer 80gcgtaatacg actcactata ggccatgaga gaatccctat ag 428141DNAArtificialPrimer 81gcgtaatacg actcactata ggctaggtct ccagccagca g 418222DNAArtificialPrimer 82cagcaacatc agcatcgggt ga 228326DNAArtificialPrimer 83ctaggtctcc agccagcaga aagaac 268443DNAArtificialPrimer 84gcgtaatacg actcactata ggcagcaaca tcagcatcgg gtg 438541DNAArtificialPrimer 85gcgtaatacg actcactata gggtaaggct aaagaactgg c 418627DNAArtificialPrimer 86gcttttggtg attctacgct gtcaaac 278726DNAArtificialPrimer 87gtaaggctaa agaactggcg gaattg 268842DNAArtificialPrimer 88gcgtaatacg actcactata ggcttttggt gattctacgc tg 428944DNAArtificialPrimer 89gcgtaatacg actcactata ggcttcggag cggtatagtt tttc 449028DNAArtificialPrimer 90ccttcaacgt cagaattgct gtgtgtac 289124DNAArtificialPrimer 91gcttcggagc ggtatagttt ttcg 249241DNAArtificialPrimer 92gcgtaatacg actcactata ggccttcaac gtcagaattg c 419346DNAArtificialPrimer 93gcgtaatacg actcactata gggctgaagc aggccaaaga agaagc 469427DNAArtificialPrimer 94ccacacacag tctattggcg gtagttc 279524DNAArtificialPrimer 95gctgaagcag gccaaagaag aagc 249649DNAArtificialPrimer 96gcgtaatacg actcactata ggccacacac agtctattgg cggtagttc 499743DNAArtificialPrimer 97gcgtaatacg actcactata ggcatgtgaa aatgagttcc ttg 439825DNAArtificialPrimer 98cttagcagct tgggcttcat cttcc 259926DNAArtificialPrimer 99gcatgtgaaa atgagttcct tgaagc 2610043DNAArtificialPrimer 100gcgtaatacg actcactata ggcttagcag cttgggcttc atc 4310150DNAArtificialPrimer 101gcgtaatacg actcactata gggatgtctg ttttgtgtcc tgaaattcca 5010222DNAArtificialPrimer 102tctgtatccg cggctgtacc ag 2210328DNAArtificialPrimer 103gatgtctgtt ttgtgtcctg aaattcca 2810444DNAArtificialPrimer 104gcgtaatacg actcactata ggtctgtatc cgcggctgta ccag 4410556DNAArtificialPrimer 105gcgtaatacg actcactata ggatgtcgtc tactctagaa gataaagcta tctggg 5610624DNAArtificialPrimer 106aatccaagtc tacaactgcc ccgt 2410734DNAArtificialPrimer 107atgtcgtcta ctctagaaga taaagctatc tggg 3410846DNAArtificialPrimer 108gcgtaatacg actcactata ggaatccaag tctacaactg ccccgt 4610941DNAArtificialPrimer 109gcgtaatacg actcactata ggaatttgga ccagagaatt g 4111029DNAArtificialPrimer 110ctccctccag ttttcaagaa gtagaactc 2911127DNAArtificialPrimer 111ggaatttgga ccagagaatt gtgtgac 2711243DNAArtificialPrimer 112gcgtaatacg actcactata ggctccctcc agttttcaag aag 4311341DNAArtificialPrimer 113gcgtaatacg actcactata gggcttgttg cccccgaatg c 4111422DNAArtificialPrimer 114ctatcgggtt ggatggaact cg 2211519DNAArtificialPrimer 115gcttgttgcc cccgaatgc 1911644DNAArtificialPrimer 116gcgtaatacg actcactata ggctatcggg ttggatggaa ctcg 4411742DNAArtificialPrimer 117gcgtaatacg actcactata gggggagcag acgatcggtt gg 4211823DNAArtificialPrimer 118tcggacagac tcgttcattt ccc 2311920DNAArtificialPrimer 119gggagcagac gatcggttgg 2012045DNAArtificialPrimer 120gcgtaatacg actcactata ggtcggacag actcgttcat ttccc 45121837DNALygus hesperus 121gaacacggta tcgtcaccaa ctgggacgat atggagaaaa tctggcacca caccttctac 60aacgagttga gagtcgcccc cgaggaacac cccgtcctcc tgactgaagc ccccctcaac 120cctaaggcca acagggagaa gatgacccag atcatgttcg aaaccttcaa cacacccgcc 180atgtacgtgg ccatccaggc tgtcctgtcg ctgtacgcct ccggtcgtac cactggtatc 240gtcctcgact ccggagatgg tgtctcccac accgtcccga tctacgaggg atacgctcty 300ccccacgcca tcctccgtct cgacttggct ggccgtgact tgaccgacta ccttatgaag 360atcctcaccg agagaggcta ctccttcacg accaccgccg aaagggagat cgtccgtgac 420atcaaggaga agctctgcta cgtcgccctc gacttcgagc aggaaatggc caccgccgcg 480tcctcctcgt ccctcgaaaa gtcctacgag cttcccgacg gtcaagtcat caccatcgga 540aacgagaggt tcaggtgccc mgaagccctc ttccagcctt ccttcttggg aatggaagcc 600tgcggtatcc acgaaaccac ttacaactcc atcatgaagt gcgacgtgga catccgtaag 660gacctgtacg ccaacaccgt gctctctgga ggcaccacca tgtacccagg aatcgccgac 720aggatgcaga aggaaatcac cgccctcgcc ccatccacca tgaagatcaa gatcatcgct 780cccccagagc gcaaatactc cgtatggatc ggaggatcca tcctcgcctc cctctcc 837122756DNALygus hesperus 122gagcacggca tcatcaccaa ctgggacgac atggagaaga tctggcacca caccttctac 60aacgagctcc gcgtcgctcc cgaggagcac cccatcctcc tcacggaggc tcccctcaac 120cccaaagcca acagggagaa gatgactcag atcatgtttg agaccttcaa cacccccgcc 180atgtacgtcg ccatccaggc cgtmctttcc ctctacgctt ccggtcgtac caccggtatc 240gtcctcgact ccggagatgg tgtctcccac accgtcccca tctaygaagg ttacgccctt 300ccycacgcca tcctccgtct ggacttggct ggmcgtgact tgactgacta cctgatgaag 360atcctcaccg agaggggtta ctctttcacs accaccgctg agagggaaat cgtccgcgac 420atcaaggaga agctctgcta cgtcgctctg gacttcgagc aggaaatggc caccgccgcc 480gcctccacct ccctcgagaa gtcctacgag cttcccgacg gacaggtcat caccatcggy 540aacgagaggt tccgttgccc cgaagccctc ttccagcctt ccttcctggg tatggaatcc 600tgcggyatcc acgagaccgt ctacaactcc atcatgaagt gcgacgtcga catcaggaaa 660gacctgtacg ccaacaccgt cctctccgga ggcaccacca tgtaccccgg tatcgccgac 720aggatgcaga aggaaatcac cgccctcgct ccctcg 756123213DNALygus hesperus 123atccccccgg atcagcagcg tcttatcttc gccggtaagc aattggaaga tggccgcacc 60ctttctgact acaacatcca gaaagaatcc accttgcact trgtgctcag gcttcgyggt 120ggtgccaaga aaaggaagaa gaagaactac tccactccca agaagatcaa gcacaagaag 180aagaagatta agttggctgt gcttaaatac tac 213124265DNALygus hesperus 124caargchaar atccargaca aggaaggsat ycccccagay cagcagaggt tgatcttcgc 60tggcaagcag ctcgaagatg gccgcacact ttcygactac aacatccaga aagagtccac 120ccttcacttg gtcctccgyc tgagaggagg agtcatcgag cccrccctca ggatyttggc 180tcagaagtac aactgcgaca aratgatctg caggaagtgc tacgctcgtc tccaccccag 240ggcgaccaac tgtcgcaaga agaaa 265125384DNALygus hesperus 125aagaccctca caggaaagac catcactctt gaggtcgagc cttctgacac catcgaaaac 60gtcaaggcta aaattcaaga caaggaaggt attcctccag atcagcagag attgatcttc 120gccggcaaac aactcgaaga tggccgtacc ctctctgact acaatattca aaaagagtcc 180acccttcact tggtgttgag attgcgtgga ggtatgcaaa tctttgtcaa aacattgact 240ggaaagacca tcacccttga agtcgaaccc tccgacacca tcgaaaatgt caaggccaag 300atccaggaca aggaaggcat ccccccagat cagcagaggt tgattttcgc tggcaaacaa 360cttgaagacg gacgtaccct ctcg 384126156DNALygus hesperus 126accctgtccg actacaacat acagaaggag tccactcttc acttggtgtt gagattgcgt 60ggtggtatgc agatcttcgt caagacgttg acaggcaaga ccatcaccct tgaagtcgag 120ccctctgaca ccatcgaaaa cgtcaaggct aagatc 156127156DNALygus hesperus 127accctgtccg actacaacat acagaaggag tcgaccctcc atcttgtcct ccgtctgcgt 60ggtggtatgc agatttttgt caaaacgctg actggcaaga caatcaccct tgaagtagag 120ccctctgaca ccatcgaaaa tgtcaaggcg aaaatc 156128141DNALygus hesperus 128cacttggtgt tgagattgcg tggtggtatg cagatcttcg tcaaaacctt gaccggcaag 60acgatcactt tggaagtgga gccctctgac accattgaga atgttaaagc caagatccag 120gacaaggaag gtatcccccc a 141129138DNALygus hesperus 129cttgtactcc gtctgcgtgg tggtatgcag attttcgtga agaccttgac tggcaagacc 60atcactcttg aggtcgagcc ctctgacacc attgaaaacg tcaaggccaa gatccaggac 120aaggaaggta tcccccca 138130228DNALygus hesperus 130agctcycacg agaacgaact gatcctcatg agcgttctyc agtgtctgta cgactcgaty 60agtcaaatcc tgaggaaaaa cgtygagaaa cgaacgatat tcgagaacct ggagatcgtc 120atgctcgcca tggacgagat ctgcgacggt gggatactcc tggaggccga ccctacgtcc 180gtcgtacagc gagtcgccat ccggaccgat gacatcccct tgggcgaa 228131418DNALygus hesperus 131cttgracgta ctcattgtca accagacagc tgacactctt caaaattgca ctctggaatt 60ggctacactt ggcgacctga aattggtcga gaagccgcaa ccctgcgttt tggcgcctca 120tgacttctgt aacataaaag ctaacgtcaa agtggcttcc actgaaaacg gaattatttt 180tggcaacatt gkttacgacg ttagtggagc agcttccgac cgaaacgtcg tcgtcctcaa 240tgacattcac atcgatatta tggactacat agttcctgca tcttgttctg acactgaatt 300ccgccaaatg tgggctgaat tcgaatggga aaacaaggta tctgtcaaca ccaacctcac 360ggacttgcac gagtatttgg cccatttggt caggagcacc aacatgaagt gcttgaca 418132348DNALygus hesperus 132gtcctagaca ttgtrgctta ccaactgaat ttctacagaa atgaaacgaa tgaagaaccg 60accgtcgaaa ttgcggccaa tgtgttccgt gatgtctact acaggtaccg wgaccagttg 120caggtcggtc tgatcatagc tggatgggay aaagtcaagg gaggacaggt gtacaatatt 180cctttgggtg ggatggtcat ccgtcaaaag ttctgcatgg gtggttctgg cagcacgttt 240gtctttggtt tcaccgacac caacttcaag gagaacatga cagaagccga gtgcaagaac 300ttcttaacra gagctattgg cctygccatc agccgcgacg gttcatct 348133348DNALygus hesperus 133gtatcggaaa tggtgacttt ccaactgaat ttatacagaa atgaaacaaa taaagaaccg 60actgttgaaa tggcggccaa tgtgttccgt gatgtctgct acaggtaccg tgaccagctg 120caggttggtc tgatcatagc tggatgggat gaagtcaaag gagcacaggt gtacatgatt 180cctttgggcg ggatggtcat ccgtcagaag ttcgccatga gtggttctgg cagcaccttc 240atttatggtt tcactgacgc ccacttcaag gagaacatga ccgaagcgga gtgcaagaac 300ttcttaacca gagctattgg ccttgccatc agccgcgacg gtgcgtct 3481341115DNALygus hesperus 134tcgcttcatt tgtatctgaa atcagtgatg aattcaaaat cgtcgtcgtc caggctattc 60gtgcgctctg cctcaagttt cccagaaagc atagtaccct aatgacattc ctgtctgcca 120tgctccgcga tgaaggtgga ttggagtaca gagcttcgat agctgatacc atcatcacaa 180tcattgaaga taatcctgaa gctaaagaaa ttggactcgc tcatctctgc gagttcattg 240aagattgtga gcacgttagt ttggcagtca gaatccttca tctacttggt aaagaaggac 300cgaaaacaat tcaaccttct cgatacatca gattcattta caatagggtt atccttgaaa 360tagctgttat tcgggctgct gcagtttctg cccttgctca gtttggagct ctatgtccag 420atcttctccc caacatcttg gttttgctgg cccgatgcca aatggacact gatgacgaag 480tgagagatag ggcgacttac tattatcatc tactgaaatt gcaggagaaa ggacttattt 540tcaattacat tgtcgaccca atgcaggttt gtctggtgag tctcgagaaa tcgttggccc 600aacatgttca cgataaggta cccactaaat tcgatttgaa gtccgttcca cctgctcctg 660tcgtgtctac tactgaagac accgcacaag aaacggtacc tgaaggctcc attagttcag 720ccccaagtaa gatcgctcct ttacaatcaa cagttagtag ctatgcagag aagctgcaag 780gagttccagg tctacaaagc atacccggga cattattcca tgtatcagaa ccagttgaac 840tcaccgaatc cgaaactgaa tacgttgtca cgtgcaccaa acttacatac cctcatcacc 900tcgtgttgca gtttgaatgc aagaacacgt tgagygatca rcttcttgag aatgtcagag 960ttcwgattga ggccagtgaa ggttacagaa tcgtcaagga aataccgatc tccaagcttc 1020cttacaacga aacacattgt gcctacgtag tgytgcaatt tccagagcaa ctttccctca 1080ccgtcackaa tttcggagct acactcagat ttatc 1115135915DNALygus hesperus 135aaggccaagg wattgggtga actgatccaa gcctccaggc ccttcctgtc tgagatatct 60aaagcaaaag ctgccaaatt agtcagaact ctggtagatt tcttcctaga tttagaggcc 120gaaactggaa gagaggttca gctgtgcaag gagtgcatag aatgggccac aaccgagaga 180agaacgttcc tcaggcaaag tctcgaagct

cgactcatcg ctttgtattt cgayacgggc 240atgtacacgg aagccctcgg tttgggatcg agccttctca aagaactgaa aaaacttgac 300gacaaaaatc tccttgtrga agtyctgctt ctagagtcga aaacctacca tgcactcagc 360aatttgtcca aggctagagc agctctcaca tcagcrcgca caacagcaaa ttccatctac 420tgtccaccta aaatgcaggc agccctggat ctccagtctg gaatacttca tgctgctgat 480gaacaagatt tcaaaactgc atattcctat ttctacgaag ctttcgaagg atatgattcg 540gtagactctc cgaaagcgtt gactgctcta aaatacatgc ttctctcaaa aattatgttg 600aacactccgg aggatgtaca gcaacttatt tcaggaaaac ttgctttgaa gcatgcaggg 660cgagacatcg acgccatgaa aaacgtagct aaggcttctg ccaagcggtc ccttgcagat 720ttccagtcca ctcttgaagg ctacaagaaa gagttgaaag aagacccgat tgtgaaggcc 780catctgggca ctctctacga caacatgctg gaacaaaatt tgtgtcgtat aatcgaaccc 840tattcaagag tacaagtgga atacgtctcg aaagccatca aactcccgac tctccaggtg 900gagaagaagc tctcc 915136537DNALygus hesperus 136ttggccgctg tatctgctgg cgccccttcc ataggcatta aagcgcaaaa tggygtggtt 60ttggcgactg agaacaartt caagtctatt ctctatgaag aacactcgat aaaaaagatt 120gagatggtcg aagaacayat tggaatggtc tacagtggta tgggacccga ttacaggctg 180ctagtgaaga gagcgcgcaa gttagctcar cagtacaagt tggtttatgg acagaggata 240ccgacgcccc aactcgttca aaaggttgcc atggtgatgc aggagtacac gcaatcagga 300ggcgtacggc cgttcggagt gtcgttactc atytgcgggt gggacgatgg ccgtccracc 360ttgttccagt gcgatccttc tggcgcctac tttgcctgga aagcaactgc gatggggaag 420aayttcatca atggaaaaac tttcytggag aagaggtaca ttgaaaccca agacatcgar 480gacgctgtmc acaccgccat attgaccttg aaagaaggat tcgaaggtca aatggat 537137241DNALygus hesperus 137tgcggaagca aagaaaagga aagctcgccg tttgaagcag gccaaggaag aggctcagga 60ggaaattgaa aggtacaagc aagrcagaga gaagcagttc aaggagttcg aagcccagca 120catgggctcc agggaggacg ttgctgccag gatagacgct gacactcgtc agagaattga 180agagatgaca aaagctgtca atgtcaacaa agaacaagtg atccaaagaa tactggaact 240t 241138538DNALygus hesperus 138cgcctcggtg atgagatgcg gcaagaagaa agtgtggttg gaccctaatg aaatcaacga 60aatcgccrmc rccaactcta ggcaaaayat ycgtaagctg atcaaggatg gtttgatcat 120caaaaagcct gtggctgtcc actccagrgc ccgcgtccgt aaaaacacag aagccagacg 180gaagggtcgt caytgtggct tyggtaagag gaagggtacs gccaacgcca gaatgcctgt 240gaaggtcctg tgggtsaacm gaatgagrgt cctgcgacgg ctccttaaaa aatacagaga 300agccaagaag atcgataggc aaatgtacca cgacctttac atgaaagcca aaggtaacgt 360cttcaaaaac aagagggtac tgatggactt cattcacaag aagaaggctg aaaaggcgag 420atcaaagatg ttgaaggacc aggcagaggc gagacgtctc aaggtcaagg aggcgaagaa 480gaggcgcgag gagaggatcg ccaccaagaa gcaagagatc atgcaggcgt acgcccga 538139657DNALygus hesperusmisc_feature(366)..(366)n is a, c, g, or t 139gagaaatttg aaaatttggg tattcaaccc cccaaggggg ttctgttata tggaccacct 60ggcactggta agactctcct ggccagagct tgtgctgccc aaaccaaatc caccttcctg 120aaacttgctg gacctcagtt ggttcaaatg tttattggag acggtgccaa actcgtcagg 180gacgccttcg ctttggccaa agaaaaagct cctgccatta ttttcatcga cgaattagac 240gcaattggta cgaaaagatt cgactctgag aaggcaggtg acagagaagt gcagagaact 300atgttggagt tgctgaacca gctggatggt ttcagttcca cagctgatat caaagttatt 360gctgcnacta accgtgtgga cattttggac cctgctttgc tacgatcggg tcgtcttgat 420cgaaaaatcg agttcccaca tcccaacgag gacgccaggg ctcgcatcat gcagatccac 480tcgcgcaaaa tgaacatcag cgtcgacgtc aatttcgagg aactcgcacg gtccaccgac 540gacttcaacg gcgctcagtg caaagcagtt tgcgtggaag ctggtatgat cgctcttcgt 600agaagcgcga gtgtcgtctc ccacgaagac ttcatggatg cgatattgga agtycag 657140276DNALygus hesperus 140aacaaaaccc ttccatattt ggtctccaac gtcattgagc tacttgatgt tgacccagaa 60gagacygagg aagatggtgc tgtggttgat ttggatgcga gaagaaaagg gaagtgcgcc 120gtgattaaaa catctactag acaaacgtat ttccttccag tcaytggktt ggttgatgcg 180gaaaaattaa agcctgggga tttggtcgga gtaaataagg attcctattt gattttggaa 240acccttccag ctgartatga cgctcgagtg aaagct 276141625DNALygus hesperus 141ctaaggccaa cagggagaag atgacccaga tcatgttcga aaccttcaac acacccgcca 60tgtacgtggc catccaggct gtcctgtcgc tgtacgcctc cggtcgtacc actggtatcg 120tcctcgactc cggagatggt gtctcccaca ccgtcccgat ctacgaggga tacgctctcc 180cccacgccat cctccgtctc gacttggctg gccgtgactt gaccgactac cttatgaaga 240tcctcaccga gagaggctac tccttcacga ccaccgccga aagggagatc gtccgtgaca 300tcaaggagaa gctctgctac gtcgccctcg acttcgagca ggaaatggcc accgccgcgt 360cctcctcgtc cctcgaaaag tcctacgagc ttcccgacgg tcaagtcatc accatcggaa 420acgagaggtt caggtgcccc gaagccctct tccagccttc cttcttggga atggaagcct 480gcggtatcca cgaaaccact tacaactcca tcatgaagtg cgacgtggac atccgtaagg 540acctgtacgc caacaccgtg ctctctggag gcaccaccat gtacccagga atcgccgaca 600ggatgcagaa ggaaatcacc gccct 625142168DNALygus hesperus 142tgcttgatct tcttgggagt ggagtagttc ttcttcttcc ttttcttggc accaccacga 60agcctgagca ccaagtgcaa ggtggattct ttctggatgt tgtagtcaga aagggtgcgg 120ccatcttcca attgcttacc ggcgaagata agacgctgct gatccggg 168143231DNALygus hesperus 143gctaaaatcc aagacaagga agggattccc ccagaccagc agaggttgat cttcgctggc 60aagcagctcg aagatggccg cacactttcc gactacaaca tccagaaaga gtccaccctt 120cacttggtcc tccgtctgag aggaggagtc atcgagccca ccctcaggat cttggctcag 180aagtacaact gcgacaagat gatctgcagg aagtgctacg ctcgtctcca c 231144300DNALygus hesperus 144cactcttgag gtcgagcctt ctgacaccat cgaaaacgtc aaggctaaaa ttcaagacaa 60ggaaggtatt cctccagatc agcagagatt gatcttcgcc ggcaaacaac tcgaagatgg 120ccgtaccctc tctgactaca atattcaaaa agagtccacc cttcacttgg tgttgagatt 180gcgtggaggt atgcaaatct ttgtcaaaac attgactgga aagaccatca cccttgaagt 240cgaaccctcc gacaccatcg aaaatgtcaa ggccaagatc caggacaagg aaggcatccc 300145172DNALygus hesperus 145gagcgttctc cagtgtctgt acgactcgat cagtcaaatc ctgaggaaaa acgttgagaa 60acgaacgata ttcgagaacc tggagatcgt catgctcgcc atggacgaga tctgcgacgg 120tgggatactc ctggaggccg accctacgtc cgtcgtacag cgagtcgcca tc 172146408DNALygus hesperus 146gaacgtactc attgtcaacc agacagctga cactcttcaa aattgcactc tggaattggc 60tacacttggc gacctgaaat tggtcgagaa gccgcaaccc tgcgttttgg cgcctcatga 120cttctgtaac ataaaagcta acgtcaaagt ggcttccact gaaaacggaa ttatttttgg 180caacattgtt tacgacgtta gtggagcagc ttccgaccga aacgtcgtcg tcctcaatga 240cattcacatc gatattatgg actacatagt tcctgcatct tgttctgaca ctgaattccg 300ccaaatgtgg gctgaattcg aatgggaaaa caaggtatct gtcaacacca acctcacgga 360cttgcacgag tatttggccc atttggtcag gagcaccaac atgaagtg 408147273DNALygus hesperus 147gaaccgaccg tcgaaattgc ggccaatgtg ttccgtgatg tctactacag gtaccgtgac 60cagttgcagg tcggtctgat catagctgga tgggataaag tcaagggagg acaggtgtac 120aatattcctt tgggtgggat ggtcatccgt caaaagttct gcatgggtgg ttctggcagc 180acgtttgtct ttggtttcac cgacaccaac ttcaaggaga acatgacaga agccgagtgc 240aagaacttct taacgagagc tattggcctt gcc 2731481041DNALygus hesperus 148gtcgtcgtcc aggctattcg tgcgctctgc ctcaagtttc ccagaaagca tagtacccta 60atgacattcc tgtctgccat gctccgcgat gaaggtggat tggagtacag agcttcgata 120gctgatacca tcatcacaat cattgaagat aatcctgaag ctaaagaaat tggactcgct 180catctctgcg agttcattga agattgtgag cacgttagtt tggcagtcag aatccttcat 240ctacttggta aagaaggacc gaaaacaatt caaccttctc gatacatcag attcatttac 300aatagggtta tccttgaaat agctgttatt cgggctgctg cagtttctgc ccttgctcag 360tttggagctc tatgtccaga tcttctcccc aacatcttgg ttttgctggc ccgatgccaa 420atggacactg atgacgaagt gagagatagg gcgacttact attatcatct actgaaattg 480caggagaaag gacttatttt caattacatt gtcgacccaa tgcaggtttg tctggtgagt 540ctcgagaaat cgttggccca acatgttcac gataaggtac ccactaaatt cgatttgaag 600tccgttccac ctgctcctgt cgtgtctact actgaagaca ccgcacaaga aacggtacct 660gaaggctcca ttagttcagc cccaagtaag atcgctcctt tacaatcaac agttagtagc 720tatgcagaga agctgcaagg agttccaggt ctacaaagca tacccgggac attattccat 780gtatcagaac cagttgaact caccgaatcc gaaactgaat acgttgtcac gtgcaccaaa 840cttacatacc ctcatcacct cgtgttgcag tttgaatgca agaacacgtt gagtgatcaa 900cttcttgaga atgtcagagt tcagattgag gccagtgaag gttacagaat cgtcaaggaa 960ataccgatct ccaagcttcc ttacaacgaa acacattgtg cctacgtagt gctgcaattt 1020ccagagcaac tttccctcac c 1041149710DNALygus hesperus 149ggtgaactga tccaagcctc caggcccttc ctgtctgaga tatctaaagc aaaagctgcc 60aaattagtca gaactctggt agatttcttc ctagatttag aggccgaaac tggaagagag 120gttcagctgt gcaaggagtg catagaatgg gccacaaccg agagaagaac gttcctcagg 180caaagtctcg aagctcgact catcgctttg tatttcgaca cgggcatgta cacggaagcc 240ctcggtttgg gatcgagcct tctcaaagaa ctgaaaaaac ttgacgacaa aaatctcctt 300gtggaagtcc tgcttctaga gtcgaaaacc taccatgcac tcagcaattt gtccaaggct 360agagcagctc tcacatcagc gcgcacaaca gcaaattcca tctactgtcc acctaaaatg 420caggcagccc tggatctcca gtctggaata cttcatgctg ctgatgaaca agatttcaaa 480actgcatatt cctatttcta cgaagctttc gaaggatatg attcggtaga ctctccgaaa 540gcgttgactg ctctaaaata catgcttctc tcaaaaatta tgttgaacac tccggaggat 600gtacagcaac ttatttcagg aaaacttgct ttgaagcatg cagggcgaga catcgacgcc 660atgaaaaacg tagctaaggc ttctgccaag cggtcccttg cagatttcca 710150368DNALygus hesperus 150aatggtgtgg ttttggcgac tgagaacaag ttcaagtcta ttctctatga agaacactcg 60ataaaaaaga ttgagatggt cgaagaacat attggaatgg tctacagtgg tatgggaccc 120gattacaggc tgctagtgaa gagagcgcgc aagttagctc aacagtacaa gttggtttat 180ggacagagga taccgacgcc ccaactcgtt caaaaggttg ccatggtgat gcaggagtac 240acgcaatcag gaggcgtacg gccgttcgga gtgtcgttac tcatctgcgg gtgggacgat 300ggccgtccga ccttgttcca gtgcgatcct tctggcgcct actttgcctg gaaagcaact 360gcgatggg 368151235DNALygus hesperus 151gcggaagcaa agaaaaggaa agctcgccgt ttgaagcagg ccaaggaaga ggctcaggag 60gaaattgaaa ggtacaagca agacagagag aagcagttca aggagttcga agcccagcac 120atgggctcca gggaggacgt tgctgccagg atagacgctg acactcgtca gagaattgaa 180gagatgacaa aagctgtcaa tgtcaacaaa gaacaagtga tccaaagaat actgg 235152511DNALygus hesperus 152ggtgatgaga tgcggcaaga agaaagtgtg gttggaccct aatgaaatca acgaaatcgc 60caacaccaac tctaggcaaa acatccgtaa gctgatcaag gatggtttga tcatcaaaaa 120gcctgtggct gtccactcca gagcccgcgt ccgtaaaaac acagaagcca gacggaaggg 180tcgtcactgt ggcttcggta agaggaaggg taccgccaac gccagaatgc ctgtgaaggt 240cctgtgggtc aacagaatga gagtcctgcg acggctcctt aaaaaataca gagaagccaa 300gaagatcgat aggcaaatgt accacgacct ttacatgaaa gccaaaggta acgtcttcaa 360aaacaagagg gtactgatgg acttcattca caagaagaag gctgaaaagg cgagatcaaa 420gatgttgaag gaccaggcag aggcgagacg tctcaaggtc aaggaggcga agaagaggcg 480cgaggagagg atcgccacca agaagcaaga g 511153495DNALygus hesperus 153tgtgctgccc aaaccaaatc caccttcctg aaacttgctg gacctcagtt ggttcaaatg 60tttattggag acggtgccaa actcgtcagg gacgccttcg ctttggccaa agaaaaagct 120cctgccatta ttttcatcga cgaattagac gcaattggta cgaaaagatt cgactctgag 180aaggcaggtg acagagaagt gcagagaact atgttggagt tgctgaacca gctggatggt 240ttcagttcca cagctgatat caaagttatt gctgctacta accgtgtgga cattttggac 300cctgctttgc tacgatcggg tcgtcttgat cgaaaaatcg agttcccaca tcccaacgag 360gacgccaggg ctcgcatcat gcagatccac tcgcgcaaaa tgaacatcag cgtcgacgtc 420aatttcgagg aactcgcacg gtccaccgac gacttcaacg gcgctcagtg caaagcagtt 480tgcgtggaag ctggt 49515445DNAArtificialPrimer 154gcgtaatacg actcactata ggctaaggcc aacagggaga agatg 4515520DNAArtificialPrimer 155agggcggtga tttccttctg 2015623DNAArtificialPrimer 156ctaaggccaa cagggagaag atg 2315742DNAArtificialPrimer 157gcgtaatacg actcactata ggagggcggt gatttccttc tg 4215845DNAArtificialPrimer 158gcgtaatacg actcactata ggtgcttgat cttcttggga gtgga 4515920DNAArtificialPrimer 159cccggatcag cagcgtctta 2016023DNAArtificialPrimer 160tgcttgatct tcttgggagt gga 2316142DNAArtificialPrimer 161gcgtaatacg actcactata ggcccggatc agcagcgtct ta 4216245DNAArtificialPrimer 162gcgtaatacg actcactata ggctaaaatc caagacaagg aaggg 4516322DNAArtificialPrimer 163gtggagacga gcgtagcact tc 2216424DNAArtificialPrimer 164gctaaaatcc aagacaagga aggg 2416543DNAArtificialPrimer 165gcgtaatacg actcactata ggtggagacg agcgtagcac ttc 4316645DNAArtificialPrimer 166gcgtaatacg actcactata ggcactcttg aggtcgagcc ttctg 4516720DNAArtificialPrimer 167gggatgcctt ccttgtcctg 2016823DNAArtificialPrimer 168cactcttgag gtcgagcctt ctg 2316942DNAArtificialPrimer 169gcgtaatacg actcactata gggggatgcc ttccttgtcc tg 4217045DNAArtificialPrimer 170gcgtaatacg actcactata gggagcgttc tccagtgtct gtacg 4517120DNAArtificialPrimer 171gatggcgact cgctgtacga 2017223DNAArtificialPrimer 172gagcgttctc cagtgtctgt acg 2317342DNAArtificialPrimer 173gcgtaatacg actcactata gggatggcga ctcgctgtac ga 4217447DNAArtificialPrimer 174gcgtaatacg actcactata ggaacgtact cattgtcaac cagacag 4717523DNAArtificialPrimer 175cacttcatgt tggtgctcct gac 2317626DNAArtificialPrimer 176gaacgtactc attgtcaacc agacag 2617745DNAArtificialPrimer 177gcgtaatacg actcactata ggcacttcat gttggtgctc ctgac 4517842DNAArtificialPrimer 178gcgtaatacg actcactata gggaaccgac cgtcgaaatt gc 4217920DNAArtificialPrimer 179ggcaaggcca atagctctcg 2018020DNAArtificialPrimer 180gaaccgaccg tcgaaattgc 2018142DNAArtificialPrimer 181gcgtaatacg actcactata ggggcaaggc caatagctct cg 4218243DNAArtificialPrimer 182gcgtaatacg actcactata ggtcgtcgtc caggctattc gtg 4318321DNAArtificialPrimer 183ggtgagggaa agttgctctg g 2118422DNAArtificialPrimer 184gtcgtcgtcc aggctattcg tg 2218541DNAArtificialPrimer 185gcgtaatacg actcactata ggtgagggaa agttgctctg g 4118644DNAArtificialPrimer 186gcgtaatacg actcactata ggggtgaact gatccaagcc tcca 4418720DNAArtificialPrimer 187tggaaatctg caagggaccg 2018822DNAArtificialPrimer 188ggtgaactga tccaagcctc ca 2218942DNAArtificialPrimer 189gcgtaatacg actcactata ggtggaaatc tgcaagggac cg 4219044DNAArtificialPrimer 190gcgtaatacg actcactata ggaatggtgt ggttttggcg actg 4419120DNAArtificialPrimer 191cccatcgcag ttgctttcca 2019222DNAArtificialPrimer 192aatggtgtgg ttttggcgac tg 2219342DNAArtificialPrimer 193gcgtaatacg actcactata ggcccatcgc agttgctttc ca 4219444DNAArtificialPrimer 194gcgtaatacg actcactata ggcggaagca aagaaaagga aagc 4419529DNAArtificialPrimer 195ccagtattct ttggatcact tgttctttg 2919623DNAArtificialPrimer 196gcggaagcaa agaaaaggaa agc 2319751DNAArtificialPrimer 197gcgtaatacg actcactata ggccagtatt ctttggatca cttgttcttt g 5119842DNAArtificialPrimer 198gcgtaatacg actcactata ggtgatgaga tgcggcaaga ag 4219922DNAArtificialPrimer 199ctcttgcttc ttggtggcga tc 2220022DNAArtificialPrimer 200ggtgatgaga tgcggcaaga ag 2220144DNAArtificialPrimer 201gcgtaatacg actcactata ggctcttgct tcttggtggc gatc 4420242DNAArtificialPrimer 202gcgtaatacg actcactata ggtgtgctgc ccaaaccaaa tc 4220320DNAArtificialPrimer 203accagcttcc acgcaaactg 2020420DNAArtificialPrimer 204tgtgctgccc aaaccaaatc 2020542DNAArtificialPrimer 205gcgtaatacg actcactata ggaccagctt ccacgcaaac tg 42206193PRTLeptinotarsa decemlineata 206Leu Arg Ile Phe Leu Phe Ala Leu Ser Trp Lys Ile Ala Gly Lys Gly1 5 10 15Asp Gly Glu Gly Glu Gly Asn Ile Leu Lys Leu Glu Asn Gln Ile Ala 20 25 30Val Ile Lys Tyr Val Leu Ile Phe Thr Asn Ile Leu Ser Trp Tyr Ile 35 40 45Gly Thr Gln Val Ala Gly Phe Ile Phe Gly Leu Ser Gly Ala Ser Val 50 55 60Leu Leu Asp Asn Ser Ala Arg Asp Ser His Phe Gln Pro Arg Ile Arg65 70 75 80Glu Ser Met Arg Arg Leu Ile Met Asn Ala His His Glu Glu Ser Arg 85 90 95Gln Thr Leu Ala Met Ile Gln Glu Asn Ile Ala Cys Cys Gly Ala Asp 100 105 110Gly Ala His Asp Tyr Leu Ser Leu Gln Gln Pro Leu Pro Ser Thr Cys 115 120 125Arg Asp Thr Val Thr Gly Asn Pro Phe Tyr His Gly Cys Val Asp Glu 130 135 140Leu

Thr Trp Phe Phe Glu Glu Lys Cys Gly Trp Val Ala Gly Leu Val145 150 155 160Met Ile Leu Cys Leu Ile Gln Val Ile Asn Thr Val Leu Ser Ile Ile 165 170 175Phe Leu Gln Ala Leu Lys Lys Glu Glu Gly Gln Ala Asp Thr Tyr Arg 180 185 190Lys207204PRTLeptinotarsa decemlineata 207Pro Ile Asn Met Cys Asp Glu Glu Val Ala Ala Leu Val Val Asp Asn1 5 10 15Gly Ser Gly Met Cys Lys Ala Gly Phe Ala Gly Asp Asp Ala Pro Arg 20 25 30Ala Val Phe Pro Ser Ile Val Gly Arg Pro Arg His Gln Gly Val Met 35 40 45Val Gly Met Gly Gln Lys Asp Ser Tyr Val Gly Asp Glu Ala Gln Ser 50 55 60Lys Arg Gly Ile Leu Thr Leu Lys Tyr Pro Ile Glu His Gly Ile Val65 70 75 80Thr Asn Trp Asp Asp Met Glu Lys Ile Trp His His Thr Phe Tyr Asn 85 90 95Glu Leu Arg Val Ala Pro Glu Glu His Pro Val Leu Leu Thr Glu Ala 100 105 110Pro Leu Asn Pro Lys Ala Asn Arg Glu Lys Met Thr Gln Ile Met Phe 115 120 125Glu Thr Phe Asn Thr Pro Ala Met Tyr Val Ala Ile Gln Ala Val Leu 130 135 140Ser Leu Tyr Ala Ser Gly Arg Thr Thr Gly Ile Val Leu Asp Ser Gly145 150 155 160Asp Gly Val Ser His Thr Val Pro Ile Tyr Glu Gly Tyr Ala Leu Pro 165 170 175His Ala Ile Leu Arg Leu Asp Leu Ala Gly Arg Asp Leu Thr Asp Tyr 180 185 190Leu Met Lys Ile Leu Thr Glu Arg Gly Tyr Ser Phe 195 20020896PRTLeptinotarsa decemlineata 208Leu Pro Lys Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile1 5 10 15Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys 20 25 30Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Leu Arg Leu Ile Phe 35 40 45Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile 50 55 60Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Ala65 70 75 80Lys Lys Arg Lys Lys Lys Asn Tyr Ser Thr Pro Lys Lys Asn Gln Ala 85 90 9520987PRTLeptinotarsa decemlineata 209Phe Asn Gln Thr Arg Asn Ala Thr Met Gln Ile Phe Val Lys Thr Leu1 5 10 15Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu 20 25 30Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln 35 40 45Gln Arg Leu Val Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu 50 55 60Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg65 70 75 80Leu Arg Gly Gly Ile Ile Glu 85210192PRTLeptinotarsa decemlineata 210Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg1 5 10 15Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu Val 20 25 30Leu Arg Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu Thr Gly 35 40 45Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val 50 55 60Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg65 70 75 80Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp 85 90 95Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg 100 105 110Gly Gly Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr 115 120 125Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile 130 135 140Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala145 150 155 160Gly Lys Arg Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln 165 170 175Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Lys Tyr 180 185 190211195PRTLeptinotarsa decemlineata 211Leu Lys Asn Lys Leu Val Cys Ser Ser Leu Glu Thr Thr Arg Ile Glu1 5 10 15Ala Met Glu Gly Ser Leu Leu Glu Pro Thr Leu Tyr Thr Ile Lys Gly 20 25 30Ile Leu Ile Leu Asp Asn Asp Gly Asn Arg Ile Leu Ala Lys Tyr Tyr 35 40 45Asp Lys Thr Thr Phe Pro Thr Ser Lys Glu Gln Lys Ala Phe Glu Lys 50 55 60Asn Leu Phe Asn Lys Thr His Arg Ala Asn Ala Glu Ile Ile Met Leu65 70 75 80Asp Gly Leu Thr Cys Leu Tyr Arg Ser Asn Val Asp Leu Phe Phe Tyr 85 90 95Val Met Gly Ser Ser His Glu Asn Glu Leu Ile Leu Met Ser Ile Leu 100 105 110Asn Cys Leu Tyr Asp Ser Val Ser Gln Ile Leu Arg Lys Asn Val Glu 115 120 125Lys Arg Ala Val Leu Glu Ser Leu Asp Ile Val Met Leu Ala Leu Asp 130 135 140Glu Ile Cys Asp Gly Gly Ile Ile Leu Asp Ala Asp Ser Asn Ser Ala145 150 155 160Val Ser Arg Val Ala Leu Arg Asn Asp Asp Ile Pro Ile Gly Glu Gln 165 170 175Thr Val Ala Gln Val Phe Gln Ser Ala Lys Glu Gln Leu Lys Trp Ser 180 185 190Leu Leu Lys 195212245PRTLeptinotarsa decemlineata 212Val Glu Gln Asp Asn Ala Val Asp Arg Phe Ser Asp Pro Val Tyr Ser1 5 10 15Glu Ala Tyr Val His Val Asn Gln Tyr Asp Ile Val Leu Asp Val Leu 20 25 30Ile Val Asn Gln Thr Asn Asp Thr Leu Gln Asn Cys Thr Leu Glu Leu 35 40 45Ala Thr Leu Gly Asp Leu Lys Leu Val Glu Lys Pro Gln Pro Val Val 50 55 60Leu Ala Pro Lys Asp Phe Cys Asn Ile Lys Ala His Val Lys Val Ala65 70 75 80Ser Thr Glu Asn Gly Ile Ile Phe Gly Asn Ile Val Tyr Asp Val Thr 85 90 95Gly Ala Ala Ser Asp Arg Asn Val Val Val Leu Asn Asp Ile His Ile 100 105 110Asp Ile Met Asp Tyr Ile Val Pro Ala Ser Cys Thr Asp Ser Glu Phe 115 120 125Met Arg Met Trp Ala Glu Phe Glu Trp Glu Asn Lys Val Thr Val Asn 130 135 140Thr Pro Leu Thr Asp Leu Ala Asp Tyr Leu Glu His Leu Ile Lys Ser145 150 155 160Thr Asn Met Lys Cys Leu Thr Pro Glu Lys Ala Leu Ser Gly Gln Cys 165 170 175Gly Phe Met Ala Ala Asn Met Tyr Ala Lys Ser Ile Phe Gly Glu Asp 180 185 190Ala Leu Ala Asn Leu Ser Ile Glu Lys Pro Phe Asn Lys Pro Glu Ala 195 200 205Pro Val Ala Gly His Ile Arg Ile Arg Ala Lys Ser Gln Gly Met Ala 210 215 220Leu Ser Leu Gly Asp Lys Ile Asn Met Thr Gln Lys Gly Ile Pro Ser225 230 235 240Lys Ile Val Ala Ser 245213166PRTLeptinotarsa decemlineata 213Glu Lys Pro Ala Asn Glu Asp Ile Glu Ser Pro Arg Asp Ile Ile Asn1 5 10 15Lys Ala Phe Arg Glu Ile Phe Glu Ala Asp Glu Asn Gly Ile Asn Gly 20 25 30Ser Leu Val Glu Pro Pro Thr Pro Thr Gln Lys Thr Phe Asp Arg Pro 35 40 45Phe Gln Glu Asp Leu Ser Glu Phe Asn Phe Arg Ile Tyr Ala Ala Thr 50 55 60Tyr Phe Thr Asn Asn Ala Asn Tyr Gln Phe Ser Lys Lys Pro Leu Lys65 70 75 80Glu Ser Leu His Tyr Leu Pro Thr Pro Asp Asp Val Ile Ala Ala Gln 85 90 95Ala Leu Trp Ile Thr Ile Leu Arg Phe Met Gly Asp Tyr Pro Glu Pro 100 105 110Lys Tyr Asp Asn Ser Thr Lys Glu Asn Val Pro Ile Met Gln Ile Ile 115 120 125Ser Glu Ser Ile Gly Lys Ser Phe Thr Asn Arg Lys Glu Tyr Gln Glu 130 135 140Ile Leu Lys Glu Glu Lys Asn Met Pro Leu Gln Gln Asn Gln Ala Lys145 150 155 160Lys Lys Lys Lys Lys Lys 165214309PRTLeptinotarsa decemlineata 214Tyr Gly Arg Leu Glu Glu Ala Asp Ala Leu Ile Gln Gln Leu Ser Ser1 5 10 15Asp Lys Asp Pro Ile Leu Arg Arg Ser Gly Met Tyr Thr Ile Ala Met 20 25 30Ala Tyr Cys Ser Thr Gly His Asn Gln Ala Ile Arg Lys Leu Leu His 35 40 45Val Ala Val Ser Asp Val Asn Asp Asp Val Arg Arg Ala Ala Val Thr 50 55 60Ala Leu Gly Phe Leu Leu Phe Arg Thr Pro Glu Gln Cys Pro Ser Val65 70 75 80Val Ser Leu Leu Ala Glu Ser Tyr Asn Pro His Val Arg Tyr Gly Ala 85 90 95Ala Met Ala Leu Gly Ile Ala Cys Ala Gly Thr Gly Leu Arg Glu Ala 100 105 110Ile Ala Leu Leu Glu Pro Met Val Met Phe Asp Pro Val Asn Phe Val 115 120 125Arg Gln Gly Ala Leu Ile Ala Ser Ala Met Ile Leu Ile Gln Gln Thr 130 135 140Glu Gln Thr Cys Pro Lys Val Ser Phe Phe Arg Gln Thr Tyr Ala Gln145 150 155 160Val Ile Ala Asn Lys His Glu Asp Val Met Ala Lys Phe Gly Ala Ile 165 170 175Leu Ala Gln Gly Ile Ile Asp Ala Gly Gly Arg Asn Val Thr Leu Ser 180 185 190Leu Gln Ser Arg Thr Gly His Thr Asn Met Leu Ala Val Val Gly Thr 195 200 205Leu Val Phe Thr Gln Tyr Trp Tyr Trp Phe Pro Leu Ser His Cys Leu 210 215 220Ala Leu Ala Phe Thr Pro Thr Cys Val Ile Ala Leu Asn Glu Gln Leu225 230 235 240Lys Met Pro Lys Leu Glu Leu Lys Ser Asn Ala Lys Pro Ser Leu Tyr 245 250 255Ala Tyr Pro Ala Pro Met Glu Glu Lys Lys Arg Glu Glu Arg Glu Lys 260 265 270Val Thr Thr Ala Val Leu Ser Ile Ala Ala Arg Gln Arg Gly Lys Asp 275 280 285His Glu Lys Lys His Arg Asp Glu Lys Asn Gly Trp Gly Arg Arg Gln 290 295 300Val Cys Arg Glu Arg305215152PRTLeptinotarsa decemlineata 215Phe Phe Asp Leu Phe Phe Val Ser Asp Phe Val Phe Arg Leu Ser Pro1 5 10 15Phe Val Lys Met Leu Leu Asn Gln Ile Ser Ile Ala Gly Ala Asp Asp 20 25 30Trp Arg Asn Ala Ala His Ser Thr Gly Thr Ser Ile Met Ala Ala Glu 35 40 45Phe Asp Gly Gly Val Ile Ile Gly Ala Asp Ser Arg Thr Thr Thr Gly 50 55 60Ala Tyr Ile Ala Asn Arg Val Thr Asp Lys Leu Thr Lys Val Thr Asp65 70 75 80His Ile Tyr Cys Cys Arg Ser Gly Ser Ala Ala Asp Thr Gln Ala Ile 85 90 95Ala Asp Ile Val Ser Tyr His Leu Asn Phe His Gly Met Glu Leu Gly 100 105 110Glu Glu Pro Leu Val Glu Val Gly Ala Ala Ile Phe Arg Glu Leu Cys 115 120 125Tyr Asn Tyr Arg Asp Ser Leu Met Ala Gly Ile Leu Val Ala Gly Trp 130 135 140Asp Lys Lys Lys Lys Lys Lys Lys145 15021674PRTLeptinotarsa decemlineata 216Val Lys Asn Ile Ile Gln Phe Leu Gly Leu Gln Pro Ala Glu Arg Thr1 5 10 15Asp Lys Val Pro Glu Glu Lys Ser Thr His Thr Leu Leu Leu Ala Gly 20 25 30Met Leu Arg Gly Gly Ile Asp Ile Leu Val Arg Ala Lys Leu Ala Leu 35 40 45Ala Asp Gly Val Thr Met Gln Leu Thr Val Arg Ser Pro Asp Ala Asp 50 55 60Val Ala Glu Leu Ile Thr Ser Ser Val Gly65 70217416PRTLeptinotarsa decemlineata 217Ser Glu Asn Met Ala Gly Ala Met Leu Phe Glu Arg Ala Gln Ser Val1 5 10 15Pro Ser Gln His Asp Lys Leu Leu Asn Leu Lys Arg Asn Glu Asp Asp 20 25 30Asp Asp Gln Asn Ile Val Asn Lys Glu Gln Asp Ile Leu Asn Leu Gly 35 40 45Glu Lys Tyr Lys Lys Glu Gly Lys Ala Lys Glu Leu Ala Glu Leu Val 50 55 60Lys Ala Thr Arg Pro Phe Leu Ser Ile Ile Ser Lys Ala Lys Ala Ala65 70 75 80Lys Leu Val Arg Ser Leu Val Asp Tyr Phe Leu Asp Leu Glu Ala Gly 85 90 95Ile Gly Ile Glu Val Gln Leu Cys Lys Glu Cys Ile Glu Trp Ala Lys 100 105 110Glu Glu Lys Arg Thr Phe Leu Arg Gln Ser Leu Glu Ala Arg Leu Ile 115 120 125Ala Leu Tyr Phe Asp Thr Gly Met Tyr Ala Glu Ala Leu Ile Leu Glu 130 135 140Ser Thr Leu Leu Lys Gly Leu Lys Lys Leu Asp Asp Lys Asn Leu Leu145 150 155 160Val Glu Val Gln Leu Leu Glu Ser Lys Thr Tyr His Ala Leu Ser Asn 165 170 175Leu Pro Lys Ala Arg Ala Ala Leu Thr Ser Ala Arg Thr Thr Ala Asn 180 185 190Ser Ile Tyr Cys Pro Pro Lys Met Gln Ala Ala Leu Asp Leu Gln Ser 195 200 205Gly Val Leu His Ala Ala Asp Glu Lys Asp Phe Lys Thr Ala Tyr Ser 210 215 220Tyr Phe Tyr Glu Ala Phe Glu Gly Phe Asp Ser Val Glu Ser Pro Lys225 230 235 240Ala Leu Thr Ala Leu Lys Tyr Met Leu Leu Ser Lys Ile Met Ile Asn 245 250 255Ser Pro Glu Asp Val Gln Gln Ile Val Ser Gly Lys Leu Ala Ile Arg 260 265 270Tyr Ala Gly Gln Asp Ile Glu Ala Met Lys Ala Val Ala Arg Ala Ser 275 280 285His Lys Arg Ser Leu Ala Asp Phe Gln Leu Ala Val Lys Gln Phe Lys 290 295 300His Glu Leu Glu Asp Asp Val Ile Val Arg Ala His Leu Gly Thr Leu305 310 315 320Tyr Asp Asn Met Leu Glu Gln Asn Leu Cys Arg Ile Ile Glu Pro Tyr 325 330 335Ser Arg Val Gln Val Asp Tyr Val Ala Lys Thr Ile Lys Leu Pro Met 340 345 350Leu Gln Val Glu Lys Lys Leu Ser Gln Met Ile Leu Asp Ala Lys Phe 355 360 365His Gly Ile Leu Asp Gln Gly Glu Gly Val Leu Ile Val Phe Glu Ala 370 375 380Thr Pro Val Asp Lys Thr Tyr Glu Met Ala Leu Glu Thr Ile Gln Ser385 390 395 400Met Ser Lys Val Val Asp Thr Leu Tyr Gln Lys Ala Lys Lys Leu Ser 405 410 415218238PRTLeptinotarsa decemlineata 218Leu Gln Val Ile Met Ala Ser Glu Arg Tyr Ser Phe Ser Leu Thr Thr1 5 10 15Ser Ser Pro Ser Gly Lys Leu Ala Gln Ile Glu Tyr Ala Leu Ala Ala 20 25 30Val Ala Ala Gly Ala Pro Ser Val Gly Ile Lys Ala Ser Asn Gly Val 35 40 45Val Ile Ala Thr Glu Asn Lys His Lys Ser Ile Leu Tyr Glu Glu His 50 55 60Ser Val His Lys Val Glu Met Ile Thr Lys His Ile Gly Met Ile Tyr65 70 75 80Ser Gly Met Gly Pro Asp Tyr Arg Leu Leu Val Lys Gln Ala Arg Lys 85 90 95Met Ala Gln Gln Tyr Tyr Leu Val Tyr Gln Glu Pro Ile Pro Thr Val 100 105 110Gln Leu Val Gln Arg Val Ala Thr Val Met Gln Glu Tyr Thr Gln Ser 115 120 125Gly Gly Val Arg Pro Phe Gly Val Ser Leu Leu Ile Cys Gly Trp Asp 130 135 140Ser Glu Arg Pro Tyr Leu Phe Gln Cys Asp Pro Ser Gly Ala Tyr Phe145 150 155 160Ala Trp Lys Ala Thr Ala Met Gly Lys Asn Phe Ile Asn Gly Lys Thr 165 170 175Phe Leu Glu Lys Arg Tyr Ser Glu Asp Leu Glu Leu Asp Asp Ala Val 180 185 190His Thr Ala Ile Leu Thr Leu Lys Glu Ser Phe Glu Gly Gln Met Thr 195 200 205Ala Asp Asn Ile Glu Val Gly Ile Cys Asp Glu Ala Gly Phe Arg Arg 210 215 220Leu Asp Pro Ser His Val Lys Asp Tyr Leu Ala Asn Ile Pro225 230 23521983PRTLeptinotarsa decemlineata 219Lys Gln Ala Lys Glu Glu Ala Gln

Asp Glu Ile Glu Lys Tyr Arg Lys1 5 10 15Glu Arg Glu Arg Gln Phe Arg Glu Phe Glu Ala Lys His Met Gly Ser 20 25 30Arg Glu Asp Val Pro Ser Lys Ile Glu Val Asp Thr Lys Arg Arg Ile 35 40 45Glu Glu Met Asn Lys Ala Ile Ile Ser Gln Lys Glu Pro Val Ile Gln 50 55 60Glu Val Leu Asn Leu Val Tyr Asp Ile Lys Pro Glu Ile His Lys Asn65 70 75 80Tyr Arg Gln220202PRTLeptinotarsa decemlineata 220Ala Cys Glu Asn Glu Phe Leu Glu Ala Thr Glu Glu Ala Arg Arg Leu1 5 10 15Gly Tyr Ala Met Trp Gln Lys Lys Val Trp Leu Asp Pro Asn Glu Ile 20 25 30Asn Glu Ile Ala Asn Thr Asn Ser Arg Gln Asn Ile Arg Lys Leu Ile 35 40 45Lys Asp Gly Leu Ile Ile Lys Lys Pro Val Ala Val His Ser Arg Ala 50 55 60Arg Val Arg Lys Asn Thr Glu Ala Arg Arg Lys Gly Arg His Cys Gly65 70 75 80Phe Gly Lys Arg Lys Gly Thr Ala Asn Ala Arg Met Pro Gln Lys Glu 85 90 95Leu Trp Ile Gln Arg Met Arg Val Leu Arg Arg Leu Leu Lys Lys Tyr 100 105 110Arg Glu Ala Lys Lys Ile Asp Arg His Leu Tyr Tyr Ala Leu Tyr Met 115 120 125Lys Ala Lys Gly Asn Val Phe Lys Asn Lys Arg Val Leu Met Glu Tyr 130 135 140Ile His Lys Lys Lys Ala Glu Lys Ala Arg Ala Lys Met Leu Ala Asp145 150 155 160Gln Ala Asn Ala Arg Arg Leu Lys Val Lys Gln Ala Arg Glu Arg Arg 165 170 175Glu Glu Arg Ile Ala Thr Lys Lys Gln Glu Val Leu Gln Asn Tyr Gln 180 185 190Arg Glu Asp Glu Ala Gln Ala Ala Lys Lys 195 200221223PRTLeptinotarsa decemlineata 221Ile Lys Met Ser Val Leu Cys Pro Glu Ile Pro Ala Pro Gly Phe Ser1 5 10 15Phe Glu Asn Cys Lys Arg Asn Ala Leu Leu Glu Gly Lys Gly Phe Ala 20 25 30Leu Pro Lys Ala Thr Lys Thr Gly Thr Thr Ile Val Gly Ile Thr Tyr 35 40 45Lys Asp Gly Val Ile Leu Gly Ala Asp Thr Ile Ala Thr Glu Asp Thr 50 55 60Thr Val Ala Asp Lys Asn Ser Glu Lys Ile His Tyr Leu Ala Pro Asn65 70 75 80Met Tyr Cys Cys Gly Ala Gly Thr Ala Ala Asp Thr Glu Met Thr Thr 85 90 95Gln Met Ile Ser Ser Gln Leu Glu Leu His Lys Leu His Thr Asn Arg 100 105 110Ile Ala Arg Val Cys Thr Ala Asn Gln Met Leu Lys Gln Tyr Leu Phe 115 120 125Arg Tyr Gln Gly Tyr Ile Gly Ala Ala Leu Ile Leu Gly Gly Val Asp 130 135 140Val Glu Gly Pro His Leu Tyr Met Ile Tyr Pro His Gly Ser Ser Asp145 150 155 160Asn Leu Pro Tyr Gly Thr Met Gly Ser Gly Ser Pro Ala Ala Ile Ala 165 170 175Val Phe Glu Ser Arg Trp Arg Pro Asn Leu Glu Glu Glu Glu Gly Val 180 185 190Gln Leu Val Arg Asp Ala Ile Ala Ala Gly Ile Phe Asn Asp Leu Gly 195 200 205Ser Gly Ser Asn Val Asp Val Cys Ile Ile Arg Lys Gly Ser Val 210 215 220222320PRTLeptinotarsa decemlineata 222Lys Gln Trp Leu Lys Leu Lys Leu Leu Phe Glu Met Ser Ser Thr Leu1 5 10 15Glu Asp Lys Ala Ile Trp Glu Asp Gly Glu Glu Ser Leu Gly Glu Glu 20 25 30Val Leu Arg Met Ser Thr Asp Glu Ile Val Ser Arg Thr Arg Leu Leu 35 40 45Asp Asn Glu Ile Lys Ile Met Lys Ser Glu Val Met Arg Ile Asn His 50 55 60Glu Leu Gln Ala Gln Asn Glu Lys Ile Lys Glu Asn Thr Glu Lys Ile65 70 75 80Lys Val Asn Lys Thr Leu Pro Tyr Leu Val Ser Asn Val Ile Glu Leu 85 90 95Leu Asp Val Asp Pro Gln Glu Glu Glu Glu Asp Gly Ala Val Val Asp 100 105 110Leu Asp Ser Gln Arg Lys Gly Lys Cys Ala Val Val Lys Thr Ser Thr 115 120 125Arg Gln Thr Tyr Phe Leu Pro Val Ile Gly Leu Val Asp Glu Glu Lys 130 135 140Leu Lys Pro Gly Asp Leu Val Gly Val Asn Lys Asp Ser Tyr Leu Ile145 150 155 160Leu Glu Thr Leu Pro Ala Glu Tyr Asp Ala Arg Val Lys Ala Met Glu 165 170 175Val Asp Glu Arg Pro Thr Glu Gln Tyr Ser Asp Ile Gly Gly Leu Asp 180 185 190Lys Gln Ile Gln Glu Leu Ile Glu Ala Val Val Leu Pro Met Thr His 195 200 205Lys Asp Lys Phe Val Asn Leu Gly Ile His Pro Pro Lys Gly Val Leu 210 215 220Leu Tyr Gly Pro Pro Gly Thr Gly Lys Thr Leu Leu Ala Arg Ala Cys225 230 235 240Ala Ala Gln Thr Lys Ser Thr Phe Leu Lys Leu Ala Gly Pro Gln Leu 245 250 255Val Gln Met Phe Ile Gly Asp Gly Ala Lys Leu Val Arg Asp Ala Phe 260 265 270Ala Leu Ala Lys Glu Lys Ala Pro Ala Ile Ile Phe Ile Asp Glu Leu 275 280 285Asp Ala Thr Gly Thr Lys Arg Phe Asp Ser Glu Lys Ala Gly Asp Arg 290 295 300Glu Val Gln Arg Thr Met Leu Gly Ala Phe Glu Ser Val Gly Trp Val305 310 315 320223171PRTLeptinotarsa decemlineata 223Asp Arg Cys Arg Thr Leu Tyr Glu Lys Phe Leu Glu Phe Gly Pro Glu1 5 10 15Asn Cys Val Thr Trp Met Lys Phe Ala Glu Leu Glu Thr Leu Leu Gly 20 25 30Asp Ile Asp Arg Ala Arg Ala Ile Tyr Glu Leu Ala Ile Ser Gln Pro 35 40 45Arg Leu Asp Met Pro Glu Leu Leu Trp Lys Ala Tyr Ile Asp Phe Glu 50 55 60Ile Ser Gln Glu Glu Pro Glu Asn Ala Arg Gln Ile Tyr Glu Arg Leu65 70 75 80Leu Glu Lys Thr Ser His Val Lys Val Trp Leu Ser Tyr Ala Lys Phe 85 90 95Glu Leu Asn Thr Gln Ser Glu Pro Asp Met Asn Val Leu Leu Ser Arg 100 105 110Arg Val Phe Glu Arg Ala Asn Glu Ser Leu Lys Asn Ser Ser Glu Lys 115 120 125Glu Ala Arg Val Leu Leu Leu Glu Asn Trp Arg Glu Phe Glu Lys Ala 130 135 140His Gly Asp Glu Thr Gly Asn Ala Lys Val Asn Ser Arg Met Pro Lys145 150 155 160Arg Ile Lys Lys Lys Lys Lys Lys Lys Lys Lys 165 170224776PRTLeptinotarsa decemlineata 224Met Ala Thr Tyr Glu Glu Tyr Ile Gln Gln Asn Glu Asp Arg Asp Gly1 5 10 15Ile Arg Phe Thr Trp Asn Val Trp Pro Ser Ser Arg Ile Glu Ala Thr 20 25 30Arg Leu Val Val Pro Leu Ala Cys Leu Tyr Gln Pro Leu Lys Glu Arg 35 40 45Pro Asp Leu Pro Pro Ile Gln Tyr Asp Pro Val Leu Cys Thr Arg Asn 50 55 60Asn Cys Arg Ala Ile Leu Asn Pro Leu Cys Gln Val Asp Tyr Arg Ala65 70 75 80Lys Leu Trp Val Cys Asn Phe Cys Phe Gln Arg Asn Pro Phe Pro Pro 85 90 95Gln Tyr Ala Ala Ile Ser Glu Gln His Gln Pro Ala Glu Leu Met Pro 100 105 110Met Phe Ser Thr Ile Glu Tyr Thr Ile Thr Arg Ala Gln Cys Leu Pro 115 120 125Pro Ile Tyr Leu Tyr Val Val Asp Thr Cys Met Asp Glu Glu Glu Leu 130 135 140Gly Ser Leu Lys Asp Ser Leu Gln Met Ser Leu Ser Leu Leu Pro Pro145 150 155 160Asn Ala Leu Ile Gly Leu Ile Thr Phe Gly Lys Met Val Gln Val His 165 170 175Glu Leu Gly Thr Glu Gly Cys Ser Lys Ser Tyr Val Phe Arg Gly Thr 180 185 190Lys Asp Leu Thr Ala Lys Gln Val Gln Glu Met Leu Glu Val Gly Arg 195 200 205Ala Ala Val Ser Ala Gln Pro Ala Pro Gln Gln Pro Gly Gln Pro Met 210 215 220Arg Pro Gly Ala Leu Gln Gln Ala Pro Thr Pro Pro Gly Ser Arg Phe225 230 235 240Leu Gln Pro Ile Ser Lys Cys Asp Met Asn Leu Thr Asp Leu Ile Gly 245 250 255Glu Leu Gln Arg Asp Pro Trp Pro Val His Gln Gly Lys Cys Ala Leu 260 265 270Arg Ser Thr Gly Thr Ala Leu Ser Ile Ala Ile Gly Leu Leu Glu Cys 275 280 285Thr Tyr Ala Asn Thr Gly Ala Arg Val Met Leu Phe Val Gly Gly Pro 290 295 300Cys Ser Gln Gly Pro Gly Gln Val Leu Asn Asp Asp Leu Lys Gln Pro305 310 315 320Ile Arg Ser His His Asp Ile Gln Lys Asp Asn Ala Lys Tyr Met Lys 325 330 335Lys Ala Ile Lys His Tyr Asp Asn Leu Ala Met Arg Ala Ala Thr Asn 340 345 350Gly His Cys Val Asp Ile Tyr Ser Cys Ala Leu Asp Gln Thr Gly Leu 355 360 365Met Glu Met Lys Gln Cys Cys Asn Ser Thr Gly Gly His Met Val Met 370 375 380Gly Asp Ser Phe Asn Ser Ser Leu Phe Lys Gln Thr Phe Gln Arg Ile385 390 395 400Phe Ser Lys Asp Gln Lys Asn Glu Leu Lys Met Ala Phe Asn Gly Thr 405 410 415Leu Glu Val Lys Cys Ser Arg Glu Leu Lys Ile Gln Gly Gly Ile Gly 420 425 430Ser Cys Val Ser Leu Asn Val Lys Asn Pro Leu Val Ser Asp Thr Glu 435 440 445Ile Gly Met Gly Asn Thr Val Gln Trp Lys Met Cys Thr Val Thr Pro 450 455 460Ser Thr Thr Met Ala Leu Phe Phe Glu Val Val Asn Gln His Ser Ala465 470 475 480Pro Ile Pro Gln Gly Gly Arg Gly Cys Ile Gln Phe Ile Thr Gln Tyr 485 490 495Gln His Ala Ser Gly Gln Lys Arg Ile Arg Val Thr Thr Val Ala Arg 500 505 510Asn Trp Ala Asp Ala Ser Ala Asn Ile His His Val Ser Ala Gly Phe 515 520 525Asp Gln Glu Ala Ala Ala Val Ile Met Ala Arg Met Ala Val Tyr Arg 530 535 540Ala Glu Ser Asp Asp Ser Pro Asp Val Leu Arg Trp Val Asp Arg Met545 550 555 560Leu Ile Arg Leu Cys Gln Lys Phe Gly Glu Tyr Asn Lys Asp Asp Pro 565 570 575Asn Ser Phe Arg Leu Gly Glu Asn Phe Ser Leu Tyr Pro Gln Phe Met 580 585 590Tyr His Leu Arg Arg Ser Gln Phe Leu Gln Val Phe Asn Asn Ser Pro 595 600 605Asp Glu Thr Ser Phe Tyr Arg His Met Leu Met Arg Glu Asp Leu Thr 610 615 620Gln Ser Leu Ile Met Ile Gln Pro Ile Leu Tyr Ser Tyr Ser Phe Asn625 630 635 640Gly Pro Pro Glu Pro Val Leu Leu Asp Thr Ser Ser Ile Gln Pro Asp 645 650 655Arg Ile Leu Leu Met Asp Thr Phe Phe Gln Ile Leu Ile Phe His Gly 660 665 670Glu Thr Ile Ala Gln Trp Arg Asn Leu Lys Tyr Gln Asp Met Pro Glu 675 680 685Tyr Glu Asn Phe Arg Gln Leu Leu Gln Ala Pro Val Asp Asp Ala Gln 690 695 700Glu Ile Leu Gln Thr Arg Phe Pro Met Pro Arg Tyr Ile Asp Thr Glu705 710 715 720Gln Gly Gly Ser Gln Ala Arg Phe Leu Leu Ser Lys Val Asn Pro Ser 725 730 735Gln Thr His Asn Asn Met Tyr Ala Tyr Gly Gly Asp Gly Gly Ala Pro 740 745 750Val Leu Thr Asp Asp Val Ser Leu Gln Val Phe Met Asp His Leu Lys 755 760 765Lys Leu Ala Val Ser Ser Thr Ala 770 775225899PRTLeptinotarsa decemlineata 225Met Pro Leu Arg Leu Asp Ile Lys Arg Lys Leu Thr Ala Arg Ser Asp1 5 10 15Arg Val Lys Cys Val Asp Leu His Pro Ser Glu Pro Trp Met Leu Cys 20 25 30Ser Leu Tyr Ser Gly Asn Ile Asn Val Trp Asn Tyr Glu Asn Gln Gln 35 40 45Gln Val Lys Ser Phe Glu Val Cys Asp Leu Pro Val Arg Ala Ala Lys 50 55 60Phe Val Pro Arg Lys Asn Trp Ile Val Ser Gly Ser Asp Asp Met Gln65 70 75 80Ile Arg Ile Phe Asn Tyr Asn Thr Leu Asp Arg Ile His Ser Phe Glu 85 90 95Ala His Ser Asp Tyr Val Arg Cys Ile Ile Val His Pro Thr Gln Pro 100 105 110Tyr Ile Leu Thr Ser Ser Asp Asp Met Leu Ile Lys Leu Trp Asn Trp 115 120 125Asp Lys Ala Trp Ala Cys Gln Gln Val Phe Glu Gly His Ser His Tyr 130 135 140Ile Met Gln Ile Ala Ile Asn Pro Lys Asp Asn Asn Thr Phe Ala Ser145 150 155 160Ala Ser Leu Asp Arg Thr Leu Lys Val Trp Gln Leu Gly Ala Ser Thr 165 170 175Ala Asn Phe Thr Leu Glu Gly His Glu Lys Gly Val Asn Cys Val Asp 180 185 190Tyr Tyr His Gly Gly Asp Lys Pro Tyr Leu Ile Ser Gly Ala Asp Asp 195 200 205Arg Leu Val Lys Ile Trp Asp Tyr Gln Asn Lys Thr Cys Val Gln Thr 210 215 220Leu Glu Gly His Ala Gln Asn Val Thr Ala Val Cys Phe His Pro Glu225 230 235 240Leu Pro Val Ala Leu Thr Gly Ser Glu Asp Gly Thr Val Arg Val Trp 245 250 255His Thr Asn Thr His Arg Leu Glu Asn Cys Leu Asn Tyr Gly Phe Glu 260 265 270Arg Val Trp Thr Ile Cys Cys Leu Lys Gly Ser Asn Asn Val Ser Leu 275 280 285Gly Tyr Asp Glu Gly Ser Ile Leu Val Lys Val Gly Arg Glu Glu Pro 290 295 300Ala Val Ser Met Asp Ala Ser Gly Gly Lys Ile Ile Trp Ala Arg His305 310 315 320Ser Glu Leu Gln Gln Ala Asn Leu Lys Ala Leu Pro Glu Gly Gly Glu 325 330 335Ile Arg Asp Gly Glu Arg Leu Pro Val Ser Val Lys Asp Met Gly Ala 340 345 350Cys Glu Ile Tyr Pro Gln Thr Ile Gln His Asn Pro Asn Gly Arg Phe 355 360 365Val Val Val Cys Gly Asp Gly Glu Tyr Ile Ile Tyr Thr Ala Met Ala 370 375 380Leu Arg Asn Lys Ala Phe Gly Ser Ala Gln Glu Phe Val Trp Ala Gln385 390 395 400Asp Ser Ser Glu Tyr Ala Ile Arg Glu Ser Gly Ser Thr Ile Arg Ile 405 410 415Phe Lys Asn Phe Lys Glu Arg Lys Asn Phe Lys Ser Asp Phe Ser Ala 420 425 430Glu Gly Ile Tyr Gly Gly Phe Leu Leu Gly Ile Lys Ser Val Ser Gly 435 440 445Leu Thr Phe Tyr Asp Trp Glu Thr Leu Asp Leu Val Arg Arg Ile Glu 450 455 460Ile Gln Pro Arg Ala Val Tyr Trp Ser Asp Ser Gly Lys Leu Val Cys465 470 475 480Leu Ala Thr Glu Asp Ser Tyr Phe Ile Leu Ser Tyr Asp Ser Glu Gln 485 490 495Val Gln Lys Ala Arg Glu Asn Asn Gln Val Ala Glu Asp Gly Val Glu 500 505 510Ala Ala Phe Asp Val Leu Gly Glu Met Asn Glu Ser Val Arg Thr Gly 515 520 525Leu Trp Val Gly Asp Cys Phe Ile Tyr Thr Asn Ala Val Asn Arg Ile 530 535 540Asn Tyr Phe Val Gly Gly Glu Leu Val Thr Ile Ala His Leu Asp Arg545 550 555 560Pro Leu Tyr Val Leu Gly Tyr Val Pro Arg Asp Asp Arg Leu Tyr Leu 565 570 575Val Asp Lys Glu Leu Gly Val Val Ser Tyr Gln Leu Leu Leu Ser Val 580 585 590Leu Glu Tyr Gln Thr Ala Val Met Arg Arg Asp Phe Pro Thr Ala Asp 595 600 605Arg Val Leu Pro Ser Ile Pro Lys Glu His Arg Thr Arg Val Ala His 610 615 620Phe Leu Glu Lys Gln Gly Phe Lys Gln Gln Ala Leu Ala Val Ser Thr625 630 635 640Asp Pro Glu His Arg Phe Glu Leu Ala Val Ala Leu Glu Asp Leu Asp 645 650 655Thr Ala Lys Val Leu Ala Gln Glu Ala Asn Asn Pro Gln Lys Trp Ser 660 665 670Gln Leu Ala Glu Leu

Ala Ala Ser Thr Asn Asn Leu Gln Leu Ala Lys 675 680 685Glu Cys Met Gln Lys Ala Gln Asp Tyr Gly Gly Leu Leu Leu Leu Ala 690 695 700Thr Ser Ser Gly Asp Glu Gln Leu Val Gln Ser Leu Gly Glu Leu Thr705 710 715 720Gln Ala Glu Gly Lys His Asn Leu Ser Phe Leu Ser Tyr Phe Leu Val 725 730 735Gly Asp Leu Pro Lys Cys Leu Asp Ile Leu Val Ser Thr Gly Arg Leu 740 745 750Pro Glu Ala Ala Phe Phe Ala Arg Ser Tyr Leu Pro Asp Arg Ile Ser 755 760 765Glu Ile Val Glu Leu Trp Lys Val Lys Leu Thr Ser Ile Asn Glu Lys 770 775 780Ala Gly Gln Ser Leu Ala Asp Pro Lys Ser Tyr Glu Asn Leu Phe Pro785 790 795 800Gly Leu Gln Glu Ala Ile Glu Thr Gln Lys Tyr Leu Glu Gln Gln Asp 805 810 815Arg Gly Leu Phe Pro Ala Ser Val Ser Thr Thr Ile Val Pro Asn His 820 825 830Glu Arg Asn Leu Val Ala Glu Ala Arg Ala Gln Met Lys Gly Gly Ala 835 840 845Ala Val Phe Gln Gln Ser Arg Leu Leu Ser Gly Glu Lys Thr Ile Ser 850 855 860Phe Glu Gln Asp Glu Asp Asp Leu Asp Leu Asp Leu Glu Gly Val Asn865 870 875 880Ile Asp Asp Asn Ile Asp Thr Thr Asp Ile Asn Ile Asp Asp Asp Leu 885 890 895Leu Ser Asp226279PRTLygus hesperus 226Glu His Gly Ile Val Thr Asn Trp Asp Asp Met Glu Lys Ile Trp His1 5 10 15His Thr Phe Tyr Asn Glu Leu Arg Val Ala Pro Glu Glu His Pro Val 20 25 30Leu Leu Thr Glu Ala Pro Leu Asn Pro Lys Ala Asn Arg Glu Lys Met 35 40 45Thr Gln Ile Met Phe Glu Thr Phe Asn Thr Pro Ala Met Tyr Val Ala 50 55 60Ile Gln Ala Val Leu Ser Leu Tyr Ala Ser Gly Arg Thr Thr Gly Ile65 70 75 80Val Leu Asp Ser Gly Asp Gly Val Ser His Thr Val Pro Ile Tyr Glu 85 90 95Gly Tyr Ala Leu Pro His Ala Ile Leu Arg Leu Asp Leu Ala Gly Arg 100 105 110Asp Leu Thr Asp Tyr Leu Met Lys Ile Leu Thr Glu Arg Gly Tyr Ser 115 120 125Phe Thr Thr Thr Ala Glu Arg Glu Ile Val Arg Asp Ile Lys Glu Lys 130 135 140Leu Cys Tyr Val Ala Leu Asp Phe Glu Gln Glu Met Ala Thr Ala Ala145 150 155 160Ser Ser Ser Ser Leu Glu Lys Ser Tyr Glu Leu Pro Asp Gly Gln Val 165 170 175Ile Thr Ile Gly Asn Glu Arg Phe Arg Cys Pro Glu Ala Leu Phe Gln 180 185 190Pro Ser Phe Leu Gly Met Glu Ala Cys Gly Ile His Glu Thr Thr Tyr 195 200 205Asn Ser Ile Met Lys Cys Asp Val Asp Ile Arg Lys Asp Leu Tyr Ala 210 215 220Asn Thr Val Leu Ser Gly Gly Thr Thr Met Tyr Pro Gly Ile Ala Asp225 230 235 240Arg Met Gln Lys Glu Ile Thr Ala Leu Ala Pro Ser Thr Met Lys Ile 245 250 255Lys Ile Ile Ala Pro Pro Glu Arg Lys Tyr Ser Val Trp Ile Gly Gly 260 265 270Ser Ile Leu Ala Ser Leu Ser 275227252PRTLygus hesperus 227Glu His Gly Ile Ile Thr Asn Trp Asp Asp Met Glu Lys Ile Trp His1 5 10 15His Thr Phe Tyr Asn Glu Leu Arg Val Ala Pro Glu Glu His Pro Ile 20 25 30Leu Leu Thr Glu Ala Pro Leu Asn Pro Lys Ala Asn Arg Glu Lys Met 35 40 45Thr Gln Ile Met Phe Glu Thr Phe Asn Thr Pro Ala Met Tyr Val Ala 50 55 60Ile Gln Ala Val Leu Ser Leu Tyr Ala Ser Gly Arg Thr Thr Gly Ile65 70 75 80Val Leu Asp Ser Gly Asp Gly Val Ser His Thr Val Pro Ile Tyr Glu 85 90 95Gly Tyr Ala Leu Pro His Ala Ile Leu Arg Leu Asp Leu Ala Gly Arg 100 105 110Asp Leu Thr Asp Tyr Leu Met Lys Ile Leu Thr Glu Arg Gly Tyr Ser 115 120 125Phe Thr Thr Thr Ala Glu Arg Glu Ile Val Arg Asp Ile Lys Glu Lys 130 135 140Leu Cys Tyr Val Ala Leu Asp Phe Glu Gln Glu Met Ala Thr Ala Ala145 150 155 160Ala Ser Thr Ser Leu Glu Lys Ser Tyr Glu Leu Pro Asp Gly Gln Val 165 170 175Ile Thr Ile Gly Asn Glu Arg Phe Arg Cys Pro Glu Ala Leu Phe Gln 180 185 190Pro Ser Phe Leu Gly Met Glu Ser Cys Gly Ile His Glu Thr Val Tyr 195 200 205Asn Ser Ile Met Lys Cys Asp Val Asp Ile Arg Lys Asp Leu Tyr Ala 210 215 220Asn Thr Val Leu Ser Gly Gly Thr Thr Met Tyr Pro Gly Ile Ala Asp225 230 235 240Arg Met Gln Lys Glu Ile Thr Ala Leu Ala Pro Ser 245 25022871PRTLygus hesperus 228Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu1 5 10 15Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu 20 25 30His Leu Val Leu Arg Leu Arg Gly Gly Ala Lys Lys Arg Lys Lys Lys 35 40 45Asn Tyr Ser Thr Pro Lys Lys Ile Lys His Lys Lys Lys Lys Ile Lys 50 55 60Leu Ala Val Leu Lys Tyr Tyr65 7022988PRTLygus hesperusmisc_feature(55)..(55)Xaa can be any naturally occurring amino acid 229Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg1 5 10 15Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp 20 25 30Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg 35 40 45Gly Gly Val Ile Glu Pro Xaa Leu Arg Ile Leu Ala Gln Lys Tyr Asn 50 55 60Cys Asp Lys Met Ile Cys Arg Lys Cys Tyr Ala Arg Leu His Pro Arg65 70 75 80Ala Thr Asn Cys Arg Lys Lys Lys 85230128PRTLygus hesperus 230Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp1 5 10 15Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro 20 25 30Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly 35 40 45Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu 50 55 60Val Leu Arg Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu Thr65 70 75 80Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn 85 90 95Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln 100 105 110Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser 115 120 12523152PRTLygus hesperus 231Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu Val1 5 10 15Leu Arg Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu Thr Gly 20 25 30Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val 35 40 45Lys Ala Lys Ile 5023247PRTLygus hesperus 232His Leu Val Leu Arg Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr1 5 10 15Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile 20 25 30Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro 35 40 4523346PRTLygus hesperus 233Leu Val Leu Arg Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu1 5 10 15Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu 20 25 30Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro 35 40 4523476PRTLygus hesperus 234Ser Ser His Glu Asn Glu Leu Ile Leu Met Ser Val Leu Gln Cys Leu1 5 10 15Tyr Asp Ser Ile Ser Gln Ile Leu Arg Lys Asn Val Glu Lys Arg Thr 20 25 30Ile Phe Glu Asn Leu Glu Ile Val Met Leu Ala Met Asp Glu Ile Cys 35 40 45Asp Gly Gly Ile Leu Leu Glu Ala Asp Pro Thr Ser Val Val Gln Arg 50 55 60Val Ala Ile Arg Thr Asp Asp Ile Pro Leu Gly Glu65 70 75235139PRTLygus hesperusmisc_feature(2)..(2)Xaa can be any naturally occurring amino acidmisc_feature(64)..(64)Xaa can be any naturally occurring amino acid 235Leu Xaa Val Leu Ile Val Asn Gln Thr Ala Asp Thr Leu Gln Asn Cys1 5 10 15Thr Leu Glu Leu Ala Thr Leu Gly Asp Leu Lys Leu Val Glu Lys Pro 20 25 30Gln Pro Cys Val Leu Ala Pro His Asp Phe Cys Asn Ile Lys Ala Asn 35 40 45Val Lys Val Ala Ser Thr Glu Asn Gly Ile Ile Phe Gly Asn Ile Xaa 50 55 60Tyr Asp Val Ser Gly Ala Ala Ser Asp Arg Asn Val Val Val Leu Asn65 70 75 80Asp Ile His Ile Asp Ile Met Asp Tyr Ile Val Pro Ala Ser Cys Ser 85 90 95Asp Thr Glu Phe Arg Gln Met Trp Ala Glu Phe Glu Trp Glu Asn Lys 100 105 110Val Ser Val Asn Thr Asn Leu Thr Asp Leu His Glu Tyr Leu Ala His 115 120 125Leu Val Arg Ser Thr Asn Met Lys Cys Leu Thr 130 135236116PRTLygus hesperus 236Val Leu Asp Ile Val Ala Tyr Gln Leu Asn Phe Tyr Arg Asn Glu Thr1 5 10 15Asn Glu Glu Pro Thr Val Glu Ile Ala Ala Asn Val Phe Arg Asp Val 20 25 30Tyr Tyr Arg Tyr Arg Asp Gln Leu Gln Val Gly Leu Ile Ile Ala Gly 35 40 45Trp Asp Lys Val Lys Gly Gly Gln Val Tyr Asn Ile Pro Leu Gly Gly 50 55 60Met Val Ile Arg Gln Lys Phe Cys Met Gly Gly Ser Gly Ser Thr Phe65 70 75 80Val Phe Gly Phe Thr Asp Thr Asn Phe Lys Glu Asn Met Thr Glu Ala 85 90 95Glu Cys Lys Asn Phe Leu Thr Arg Ala Ile Gly Leu Ala Ile Ser Arg 100 105 110Asp Gly Ser Ser 115237116PRTLygus hesperus 237Val Ser Glu Met Val Thr Phe Gln Leu Asn Leu Tyr Arg Asn Glu Thr1 5 10 15Asn Lys Glu Pro Thr Val Glu Met Ala Ala Asn Val Phe Arg Asp Val 20 25 30Cys Tyr Arg Tyr Arg Asp Gln Leu Gln Val Gly Leu Ile Ile Ala Gly 35 40 45Trp Asp Glu Val Lys Gly Ala Gln Val Tyr Met Ile Pro Leu Gly Gly 50 55 60Met Val Ile Arg Gln Lys Phe Ala Met Ser Gly Ser Gly Ser Thr Phe65 70 75 80Ile Tyr Gly Phe Thr Asp Ala His Phe Lys Glu Asn Met Thr Glu Ala 85 90 95Glu Cys Lys Asn Phe Leu Thr Arg Ala Ile Gly Leu Ala Ile Ser Arg 100 105 110Asp Gly Ala Ser 115238371PRTLygus hesperusmisc_feature(321)..(321)Xaa can be any naturally occurring amino acid 238Ala Ser Phe Val Ser Glu Ile Ser Asp Glu Phe Lys Ile Val Val Val1 5 10 15Gln Ala Ile Arg Ala Leu Cys Leu Lys Phe Pro Arg Lys His Ser Thr 20 25 30Leu Met Thr Phe Leu Ser Ala Met Leu Arg Asp Glu Gly Gly Leu Glu 35 40 45Tyr Arg Ala Ser Ile Ala Asp Thr Ile Ile Thr Ile Ile Glu Asp Asn 50 55 60Pro Glu Ala Lys Glu Ile Gly Leu Ala His Leu Cys Glu Phe Ile Glu65 70 75 80Asp Cys Glu His Val Ser Leu Ala Val Arg Ile Leu His Leu Leu Gly 85 90 95Lys Glu Gly Pro Lys Thr Ile Gln Pro Ser Arg Tyr Ile Arg Phe Ile 100 105 110Tyr Asn Arg Val Ile Leu Glu Ile Ala Val Ile Arg Ala Ala Ala Val 115 120 125Ser Ala Leu Ala Gln Phe Gly Ala Leu Cys Pro Asp Leu Leu Pro Asn 130 135 140Ile Leu Val Leu Leu Ala Arg Cys Gln Met Asp Thr Asp Asp Glu Val145 150 155 160Arg Asp Arg Ala Thr Tyr Tyr Tyr His Leu Leu Lys Leu Gln Glu Lys 165 170 175Gly Leu Ile Phe Asn Tyr Ile Val Asp Pro Met Gln Val Cys Leu Val 180 185 190Ser Leu Glu Lys Ser Leu Ala Gln His Val His Asp Lys Val Pro Thr 195 200 205Lys Phe Asp Leu Lys Ser Val Pro Pro Ala Pro Val Val Ser Thr Thr 210 215 220Glu Asp Thr Ala Gln Glu Thr Val Pro Glu Gly Ser Ile Ser Ser Ala225 230 235 240Pro Ser Lys Ile Ala Pro Leu Gln Ser Thr Val Ser Ser Tyr Ala Glu 245 250 255Lys Leu Gln Gly Val Pro Gly Leu Gln Ser Ile Pro Gly Thr Leu Phe 260 265 270His Val Ser Glu Pro Val Glu Leu Thr Glu Ser Glu Thr Glu Tyr Val 275 280 285Val Thr Cys Thr Lys Leu Thr Tyr Pro His His Leu Val Leu Gln Phe 290 295 300Glu Cys Lys Asn Thr Leu Ser Asp Gln Leu Leu Glu Asn Val Arg Val305 310 315 320Xaa Ile Glu Ala Ser Glu Gly Tyr Arg Ile Val Lys Glu Ile Pro Ile 325 330 335Ser Lys Leu Pro Tyr Asn Glu Thr His Cys Ala Tyr Val Val Leu Gln 340 345 350Phe Pro Glu Gln Leu Ser Leu Thr Val Thr Asn Phe Gly Ala Thr Leu 355 360 365Arg Phe Ile 370239305PRTLygus hesperusmisc_feature(4)..(4)Xaa can be any naturally occurring amino acid 239Lys Ala Lys Xaa Leu Gly Glu Leu Ile Gln Ala Ser Arg Pro Phe Leu1 5 10 15Ser Glu Ile Ser Lys Ala Lys Ala Ala Lys Leu Val Arg Thr Leu Val 20 25 30Asp Phe Phe Leu Asp Leu Glu Ala Glu Thr Gly Arg Glu Val Gln Leu 35 40 45Cys Lys Glu Cys Ile Glu Trp Ala Thr Thr Glu Arg Arg Thr Phe Leu 50 55 60Arg Gln Ser Leu Glu Ala Arg Leu Ile Ala Leu Tyr Phe Asp Thr Gly65 70 75 80Met Tyr Thr Glu Ala Leu Gly Leu Gly Ser Ser Leu Leu Lys Glu Leu 85 90 95Lys Lys Leu Asp Asp Lys Asn Leu Leu Val Glu Val Leu Leu Leu Glu 100 105 110Ser Lys Thr Tyr His Ala Leu Ser Asn Leu Ser Lys Ala Arg Ala Ala 115 120 125Leu Thr Ser Ala Arg Thr Thr Ala Asn Ser Ile Tyr Cys Pro Pro Lys 130 135 140Met Gln Ala Ala Leu Asp Leu Gln Ser Gly Ile Leu His Ala Ala Asp145 150 155 160Glu Gln Asp Phe Lys Thr Ala Tyr Ser Tyr Phe Tyr Glu Ala Phe Glu 165 170 175Gly Tyr Asp Ser Val Asp Ser Pro Lys Ala Leu Thr Ala Leu Lys Tyr 180 185 190Met Leu Leu Ser Lys Ile Met Leu Asn Thr Pro Glu Asp Val Gln Gln 195 200 205Leu Ile Ser Gly Lys Leu Ala Leu Lys His Ala Gly Arg Asp Ile Asp 210 215 220Ala Met Lys Asn Val Ala Lys Ala Ser Ala Lys Arg Ser Leu Ala Asp225 230 235 240Phe Gln Ser Thr Leu Glu Gly Tyr Lys Lys Glu Leu Lys Glu Asp Pro 245 250 255Ile Val Lys Ala His Leu Gly Thr Leu Tyr Asp Asn Met Leu Glu Gln 260 265 270Asn Leu Cys Arg Ile Ile Glu Pro Tyr Ser Arg Val Gln Val Glu Tyr 275 280 285Val Ser Lys Ala Ile Lys Leu Pro Thr Leu Gln Val Glu Lys Lys Leu 290 295 300Ser305240179PRTLygus hesperus 240Leu Ala Ala Val Ser Ala Gly Ala Pro Ser Ile Gly Ile Lys Ala Gln1 5 10 15Asn Gly Val Val Leu Ala Thr Glu Asn Lys Phe Lys Ser Ile Leu Tyr 20 25 30Glu Glu His Ser Ile Lys Lys Ile Glu Met Val Glu Glu His Ile Gly 35 40 45Met Val Tyr Ser Gly Met Gly Pro Asp Tyr Arg Leu Leu Val Lys Arg 50 55 60Ala Arg Lys Leu Ala Gln Gln Tyr Lys Leu Val Tyr Gly Gln Arg Ile65 70 75 80Pro Thr Pro Gln Leu Val Gln

Lys Val Ala Met Val Met Gln Glu Tyr 85 90 95Thr Gln Ser Gly Gly Val Arg Pro Phe Gly Val Ser Leu Leu Ile Cys 100 105 110Gly Trp Asp Asp Gly Arg Pro Thr Leu Phe Gln Cys Asp Pro Ser Gly 115 120 125Ala Tyr Phe Ala Trp Lys Ala Thr Ala Met Gly Lys Asn Phe Ile Asn 130 135 140Gly Lys Thr Phe Leu Glu Lys Arg Tyr Ile Glu Thr Gln Asp Ile Glu145 150 155 160Asp Ala Val His Thr Ala Ile Leu Thr Leu Lys Glu Gly Phe Glu Gly 165 170 175Gln Met Asp24180PRTLygus hesperusmisc_feature(28)..(28)Xaa can be any naturally occurring amino acid 241Ala Glu Ala Lys Lys Arg Lys Ala Arg Arg Leu Lys Gln Ala Lys Glu1 5 10 15Glu Ala Gln Glu Glu Ile Glu Arg Tyr Lys Gln Xaa Arg Glu Lys Gln 20 25 30Phe Lys Glu Phe Glu Ala Gln His Met Gly Ser Arg Glu Asp Val Ala 35 40 45Ala Arg Ile Asp Ala Asp Thr Arg Gln Arg Ile Glu Glu Met Thr Lys 50 55 60Ala Val Asn Val Asn Lys Glu Gln Val Ile Gln Arg Ile Leu Glu Leu65 70 75 80242179PRTLygus hesperusmisc_feature(23)..(24)Xaa can be any naturally occurring amino acid 242Ala Ser Val Met Arg Cys Gly Lys Lys Lys Val Trp Leu Asp Pro Asn1 5 10 15Glu Ile Asn Glu Ile Ala Xaa Xaa Asn Ser Arg Gln Asn Ile Arg Lys 20 25 30Leu Ile Lys Asp Gly Leu Ile Ile Lys Lys Pro Val Ala Val His Ser 35 40 45Arg Ala Arg Val Arg Lys Asn Thr Glu Ala Arg Arg Lys Gly Arg His 50 55 60Cys Gly Phe Gly Lys Arg Lys Gly Thr Ala Asn Ala Arg Met Pro Val65 70 75 80Lys Val Leu Trp Val Asn Arg Met Arg Val Leu Arg Arg Leu Leu Lys 85 90 95Lys Tyr Arg Glu Ala Lys Lys Ile Asp Arg Gln Met Tyr His Asp Leu 100 105 110Tyr Met Lys Ala Lys Gly Asn Val Phe Lys Asn Lys Arg Val Leu Met 115 120 125Asp Phe Ile His Lys Lys Lys Ala Glu Lys Ala Arg Ser Lys Met Leu 130 135 140Lys Asp Gln Ala Glu Ala Arg Arg Leu Lys Val Lys Glu Ala Lys Lys145 150 155 160Arg Arg Glu Glu Arg Ile Ala Thr Lys Lys Gln Glu Ile Met Gln Ala 165 170 175Tyr Ala Arg243219PRTLygus hesperus 243Glu Lys Phe Glu Asn Leu Gly Ile Gln Pro Pro Lys Gly Val Leu Leu1 5 10 15Tyr Gly Pro Pro Gly Thr Gly Lys Thr Leu Leu Ala Arg Ala Cys Ala 20 25 30Ala Gln Thr Lys Ser Thr Phe Leu Lys Leu Ala Gly Pro Gln Leu Val 35 40 45Gln Met Phe Ile Gly Asp Gly Ala Lys Leu Val Arg Asp Ala Phe Ala 50 55 60Leu Ala Lys Glu Lys Ala Pro Ala Ile Ile Phe Ile Asp Glu Leu Asp65 70 75 80Ala Ile Gly Thr Lys Arg Phe Asp Ser Glu Lys Ala Gly Asp Arg Glu 85 90 95Val Gln Arg Thr Met Leu Glu Leu Leu Asn Gln Leu Asp Gly Phe Ser 100 105 110Ser Thr Ala Asp Ile Lys Val Ile Ala Ala Thr Asn Arg Val Asp Ile 115 120 125Leu Asp Pro Ala Leu Leu Arg Ser Gly Arg Leu Asp Arg Lys Ile Glu 130 135 140Phe Pro His Pro Asn Glu Asp Ala Arg Ala Arg Ile Met Gln Ile His145 150 155 160Ser Arg Lys Met Asn Ile Ser Val Asp Val Asn Phe Glu Glu Leu Ala 165 170 175Arg Ser Thr Asp Asp Phe Asn Gly Ala Gln Cys Lys Ala Val Cys Val 180 185 190Glu Ala Gly Met Ile Ala Leu Arg Arg Ser Ala Ser Val Val Ser His 195 200 205Glu Asp Phe Met Asp Ala Ile Leu Glu Val Gln 210 21524492PRTLygus hesperusmisc_feature(55)..(55)Xaa can be any naturally occurring amino acid 244Asn Lys Thr Leu Pro Tyr Leu Val Ser Asn Val Ile Glu Leu Leu Asp1 5 10 15Val Asp Pro Glu Glu Thr Glu Glu Asp Gly Ala Val Val Asp Leu Asp 20 25 30Ala Arg Arg Lys Gly Lys Cys Ala Val Ile Lys Thr Ser Thr Arg Gln 35 40 45Thr Tyr Phe Leu Pro Val Xaa Gly Leu Val Asp Ala Glu Lys Leu Lys 50 55 60Pro Gly Asp Leu Val Gly Val Asn Lys Asp Ser Tyr Leu Ile Leu Glu65 70 75 80Thr Leu Pro Ala Glu Tyr Asp Ala Arg Val Lys Ala 85 90245258DNAArtificialGFP 245agatacccag atcatatgaa acggcatgac tttttcaaga gtgccatgcc cgaaggttat 60gtacaggaaa gaactatatt tttcaaagat gacgggaact acaagacacg taagtttaaa 120cagttcggta ctaactaacc atacatattt aaattttcag gtgctgaagt caagtttgaa 180ggtgataccc ttgttaatag aatcgagtta aaaggtattg attttaaaga agatggaaac 240attcttggac acaaattg 25824646DNAArtificialPrimer 246gcgtaatacg actcactata ggagataccc agatcatatg aaacgg 4624724DNAArtificialPrimer 247caatttgtgt ccaagaatgt ttcc 2424824DNAArtificialPrimer 248agatacccag atcatatgaa acgg 2424946DNAArtificialPrimer 249gcgtaatacg actcactata ggcaatttgt gtccaagaat gtttcc 46250170DNAArtificialIntron 250ctcgagcctg agagaaaagc atgaagtata cccataacta acccattagt tatgcattta 60tgttatatct attcatgctt ctactttaga taatcaatca ccaaacaatg agaatctcaa 120cggtcgcaat aatgttcatg aaaatgtagt gtgtacactt accttctaga 1702512752DNALygus hesperus 251gaagtgacgt gtgacgtgtt cttttgccta tgtcaaatta ttgcatgtcc gtgattttct 60tcgtaatttt gttccaaaaa ctctaaattc ccatgtgatt tcttctacgg cgaagcccca 120ggaaaaaaga atgacgacct acgaggagtt cattcaacag agcgaggagc gcgacggtat 180caggttcact tggaacgtct ggccatcaag tcgcatcgaa gccaccaggt tggtcgtacc 240cgtaggatgt ctctatcaac cactaaaaga acgcacggat cttccagcta ttcaatacga 300tcccgttcta tgcactagga atacctgtag agccatactc aacccgatgt gccaagtaaa 360ctatagggca aagttgtggg tgtgtaactt ctgtttccag aggaatccgt tcccaccaca 420atacgccgca atttccgagc agcatcagcc tgctgagttg attccatcat tctcaactat 480agagtatact atatctagag ctcaattttt gcctcctata ttcctattgg tggtggatac 540gtgtttggat gatgacgagc taggagctct gaaagattcg ttacaaacgt ctctatcttt 600gctaccaacc aactccctag ttggtctgat cacgtttggt aaaatggtcc aagttcacga 660acttgggtgt gaaggttgtt cccggagcta cgtgttcaga ggcaccaagg atttgacgtc 720caagcaagta caggacatgc ttgggatcgg aaaggtttcc gcttctcctc agcaacagca 780gcaaagggca atgggcggtc agcagccatt ccccaccaat cggttcattc agccgattca 840aagttgtgac atgagcctca ccgacttgtt gggcgaaatg cagcgtgatc catggccagt 900gggtcagggt aagcgacctc ttagatcaac gggtgctgct ctagctattg ccattgggtt 960gttggagtgc tcctacccca acacgggagc aaaagtcatg ttgttccttg gtggcccttg 1020ttcccaaggg cctggtcaag ttgtcaatga tgacctgagg gaacctatcc gctctcatca 1080tgacatccag aaagataatg cccgctacat gaaaaaagcc attaaacatt acgattcttt 1140ggcattgaga gcagccacta atgggcattc agtagacatt tattcctgtg ctttagatca 1200gacaggtttg gcggaaatga agcaatgttg caattctact gggggtcata tggtgatggg 1260tgacaccttc aactccactt tgttcaaaca gacgttccag agggtgctct cccgtgatca 1320aaaaggcgaa ttcaaaatgg ctttcaatgg cgtagttgaa gtcaaaacct cccgagagct 1380aaaagttatg ggagccattg ggccttgcgt ttcattgaat acgaaaggtc cgtgtgttag 1440tgaaactgac atagggcttg gaggaacttg ccagtggaag ttctgcacat ttaaccaaaa 1500taccactgct gccatgttct ttgaggtagt aaaccaacac gctgctccta tccctcaagg 1560tggaagagga tgtatacagt tcataactca ataccagcat gcgtcgggcc aaaggcgcat 1620ccgagtaacc actgtagcca ggaattgggc tgatgcgact accaacatgc accatgttag 1680tgcaggattt gatcaggaag ctggagcggt actcatggcc aggatggtcg ttcacagagc 1740tgaaactgat gatggacctg atgtcatgag atgggctgat cgcatgttga ttcgtctttg 1800ccagaaattc ggcgagtaca acaaggatga tccaaatagt ttccgcctcc cagaaaactt 1860ctcgctttac ccacagttca tgtatcactt gagaaggtcc caattcttgc aggtattcaa 1920caacagccca gacgaaacgt cgtactatcg tcacatcttg atgcgggaag atttgtcgca 1980gagcttgatc atgattcagc cgatcctgta cagttacagt ttcaacggtc cagaaccagt 2040ccttttggac acttccagca ttcaacctga tcggatcctg ctgatggaca ccttcttcca 2100aatcctcatc ttccacggcg agaccatcgc ccagtggcgt gcccaaaggt accaggacct 2160acctgaatat gagaacttca agcagctcct acaggctcct gtagacgatg ctaaggaaat 2220cctgcacact cggttcccca tgccgaggta cattgacacc gaacagggcg gatcacaagc 2280tagattcctt ctctccaaag tcaacccatc ccaaactcac aacaacatgt acggctatgg 2340aggggaattt ggagcccctg tgctcactga tgatgtttcc ctccaagtct tcatggaaca 2400ccttaaaaag ctagccgttt catttactgc ctagatgttt attcccagct caaaaatcca 2460tttagaaaag aagcctgttt tttttcagta tcaaattcac aatttttttt tgttaatatt 2520ttcgtgcaat gagtgaaata cttacacttt attgatcact ttgttttgga ccatagtaaa 2580cattttttca ttttttacca ccttactaag aatgaagtat ttgggtaaat ttacgttgca 2640aattatattt aaaattattg tttatatcaa tgggtatatt tttaattaaa tcgttgatac 2700attgattttg tattagctca ttaagttatt aaaaataaat ttatatatta cc 27522523191DNALygus hesperus 252gatctgataa gagattgatg tggtttagtt tgtttgacgt agatttgtaa cattttgatt 60ccgaatttaa ttgatatttc tcacaatgcc tctcaaattg gacatcaaga gaaagctgtc 120tgctcgatca gaccgtgtga aatgtgtcga tctgcaccca actgagccgt ggatgttggc 180ttctctctac aacggaaacg ttcacatttg gaaccacgaa actcaacagc ttctgaaatc 240cttcgaagta tgcgagcttc caatcagggc tgcagttttc gtaccgagga agaactgggt 300ggtcacaggc tcggacgaca tgcacgttcg tgtcttcaac tacaacactc tcgagcgtgt 360acattccttc gaggcccatt ctgattattt gagatgcatc atcgtacatc ctacacagcc 420ttacatattg acgtgcagcg atgacatgct gatcaagctg tggaactggg aaaaaaattg 480gctatgccag caagtcttcg aaagccacac ccattacgtc atgcagatcg tgctgaaccc 540gaaggataac aacactttcg cctctgcctc gctcgaccac accctcaaag tgtggcagtt 600ggactctgca gcggccaact tcactttgga cggacacgaa aaaggagtta actgcgtcga 660ctactaccac ggaggagata agccgtatct catctctggc gcggacgatc acatggtcaa 720aatatgggat taccagaaca aaacgtgcgt tcagactttg gagggacacg ctcaaaatat 780aactgcagtt tgcctccaca ctgaactacc aatcgcaatt actggctcgg aagatggaac 840cgttcgcttg tggcactcag caacctatcg acttgaatcg tccttgaact acggctttga 900aagagtatgg gccatacgct gtctcaaagg ctcaaaccac attgctcttg ggtacgacga 960gggttccatt atggtcaagg ttggtcgaga agaaccggcc atttccatgg atgttaatgg 1020agaaaaaatt gtttgggctc gacattctga aatccagcag gtcaatttga agtctctcat 1080gactgacgag agtgaaattc gcgatgggga gaaactccca gtagcagcta aagacatggg 1140tccctgcgaa gttttcccgc aaagcatcgc ccacaacccc aatgggaggt ttgtggttgt 1200ttgcggtgat ggagaataca tcatctacac tgccatggct ttgcgtaata aaagtttcgg 1260ttccgcccaa gagttcgtct gggcccagga ctcttctgac tacgccatcc gcgaagggac 1320gtctaccgtc cgacttttca ggcagttcaa ggaaaggaag aacttcaagc ctgaatttgg 1380agctgaaggt atttttgggg gacagcttct cggagttagg actgtaactg gactgtccct 1440ctacgactgg gaaactttgg agttgatcag aagcatcgac attcaagcga aagcgccgta 1500ctggtccgaa gcagggcatc tcttggcaat cgttactgac gacagttact atctcttgaa 1560attcgaccag agcgccatct cgacgtccac ccctggaact gacggctacg aagatgcctt 1620tgagctcgtc ggtgaagtca atgatactgt caagaccgga ttgtgggttg gtgactgttt 1680catctacaca aatgccgttt gtcggatcaa ctactacgtt ggtggtgaga tcgtcaccgt 1740ggctcacctc gacactacaa tgtacctcct aggatacgtg gcccgccaga acctgctgta 1800cctgtgcgac aagcatcata acatcatttg ttacacgttg cttctgtctg tcctcgaata 1860tcagactgct gtgatgagga gagactttga aactgctgac cgagttttgc ccactattcc 1920tgttcagcat cgctcaagag ttgctcattt cctggaaaaa cagggcttca aaaggcaagc 1980tctggctgtg tccacggatg ccgagcacaa gtttgaactt gcgcttcagc tcagtgattt 2040ggaagcagca gtcggcctag cgagggaaat cggcagcaaa gccaagtggg tgcaggtcgc 2100agagttggcg atgtcagagg ccaagctagg actcgctcag atgtgcttgc atcaggcaca 2160gcactacgga ggacttctgc tcctgtcaac ttctgccgga aatgtggaca tgatggagaa 2220actggcagaa agctcgctgt ccgatggcaa aaacaacgtc tcgttcctca cttacttcct 2280gatgggtaac gtggaaaagt gtctccaaat cctcatcgat actggaagaa ttccggaagc 2340agctttcttc gcccggacct atatgcctaa agaagtgtct cgcgtggtcg acatgtggaa 2400aaccctttct aaggacaaga cggggcaatc gctcgctgac ccagcccaat acccgaatct 2460attccccaag cacaccgagg ctctgaaagc cgaacagttc atgaagaagg aattgactca 2520aaggattccc gcctcgtcgc acaaggatat aaaacccaac tacgaaagga atgccattga 2580agaaatgaaa gaagccgaag caaacggtct gttcacgtat gatcctccag tggctcctgc 2640cagtatcaac aatctaattg atgtttctga accggcgaat cgatctgagc ccagcccgtc 2700tgaaatcttc tccgaagcgc ccgtcgtgtc caagatgacc agcgacgctc ggccgctggt 2760cgcgccagtt ccgcctgccg cgagacctca aaaacggccg tcggccttcg atgatgacga 2820cctcgaattg gaaatcgaaa atatgaattt ggatgacatc gatgctagtg atttgaacga 2880agaagacctc cttatagatt agggatcatt gttttatcta tttaaaatta ctttatttat 2940caattataat ccacataatt aagtattatc gtacatgaaa gtgaattcca aatattttta 3000tgggtggtat tctgttctca cgttttcatt cggttgccaa tctgatgtaa ataaatggaa 3060aactataaaa tgcaatattt atatgaagtt aggctgtcac tattttagaa taagattctt 3120ggatgatgta tcaattattg tgttccataa gtttaggttg ttatttccta ataaacgttt 3180attacagcct c 3191253859DNALygus hesperus 253aagcagtggt atcaacgcag agtacttttt tttttttttt tttttttttt ctttctgaaa 60gtgtggttct cttcgtccga ccatgagttc gctcaaactg cagaagaggc tcgccgcctc 120ggtgatgaga tgcggcaaga agaaagtgtg gttggaccct aatgaaatca acgaaatcgc 180caacaccaac tctaggcaaa acatccgtaa gctgatcaag gatggtttga tcatcaaaaa 240gcctgtggct gtccactcca gagcccgcgt ccgtaaaaac acagaagcca gacggaaggg 300tcgtcattgt ggcttcggta agaggaaggg taccgccaac gccagaatgc ctgtgaaggt 360cctgtgggtc aacagaatga gagtcctgcg acggctcctt aaaaaataca gagaagccaa 420gaagatcgat aggcaaatgt accacgacct ttacatgaaa gccaaaggta acgtcttcaa 480aaacaagagg gtactgatgg acttcattca caagaagaag gctgaaaagg cgagatcaaa 540gatgttgaag gaccaggcag aggcgagacg tttcaaggtc aaggaggcga agaagaggcg 600cgaggagagg atcgccacca agaagcaaga gatcatgcag gcgtacgccc gagaagacga 660ggctgccgtc aaaaagtgat ctcgccccct ccgtttttaa attttaaaca aaaaacgtat 720tttgtacaaa aatttacaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaagtactc 780tgcgttgata ccactgcttg ccctctattg agtcgaaaaa aaaaaaaaaa aaaaaagtac 840tctgcgttga taccactgc 8592541145DNALygus hesperus 254tgggttgttg gagtgctcct accccaacac gggagcaaaa gtcatgttgt tccttggtgg 60cccttgttcc caagggcctg gtcaagttgt caatgatgac ctgagggaac ctatccgctc 120tcatcatgac atccagaaag ataatgcccg ctacatgaaa aaagccatta aacattacga 180ttctttggca ttgagagcag ccactaatgg gcattcagta gacatttatt cctgtgcttt 240agatcagaca ggtttggcgg aaatgaagca atgttgcaat tctactgggg gtcatatggt 300gatgggtgac accttcaact ccactttgtt caaacagacg ttccagaggg tgctctcccg 360tgatcaaaaa ggcgaattca aaatggcttt caatggcgta gttgaagtca aaacctcccg 420agagctaaaa gttatgggag ccattgggcc ttgcgtttca ttgaatacga aaggtccgtg 480tgttagtgaa actgacatag ggcttggagg aacttgccag tggaagttct gcacatttaa 540ccaaaatacc actgctgcca tgttctttga ggtagtaaac caacacgctg ctcctatccc 600tcaaggtgga agaggatgta tacagttcat aactcaatac cagcatgcgt cgggccaaag 660gcgcatccga gtaaccactg tagccaggaa ttgggctgat gcgactacca acatgcacca 720tgttagtgca ggatttgatc aggaagctgg agcggtactc atggccagga tggtcgttca 780cagagctgaa actgatgatg gacctgatgt catgagatgg gctgatcgca tgttgattcg 840tctttgccag aaattcggcg agtacaacaa ggatgatcca aatagtttcc gcctcccaga 900aaacttctcg ctttacccac agttcatgta tcacttgaga aggtcccaat tcttgcaggt 960attcaacaac agcccagacg aaacgtcgta ctatcgtcac atcttgatgc gggaagattt 1020gtcgcagagc ttgatcatga ttcagccgat cctgtacagt tacagtttca acggtccaga 1080accagtcctt ttggacactt ccagcattca acctgatcgg atcctgctga tggacacctt 1140cttcc 1145255350DNALygus hesperus 255gagactttga aactgctgac cgagttttgc ccactattcc tgttcagcat cgctcaagag 60ttgctcattt cctggaaaaa cagggcttca aaaggcaagc tctggctgtg tccacggatg 120ccgagcacaa gtttgaactt gcgcttcagc tcagtgattt ggaagcagca gtcggcctag 180cgagggaaat cggcagcaaa gccaagtggg tgcaggtcgc agagttggcg atgtcagagg 240ccaagctagg actcgctcag atgtgcttgc atcaggcaca gcactacgga ggacttctgc 300tcctgtcaac ttctgccgga aatgtggaca tgatggagaa actggccgaa 350256407DNALygus hesperus 256cgaggcccat tctgattatt tgagatgcat catcgtacat cctacacagc cttacatatt 60gacgtgcagc gatgacatgc tgatcaagct gtggaactgg gaaaaaaatt ggctatgcca 120gcaagtcttc gaaagccaca cccattacgt catgcagatc gtgctgaacc cgaaggataa 180caacactttc gcctctgcct cgctcgacca caccctcaaa gtgtggcagt tggactctgc 240agcggccaac ttcactttgg acggacacga aaaaggagtt aactgcgtcg actactacca 300cggaggagat aagccgtatc tcatctctgg cgcggacgat cacatggtca aaatatggga 360ttaccagaac aaaacgtgcg ttcagacttt ggagggacac gctcaaa 40725744DNAArtificialPrimer 257gcgtaatacg actcactata ggtgggttgt tggagtgctc ctac 4425822DNAArtificialPrimer 258ggaagaaggt gtccatcagc ag 2225922DNAArtificialPrimer 259tgggttgttg gagtgctcct ac 2226044DNAArtificialPrimer 260gcgtaatacg actcactata ggggaagaag gtgtccatca gcag 4426145DNAArtificialPrimer 261gcgtaatacg actcactata gggagacttt gaaactgctg accga 4526220DNAArtificialPrimer 262ttcggccagt ttctccatca 2026323DNAArtificialPrimer 263gagactttga aactgctgac cga 2326440DNAArtificialPrimer 264gcgtaatacg actcactata ggttcggcca gtttctccat 4026544DNAArtificialPrimer 265gcgtaatacg actcactata ggcgaggccc attctgatta tttg 4426620DNAArtificialPrimer 266tttgagcgtg

tccctccaaa 2026722DNAArtificialPrimer 267cgaggcccat tctgattatt tg 2226842DNAArtificialPrimer 268gcgtaatacg actcactata ggtttgagcg tgtccctcca aa 42269767PRTLygus hesperus 269Met Thr Thr Tyr Glu Glu Phe Ile Gln Gln Ser Glu Glu Arg Asp Gly1 5 10 15Ile Arg Phe Thr Trp Asn Val Trp Pro Ser Ser Arg Ile Glu Ala Thr 20 25 30Arg Leu Val Val Pro Val Gly Cys Leu Tyr Gln Pro Leu Lys Glu Arg 35 40 45Thr Asp Leu Pro Ala Ile Gln Tyr Asp Pro Val Leu Cys Thr Arg Asn 50 55 60Thr Cys Arg Ala Ile Leu Asn Pro Met Cys Gln Val Asn Tyr Arg Ala65 70 75 80Lys Leu Trp Val Cys Asn Phe Cys Phe Gln Arg Asn Pro Phe Pro Pro 85 90 95Gln Tyr Ala Ala Ile Ser Glu Gln His Gln Pro Ala Glu Leu Ile Pro 100 105 110Ser Phe Ser Thr Ile Glu Tyr Thr Ile Ser Arg Ala Gln Phe Leu Pro 115 120 125Pro Ile Phe Leu Leu Val Val Asp Thr Cys Leu Asp Asp Asp Glu Leu 130 135 140Gly Ala Leu Lys Asp Ser Leu Gln Thr Ser Leu Ser Leu Leu Pro Thr145 150 155 160Asn Ser Leu Val Gly Leu Ile Thr Phe Gly Lys Met Val Gln Val His 165 170 175Glu Leu Gly Cys Glu Gly Cys Ser Arg Ser Tyr Val Phe Arg Gly Thr 180 185 190Lys Asp Leu Thr Ser Lys Gln Val Gln Asp Met Leu Gly Ile Gly Lys 195 200 205Val Ser Ala Ser Pro Gln Gln Gln Gln Gln Arg Ala Met Gly Gly Gln 210 215 220Gln Pro Phe Pro Thr Asn Arg Phe Ile Gln Pro Ile Gln Ser Cys Asp225 230 235 240Met Ser Leu Thr Asp Leu Leu Gly Glu Met Gln Arg Asp Pro Trp Pro 245 250 255Val Gly Gln Gly Lys Arg Pro Leu Arg Ser Thr Gly Ala Ala Leu Ala 260 265 270Ile Ala Ile Gly Leu Leu Glu Cys Ser Tyr Pro Asn Thr Gly Ala Lys 275 280 285Val Met Leu Phe Leu Gly Gly Pro Cys Ser Gln Gly Pro Gly Gln Val 290 295 300Val Asn Asp Asp Leu Arg Glu Pro Ile Arg Ser His His Asp Ile Gln305 310 315 320Lys Asp Asn Ala Arg Tyr Met Lys Lys Ala Ile Lys His Tyr Asp Ser 325 330 335Leu Ala Leu Arg Ala Ala Thr Asn Gly His Ser Val Asp Ile Tyr Ser 340 345 350Cys Ala Leu Asp Gln Thr Gly Leu Ala Glu Met Lys Gln Cys Cys Asn 355 360 365Ser Thr Gly Gly His Met Val Met Gly Asp Thr Phe Asn Ser Thr Leu 370 375 380Phe Lys Gln Thr Phe Gln Arg Val Leu Ser Arg Asp Gln Lys Gly Glu385 390 395 400Phe Lys Met Ala Phe Asn Gly Val Val Glu Val Lys Thr Ser Arg Glu 405 410 415Leu Lys Val Met Gly Ala Ile Gly Pro Cys Val Ser Leu Asn Thr Lys 420 425 430Gly Pro Cys Val Ser Glu Thr Asp Ile Gly Leu Gly Gly Thr Cys Gln 435 440 445Trp Lys Phe Cys Thr Phe Asn Gln Asn Thr Thr Ala Ala Met Phe Phe 450 455 460Glu Val Val Asn Gln His Ala Ala Pro Ile Pro Gln Gly Gly Arg Gly465 470 475 480Cys Ile Gln Phe Ile Thr Gln Tyr Gln His Ala Ser Gly Gln Arg Arg 485 490 495Ile Arg Val Thr Thr Val Ala Arg Asn Trp Ala Asp Ala Thr Thr Asn 500 505 510Met His His Val Ser Ala Gly Phe Asp Gln Glu Ala Gly Ala Val Leu 515 520 525Met Ala Arg Met Val Val His Arg Ala Glu Thr Asp Asp Gly Pro Asp 530 535 540Val Met Arg Trp Ala Asp Arg Met Leu Ile Arg Leu Cys Gln Lys Phe545 550 555 560Gly Glu Tyr Asn Lys Asp Asp Pro Asn Ser Phe Arg Leu Pro Glu Asn 565 570 575Phe Ser Leu Tyr Pro Gln Phe Met Tyr His Leu Arg Arg Ser Gln Phe 580 585 590Leu Gln Val Phe Asn Asn Ser Pro Asp Glu Thr Ser Tyr Tyr Arg His 595 600 605Ile Leu Met Arg Glu Asp Leu Ser Gln Ser Leu Ile Met Ile Gln Pro 610 615 620Ile Leu Tyr Ser Tyr Ser Phe Asn Gly Pro Glu Pro Val Leu Leu Asp625 630 635 640Thr Ser Ser Ile Gln Pro Asp Arg Ile Leu Leu Met Asp Thr Phe Phe 645 650 655Gln Ile Leu Ile Phe His Gly Glu Thr Ile Ala Gln Trp Arg Ala Gln 660 665 670Arg Tyr Gln Asp Leu Pro Glu Tyr Glu Asn Phe Lys Gln Leu Leu Gln 675 680 685Ala Pro Val Asp Asp Ala Lys Glu Ile Leu His Thr Arg Phe Pro Met 690 695 700Pro Arg Tyr Ile Asp Thr Glu Gln Gly Gly Ser Gln Ala Arg Phe Leu705 710 715 720Leu Ser Lys Val Asn Pro Ser Gln Thr His Asn Asn Met Tyr Gly Tyr 725 730 735Gly Gly Glu Phe Gly Ala Pro Val Leu Thr Asp Asp Val Ser Leu Gln 740 745 750Val Phe Met Glu His Leu Lys Lys Leu Ala Val Ser Phe Thr Ala 755 760 765270938PRTLygus hesperus 270Met Pro Leu Lys Leu Asp Ile Lys Arg Lys Leu Ser Ala Arg Ser Asp1 5 10 15Arg Val Lys Cys Val Asp Leu His Pro Thr Glu Pro Trp Met Leu Ala 20 25 30Ser Leu Tyr Asn Gly Asn Val His Ile Trp Asn His Glu Thr Gln Gln 35 40 45Leu Leu Lys Ser Phe Glu Val Cys Glu Leu Pro Ile Arg Ala Ala Val 50 55 60Phe Val Pro Arg Lys Asn Trp Val Val Thr Gly Ser Asp Asp Met His65 70 75 80Val Arg Val Phe Asn Tyr Asn Thr Leu Glu Arg Val His Ser Phe Glu 85 90 95Ala His Ser Asp Tyr Leu Arg Cys Ile Ile Val His Pro Thr Gln Pro 100 105 110Tyr Ile Leu Thr Cys Ser Asp Asp Met Leu Ile Lys Leu Trp Asn Trp 115 120 125Glu Lys Asn Trp Leu Cys Gln Gln Val Phe Glu Ser His Thr His Tyr 130 135 140Val Met Gln Ile Val Leu Asn Pro Lys Asp Asn Asn Thr Phe Ala Ser145 150 155 160Ala Ser Leu Asp His Thr Leu Lys Val Trp Gln Leu Asp Ser Ala Ala 165 170 175Ala Asn Phe Thr Leu Asp Gly His Glu Lys Gly Val Asn Cys Val Asp 180 185 190Tyr Tyr His Gly Gly Asp Lys Pro Tyr Leu Ile Ser Gly Ala Asp Asp 195 200 205His Met Val Lys Ile Trp Asp Tyr Gln Asn Lys Thr Cys Val Gln Thr 210 215 220Leu Glu Gly His Ala Gln Asn Ile Thr Ala Val Cys Leu His Thr Glu225 230 235 240Leu Pro Ile Ala Ile Thr Gly Ser Glu Asp Gly Thr Val Arg Leu Trp 245 250 255His Ser Ala Thr Tyr Arg Leu Glu Ser Ser Leu Asn Tyr Gly Phe Glu 260 265 270Arg Val Trp Ala Ile Arg Cys Leu Lys Gly Ser Asn His Ile Ala Leu 275 280 285Gly Tyr Asp Glu Gly Ser Ile Met Val Lys Val Gly Arg Glu Glu Pro 290 295 300Ala Ile Ser Met Asp Val Asn Gly Glu Lys Ile Val Trp Ala Arg His305 310 315 320Ser Glu Ile Gln Gln Val Asn Leu Lys Ser Leu Met Thr Asp Glu Ser 325 330 335Glu Ile Arg Asp Gly Glu Lys Leu Pro Val Ala Ala Lys Asp Met Gly 340 345 350Pro Cys Glu Val Phe Pro Gln Ser Ile Ala His Asn Pro Asn Gly Arg 355 360 365Phe Val Val Val Cys Gly Asp Gly Glu Tyr Ile Ile Tyr Thr Ala Met 370 375 380Ala Leu Arg Asn Lys Ser Phe Gly Ser Ala Gln Glu Phe Val Trp Ala385 390 395 400Gln Asp Ser Ser Asp Tyr Ala Ile Arg Glu Gly Thr Ser Thr Val Arg 405 410 415Leu Phe Arg Gln Phe Lys Glu Arg Lys Asn Phe Lys Pro Glu Phe Gly 420 425 430Ala Glu Gly Ile Phe Gly Gly Gln Leu Leu Gly Val Arg Thr Val Thr 435 440 445Gly Leu Ser Leu Tyr Asp Trp Glu Thr Leu Glu Leu Ile Arg Ser Ile 450 455 460Asp Ile Gln Ala Lys Ala Pro Tyr Trp Ser Glu Ala Gly His Leu Leu465 470 475 480Ala Ile Val Thr Asp Asp Ser Tyr Tyr Leu Leu Lys Phe Asp Gln Ser 485 490 495Ala Ile Ser Thr Ser Thr Pro Gly Thr Asp Gly Tyr Glu Asp Ala Phe 500 505 510Glu Leu Val Gly Glu Val Asn Asp Thr Val Lys Thr Gly Leu Trp Val 515 520 525Gly Asp Cys Phe Ile Tyr Thr Asn Ala Val Cys Arg Ile Asn Tyr Tyr 530 535 540Val Gly Gly Glu Ile Val Thr Val Ala His Leu Asp Thr Thr Met Tyr545 550 555 560Leu Leu Gly Tyr Val Ala Arg Gln Asn Leu Leu Tyr Leu Cys Asp Lys 565 570 575His His Asn Ile Ile Cys Tyr Thr Leu Leu Leu Ser Val Leu Glu Tyr 580 585 590Gln Thr Ala Val Met Arg Arg Asp Phe Glu Thr Ala Asp Arg Val Leu 595 600 605Pro Thr Ile Pro Val Gln His Arg Ser Arg Val Ala His Phe Leu Glu 610 615 620Lys Gln Gly Phe Lys Arg Gln Ala Leu Ala Val Ser Thr Asp Ala Glu625 630 635 640His Lys Phe Glu Leu Ala Leu Gln Leu Ser Asp Leu Glu Ala Ala Val 645 650 655Gly Leu Ala Arg Glu Ile Gly Ser Lys Ala Lys Trp Val Gln Val Ala 660 665 670Glu Leu Ala Met Ser Glu Ala Lys Leu Gly Leu Ala Gln Met Cys Leu 675 680 685His Gln Ala Gln His Tyr Gly Gly Leu Leu Leu Leu Ser Thr Ser Ala 690 695 700Gly Asn Val Asp Met Met Glu Lys Leu Ala Glu Ser Ser Leu Ser Asp705 710 715 720Gly Lys Asn Asn Val Ser Phe Leu Thr Tyr Phe Leu Met Gly Asn Val 725 730 735Glu Lys Cys Leu Gln Ile Leu Ile Asp Thr Gly Arg Ile Pro Glu Ala 740 745 750Ala Phe Phe Ala Arg Thr Tyr Met Pro Lys Glu Val Ser Arg Val Val 755 760 765Asp Met Trp Lys Thr Leu Ser Lys Asp Lys Thr Gly Gln Ser Leu Ala 770 775 780Asp Pro Ala Gln Tyr Pro Asn Leu Phe Pro Lys His Thr Glu Ala Leu785 790 795 800Lys Ala Glu Gln Phe Met Lys Lys Glu Leu Thr Gln Arg Ile Pro Ala 805 810 815Ser Ser His Lys Asp Ile Lys Pro Asn Tyr Glu Arg Asn Ala Ile Glu 820 825 830Glu Met Lys Glu Ala Glu Ala Asn Gly Leu Phe Thr Tyr Asp Pro Pro 835 840 845Val Ala Pro Ala Ser Ile Asn Asn Leu Ile Asp Val Ser Glu Pro Ala 850 855 860Asn Arg Ser Glu Pro Ser Pro Ser Glu Ile Phe Ser Glu Ala Pro Val865 870 875 880Val Ser Lys Met Thr Ser Asp Ala Arg Pro Leu Val Ala Pro Val Pro 885 890 895Pro Ala Ala Arg Pro Gln Lys Arg Pro Ser Ala Phe Asp Asp Asp Asp 900 905 910Leu Glu Leu Glu Ile Glu Asn Met Asn Leu Asp Asp Ile Asp Ala Ser 915 920 925Asp Leu Asn Glu Glu Asp Leu Leu Ile Asp 930 935271198PRTLygus hesperus 271Met Ser Ser Leu Lys Leu Gln Lys Arg Leu Ala Ala Ser Val Met Arg1 5 10 15Cys Gly Lys Lys Lys Val Trp Leu Asp Pro Asn Glu Ile Asn Glu Ile 20 25 30Ala Asn Thr Asn Ser Arg Gln Asn Ile Arg Lys Leu Ile Lys Asp Gly 35 40 45Leu Ile Ile Lys Lys Pro Val Ala Val His Ser Arg Ala Arg Val Arg 50 55 60Lys Asn Thr Glu Ala Arg Arg Lys Gly Arg His Cys Gly Phe Gly Lys65 70 75 80Arg Lys Gly Thr Ala Asn Ala Arg Met Pro Val Lys Val Leu Trp Val 85 90 95Asn Arg Met Arg Val Leu Arg Arg Leu Leu Lys Lys Tyr Arg Glu Ala 100 105 110Lys Lys Ile Asp Arg Gln Met Tyr His Asp Leu Tyr Met Lys Ala Lys 115 120 125Gly Asn Val Phe Lys Asn Lys Arg Val Leu Met Asp Phe Ile His Lys 130 135 140Lys Lys Ala Glu Lys Ala Arg Ser Lys Met Leu Lys Asp Gln Ala Glu145 150 155 160Ala Arg Arg Phe Lys Val Lys Glu Ala Lys Lys Arg Arg Glu Glu Arg 165 170 175Ile Ala Thr Lys Lys Gln Glu Ile Met Gln Ala Tyr Ala Arg Glu Asp 180 185 190Glu Ala Ala Val Lys Lys 195272311DNAArtificialGUS 272ccagcgtatc gtgctgcgtt tcgatgcggt cactcattac ggcaaagtgt gatggagcat 60cagggcggct atacgccatt tgaagccgat gtcacgccgt atgttattgc cgggaaaagt 120gtacgtatct gaaatcaaaa aactcgacgg cctgtgggca ttcagtctgg atcgcgaaaa 180ctgtggaatt gatccagcgc cgtcgtcggt gaacaggtat ggaatttcgc cgattttgcg 240acctcgcaag gcatattcgg gtgaaggtta tctctatgaa ctgtgcgtca cagccaaaag 300ccagacagag t 311273596DNALygus hesperus 273gtgtagtgca tggtgttact gaaagtttgg taacgcccta gcgcaaacat gcagattttc 60gtcaaaaccc tcacgggtaa gaccatcacc cttgaggtcg agccttctga taccatcgag 120aatgtgaagg ctaagatcca ggacaaggag ggaatccccc cggatcagca gcgtcttatc 180ttcgccggta agcaattgga agatggccgc accctttctg actacaacat ccagaaagaa 240tccaccttgc acttggtgct caggcttcgt ggtggtgcca agaaaaggaa gaagaagaac 300tactccactc ccaagaagat caagcacaag aagaagaaga ttaagttggc tgtgcttaaa 360tactacaagg ttgacgagaa cggcaaaatc agccgattga ggagggagtg tccgtcagag 420caatgcggtg ccggtgtttt catggctgcc atggaagata ggcattactg tggaaagtgc 480agttacactc ttgtttttaa taaacccgag gagaaataaa tttttttaaa tataatgtta 540cgccgttaaa atacacattt gaacggttaa aaaaaaaaaa aaaaaaaaaa aaaaaa 596274603DNALygus hesperus 274ttacttgcgt tactcaggat tgtcgctaaa attgttgaat tttcgttttg ttcatcatag 60gtgaacgatg caaattttcg tcaaaaccct cacgggtaaa actattaccc tcgaagttga 120gccttcggac actatcgaaa atgtcaaagc taaaatccaa gacaaggaag ggattccccc 180agaccagcag aggttgatct tcgctggcaa gcagctcgaa gatggccgca cactttccga 240ctacaacatc cagaaagagt ccacccttca cttggtcctc cgtttgagag gaggagtcat 300cgagcccacc ctcaggatct tggctcagaa gtacaactgc gacaagatga tttgcaggaa 360gtgctacgct cgtctccacc ccagggcgac caactgtcgc aagaagaaat gcggacacac 420caacaacatc cgccccaaga agaagctgaa gtaaactata atttcccttt gggaaccatc 480cttcaagggg gttccctctc accaatattt ttttcttttt tcatggacaa aatcctgatg 540ttaactttca aggataaata aaatcaagag tttaaaaaaa aaaaaaaaaa aaaaaaaaaa 600aaa 6032753278DNALygus hesperus 275gataacgccg cggagcttta tgcttgtctt gtctcatttt ccgtgttttt cgtataaatt 60gggaatttgt tcgtgatatt tgtggttttg aaatattaaa aacaacttgc aaaactatca 120acattcacgg taaagatggg gatggtcgta gagcagccat gttactcgct gatcaatttt 180gcggcggact cggagccagt tagcgaaatg cagctgaaac aagattttga atctgggagc 240acagctcaga aagttgaagc tctcaagaaa acgattcaca tgatttccaa cggcgagcgt 300ttaccgggtc ttctgatgca tatcatcaga ttcattctgc cttcccagga ccacacgatc 360aaaaagttgc tgctaatatt ctgggagatc gttcctaaaa cttaccccga tggaaaactg 420cttcaagaaa tgatacttgt ttgcgacgcc tacagaaagg atttacaaca ccccaatgag 480ttcgtgcgcg ggtcgacttt gagattcctc tgcaaattga aggagccaga acttctggaa 540ccgctgatgc ctgccattcg gtcgtgcctc gagcacagag tgtcttacgt ccgcaggaac 600gctgtccttg ccattttcac gatctacaag aatttcgaat ttctaatccc tgatgctccc 660gaactcattg ccaatttcct cgacggagag caagatatgt cttgcaaaag gaatgccttc 720ttgatgctcc tccacgctga ccaagacaga gcactctcct atcttgcttc ttgtctggac 780caagtcacca gctttggcga catcctccag cttgtcatcg ttgaattgat ttacaaggtt 840tgtcatgcga atccctcaga acgttctcgg ttcattaggt gcatatacaa cctattgaat 900tcaagcagcc ctgctgtccg atatgaagct gctggtacgc tgataaccct gtccaacgca 960cctactgcca tcaaggctgc tgcatcatgc tacattgatc taatcatcaa ggaaagcgat 1020aacaacgtca aactgatcgt cctcgatcgc ctggtcgccc tcaaagacat cccgacgtac 1080gaaagagtct tgcaggatct cgtcatggac atcctccgcg tcttggccag cccggatatg 1140gaagtcagga agaaggcttt gaatctcgct cttgatctta caacttcgcg ttgtgtcgaa 1200gaagtagttt tgatgctgaa gaaagaggtt gccaaaactc ataacttgtc cgagcacgag 1260gaaacaggaa aatataggca actccttgtg agaactctgc actcttgcag catgaaattc 1320cctgatgtgg ctgcttcagt catcccagtg ctcatggaat ttttgtctga ctccaacgag 1380ctcgcttccc aagacgtcct tattttcgta agggaagcca ttcacaaatt tgaaaatctg 1440aggaacacaa

tcattgagaa attgcttgaa gcttttccgt ccataaagtt cgtcaaagtc 1500catcgtgctg cgttgtggat attaggagag tacgctgctt ccatcgatga cgtcagagct 1560gtcatgaaac aaattaaaca gaatttgggt gaggttccta tggtggaaga tgaaatgaag 1620cgggccgctg gagagaagac ggaagagtca tctgaacaga acagcggggg tgcaatgccg 1680tcaagcgctt ccaaactagt aacgtctgat gggacctatg cttctcagtc tgtgttcagc 1740actgtatcca catccaaaaa agaggaccga ccacctttga ggcagtatct gattgatggt 1800gattatttta ttggctccac catcgcgtcc actttggtga aactttctct gaagtttgac 1860aacttggaat ccaacacggc tgcgcagaac gaattctgca atgaatgcat gctgatcatc 1920gcttgcaccc tccatcttgg aagatctggc ctttgcacaa agaatttgaa taacgacgac 1980gctgagagga tgctgttttg tcttcgagtt ctttgggatg gaagcccaac cattgagaag 2040atttttactc aagaatgccg agaagctctt gcgtctatgc ttaccgctca acaccatgag 2100gaaatcgcct tgaataaggc caaagaaaag accgcacatc tcatccacgt agacgaccca 2160gtctcattcc tgcaattatc atctctgaga aactctgaac ttggttctga aaacgtgttc 2220gagctaagtc ttactcaggc gcttggtggt cccaccagtg gtggctcctc caactcggac 2280ctcttcttct ctgccagcaa gctcaacaaa gtcacgcagc ttactggctt ttctgaccct 2340gtctacgctg aagcttacgt ccaagtcaac cagtatgata tcgtcttgga cgtactcatt 2400gtcaaccaga cagctgacac tcttcaaaat tgcactctgg aattggctac acttggcgac 2460ctgaaattgg tcgagaagcc gcaaccctgc gttttggcgc ctcatgactt ctgtaacata 2520aaagctaacg tcaaagtggc ttccactgaa aacggaatta tttttggcaa cattgtttac 2580gacgttagtg gagcagcttc cgaccgaaac gtcgtcgtcc tcaatgacat tcacatcgat 2640attatggact acatagttcc tgcatcttgt tctgacactg aattccgcca aatgtgggct 2700gaattcgaat gggaaaacaa ggtatctgtc aacaccaacc tcacggactt gcacgagtat 2760ttggcccatt tggtcaggag caccaacatg aagtgcttga caccagagaa agcgctctgc 2820ggtcaatgtg ggttcatggc tgccaacatg tatgcgcgct cgattttcgg agaagatgcg 2880ttggcgaacc tgagcatcga gaaacccttc aacaagcctg atgcacctgt cactggacac 2940atccgcatcc gagccaaaag ccagggaatg gcactcagtt tgggagacaa aatcaacatg 3000acccagaaga gaccgcagaa aatgtacggt gcctaagccc tcatagatcc caccacctcg 3060gttcaacttt ccatttcctt tgtgagagca ccctactgct tacctgcgcc acactgcaag 3120taaacttggc ttcggcctcc tatttatcat attttacggt attctttgtt atcgaaatat 3180ttatgcatat tatattattg gcatttcgtt atcccaattc attcaataaa tatatagatt 3240aatttactaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 3278276806DNALygus hesperus 276tccttcgcct gttggatttt tggtcgctcc acttttcccc atacatacgt tttgtcagga 60aacttctgta aaggtttgtt cgagtaattg attatggcga gtcaaactca aggaatccaa 120cagctcctcg cagctgagaa acgagccgcc gagaaggttg cggaagcaaa gaaaaggaaa 180gctcgccgtt tgaagcaggc caaggaagag gctcaggagg aaattgaaag gtacaagcaa 240gacagagaga agcagttcaa ggagttcgaa gcccagcaca tgggctccag ggaggacgtt 300gctgccagga tagacgctga cactcgtcag agaattgaag agatgacaaa agctgtcaat 360gtcaacaaag aacaagtgat ccaaagaata ctggaacttg tgtacgacat cagacctgaa 420atgcacaaga attaccgtcc taccttgtag aaaaatgtac attaaacgca ttatactgaa 480ttaaattcaa tatattgaac aaatcattat tataatatcg agtatttttg aattctgtga 540tggtttttgt tgtcaaaatt atttgccact cgaggcttgt atccctacaa atgttgtagg 600ttagctgtac ttcctgtgtg ctgcacacaa tgaataaatt cagtagaatt acattccacg 660attctatttc tgttaatact attgttgttt ttttccgtgt ttttacgaaa cccattctgt 720gaaatggaac ttgtatgtat cataactaac ccaaatacat tattagacta actagtaaaa 780aaaaaaaaaa aaaaaaaaaa aaaaaa 806277717DNALygus hesperus 277aaagtgtggt tctcttcgtc cgaccatgag ttcgctcaaa ctgcagaaga ggctcgccgc 60ctcggtgatg agatgcggca agaagaaagt gtggttggac cctaatgaaa tcaacgaaat 120cgccaacacc aactctaggc aaaacatccg taagctgatc aaggatggtt tgatcatcaa 180aaagcctgtg gctgtccact ccagagcccg cgtccgtaaa aacacagaag ccagacggaa 240gggtcgtcat tgtggcttcg gtaagaggaa gggtaccgcc aacgccagaa tgcctgtgaa 300ggtcctgtgg gtcaacagaa tgagagtcct gcgacggctc cttaaaaaat acagagaagc 360caagaagatc gataggcaaa tgtaccacga cctttacatg aaagccaaag gtaacgtctt 420caaaaacaag agggtactga tggacttcat tcacaagaag aaggctgaaa aggcgagatc 480aaagatgttg aaggaccagg cagaggcgag acgtttcaag gtcaaggagg cgaagaagag 540gcgcgaggag aggatcgcca ccaagaagca agagatcatg caggcgtacg cccgagaaga 600cgaggctgcc gtcaaaaagt gatctcgccc cctccgtttt taaattttaa acaaaaaacg 660tattttgtac aaaaatttac aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 7172782304DNALygus hesperus 278atgacgacct acgaggagtt cattcaacag agcgaggagc gcgacggtat caggttcact 60tggaacgtct ggccatcaag tcgcatcgaa gccaccaggt tggtcgtacc cgtaggatgt 120ctctatcaac cactaaaaga acgcacggat cttccagcta ttcaatacga tcccgttcta 180tgcactagga atacctgtag agccatactc aacccgatgt gccaagtaaa ctatagggca 240aagttgtggg tgtgtaactt ctgtttccag aggaatccgt tcccaccaca atacgccgca 300atttccgagc agcatcagcc tgctgagttg attccatcat tctcaactat agagtatact 360atatctagag ctcaattttt gcctcctata ttcctattgg tggtggatac gtgtttggat 420gatgacgagc taggagctct gaaagattcg ttacaaacgt ctctatcttt gctaccaacc 480aactccctag ttggtctgat cacgtttggt aaaatggtcc aagttcacga acttgggtgt 540gaaggttgtt cccggagcta cgtgttcaga ggcaccaagg atttgacgtc caagcaagta 600caggacatgc ttgggatcgg aaaggtttcc gcttctcctc agcaacagca gcaaagggca 660atgggcggtc agcagccatt ccccaccaat cggttcattc agccgattca aagttgtgac 720atgagcctca ccgacttgtt gggcgaaatg cagcgtgatc catggccagt gggtcagggt 780aagcgacctc ttagatcaac gggtgctgct ctagctattg ccattgggtt gttggagtgc 840tcctacccca acacgggagc aaaagtcatg ttgttccttg gtggcccttg ttcccaaggg 900cctggtcaag ttgtcaatga tgacctgagg gaacctatcc gctctcatca tgacatccag 960aaagataatg cccgctacat gaaaaaagcc attaaacatt acgattcttt ggcattgaga 1020gcagccacta atgggcattc agtagacatt tattcctgtg ctttagatca gacaggtttg 1080gcggaaatga agcaatgttg caattctact gggggtcata tggtgatggg tgacaccttc 1140aactccactt tgttcaaaca gacgttccag agggtgctct cccgtgatca aaaaggcgaa 1200ttcaaaatgg ctttcaatgg cgtagttgaa gtcaaaacct cccgagagct aaaagttatg 1260ggagccattg ggccttgcgt ttcattgaat acgaaaggtc cgtgtgttag tgaaactgac 1320atagggcttg gaggaacttg ccagtggaag ttctgcacat ttaaccaaaa taccactgct 1380gccatgttct ttgaggtagt aaaccaacac gctgctccta tccctcaagg tggaagagga 1440tgtatacagt tcataactca ataccagcat gcgtcgggcc aaaggcgcat ccgagtaacc 1500actgtagcca ggaattgggc tgatgcgact accaacatgc accatgttag tgcaggattt 1560gatcaggaag ctggagcggt actcatggcc aggatggtcg ttcacagagc tgaaactgat 1620gatggacctg atgtcatgag atgggctgat cgcatgttga ttcgtctttg ccagaaattc 1680ggcgagtaca acaaggatga tccaaatagt ttccgcctcc cagaaaactt ctcgctttac 1740ccacagttca tgtatcactt gagaaggtcc caattcttgc aggtattcaa caacagccca 1800gacgaaacgt cgtactatcg tcacatcttg atgcgggaag atttgtcgca gagcttgatc 1860atgattcagc cgatcctgta cagttacagt ttcaacggtc cagaaccagt ccttttggac 1920acttccagca ttcaacctga tcggatcctg ctgatggaca ccttcttcca aatcctcatc 1980ttccacggcg agaccatcgc ccagtggcgt gcccaaaggt accaggacct acctgaatat 2040gagaacttca agcagctcct acaggctcct gtagacgatg ctaaggaaat cctgcacact 2100cggttcccca tgccgaggta cattgacacc gaacagggcg gatcacaagc tagattcctt 2160ctctccaaag tcaacccatc ccaaactcac aacaacatgt acggctatgg aggggaattt 2220ggagcccctg tgctcactga tgatgtttcc ctccaagtct tcatggaaca ccttaaaaag 2280ctagccgttt catttactgc ctag 23042792962DNALygus hesperus 279atgtggttta atttgtttga cgtaaatttg taacattttg attccgaatt taattgatat 60ttcgccctta tgcctctcag attggacatc aagagaaagc tgtctgctcg atcagaccgt 120gtgaaatgtg tcgatctgca cccaactgag ccgtggatgt tggcttctct ctacaacgga 180aacgtacaca tttggaacca cgaaactcaa cagcttctga aatccttcga agtatgcgag 240cttccaatca gggctgcagt tttcgtaccg aggaagaact gggtggtcac aggctcggac 300gacatgcacg ttcgtgtctt caactacaac actctcgagc gtgtacattc cttcgaggcc 360cattctgatt atttgagatg catcatcgta catcctacac agccttacat attgacgtgc 420agcgatgaca tgctgatcaa gctgtggaac tgggaaaaaa actggctatg ccagcaagtc 480ttcgaaagcc acacccatta cgtcatgcag atcgtgctga acccgaagga taacaatact 540ttcgcctctg cctcgctcga ccacaccctc aaagtgtggc agttgggatc agcagcggcc 600aacttcactt tggacggaca cgaaaaagga gtgaactgcg tcgactacta ccacggagga 660gataagcctt atctcatctc tggcgcggac gatcacatgg tcaaaatatg ggattaccag 720aacaaaacgt gcgtccagac tttggaggga cacgctcaaa atataactgc agtttgcttc 780cacactgaac taccaatcgc aattactggc tcggaagacg gaaccgttcg cttgtggcac 840tcagccacct atcgacttga atcgtccttg aactacggct ttgaaagagt atggaccata 900cgctgtctca aaggctcaaa ccacattgct cttgggtacg acgagggttc cattatggtc 960aaagttggtc gagaagaacc ggccatttcc atggatgtta atggagaaaa aattgtttgg 1020gctcgacatt ctgaaatcca gcaggtcaat ttgaagtctc tcatgactga cgagagtgaa 1080attcgcgatg gggagaaact cccagtagca gctaaagaca tgggtccctg cgaagttttc 1140ccacaaagca tcgcccacaa ccccaatgga agatttgtgg ttgtttgcgg tgatggagaa 1200tacatcatct acactgccat ggctttgcgt aataaaagtt tcggttccgc ccaagagttc 1260gtctgggccc aggactcttc tgactacgcc atccgcgaag ggacgtctac cgtccgactt 1320ttcaggcagt tcaaggaaag gaagaacttc aagcctgaat ttggagctga aggtattttt 1380gggggacagc ttctcggagt taggactgta actggactgt ccctctacga ctgggaaact 1440ttggagttga tcagaagcat cgacattcaa gcgaaagcgc cgtactggtc cgaagcaggg 1500catctcttgg caatcgttac tgacgacagt tactatctct tgaaattcga ccagagcgcc 1560atctcgacgt ccacccctgg aactgacggc tacgaagatg cctttgagct cgtcggtgaa 1620gtcaatgata ctgtcaagac cggattgtgg gttggtgact gtttcatcta cacaaacgcc 1680gtttgtcgga tcaactacta cgtaggtggt gagatcgtca ccgtggctca cctcgacact 1740acaatgtacc tcctaggata cgtggcccgc cagaacctgc tgtacctgtg cgacaagcat 1800cataacatca tttgttacac gttgcttctg tctgtcctcg aatatcagac tgctgtgatg 1860aggagagact ttgaaactgc tgaccgagtt ttgcccacta ttcctgttca gcatcgctca 1920agagttgctc atttcctgga aaaacagggc ttcaaaaggc aagctctggc tgtgtccacg 1980gatgccgagc acaagtttga acttgcgctt cagctcagtg atttggaagc agcagtcggc 2040ctagcgaggg aaatcggcag caaagccaag tgggtgcagg tcgccgagtt ggcgatgtca 2100gaggccaagc taggactcgc tcagatgtgc ttgcatcagg cacagcacta cggaggactt 2160ctgctcctgt caacttctgc cggaaatgtg gacatgatgg agaaactggc cgaaagctcg 2220ctgtccgatg gcaaaaacaa cgtctcgttc ctcacttact tcctgatggg taacgtggaa 2280aagtgtctcc aaatcctcat cgatactgga agaattccgg aagcagcttt cttcgcccgg 2340acctatatgc ctaaagaagt gtctcgcgtg gtcgacatgt ggaaaaccct ttctaaggac 2400aagacggggc aatcgctcgc tgacccagcc caatacccga atctattccc caagcacacc 2460gaggctctga aagccgaaca gttcatgaag aaggaattga ctcaaaggat tcccgcctcg 2520tcgcacaagg atataaaacc caactacgaa aggaatgcca ttgaagaaat gaaagaagcc 2580gaagcaaacg gtctgttcac gtatgatcct ccagtggctc ctgccagtat caacaatcta 2640attgatgttt ctgaaccggc gaatcgatct gagcccagcc cgtctgaaat cttctccgaa 2700gcgcccgccg tgtccaagat gaccagcgac gctcggccgc tggtcgcgcc agttccgcct 2760gccgcgagac ctcaaaaacg gccgtcggcc ttcgatgatg acgacctcga attggaaatc 2820gaaaatatga atttggatga catcgatgct agtgatttga acgaagaaga cctccttata 2880gattagggat cattgtttta tctatttaaa attactttat ttatcaatta taatccacat 2940aattaagtat tatcgtacat ga 29622801184DNALygus hesperus 280ggtcggtgga cgaggtcgag aactcttcta gagtcagagt ctgatgtgca cacaatcatc 60ctggagttga gtcaggccga ttttcctagt gaatgtcaat gtttttctca acgtaaccag 120ggtcagcttc ctccttaagt ttatttaggt ttacagtgaa aaaatgagtt tcttcagcaa 180agtgttcgga gggaagaaag atgacaaggg ccctacggct tcggaagcga ttcagaaact 240ccgcgagact gaagacatgc tagtgaagaa acaggaatat ttggaaacca aaattgaagc 300tgaaatgaag attatcaaaa agaatgggac ggccaacagg cgtgtatcta tacaagctct 360aaagaagaaa aagcggtttg aaaaacaact tcaacagatt gatggaactc tgtcgacgat 420tgaaatgcag agagaagcct tggaatcagc caatactagt tccaaggttg tacaaactat 480gaaattagct gctgatacac tgaagacagc tcatcagcac atggacgttg atcaagtaca 540tgacatgatg gatgaaatcg ccgaacagca tgaagcagcg aaggaaatat cagaagccat 600atctaatcca gttgcttttg gaaacgacat agacgaggat gaactcgaga gggaattaga 660agaattagaa cagcaagaac tggatagaga acttcttgga acccatactc ctgctgctga 720tcatttgccg gatgtacctg ctaccattcc agttccacat aaaccaaagc aaactgttgc 780tgatgaagat gatgatttga agcaacttca ggaatgggca acctaaattg cttgtggtct 840atcaaagatg ctgcgttact aaatttttga tatgaaaatg tattattctt atgtttattg 900tttgttccaa agctagaagc attttgaaga atacctacgt gcatatttca gctcaggaat 960ttttaaaacg agagttgtgt aaataggtct atgtaatgct taataatatt ccaagttcac 1020taaaactact cattataaca ggaaaaaaaa aagatattct tatactttca atgatgaagt 1080ttatttagag ccaccattta ttttcgatga gagaacagaa aatagatcct ctcaataaat 1140aagttcgata caataaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1184281156PRTLygus hesperus 281Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu1 5 10 15Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp 20 25 30Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys 35 40 45Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu 50 55 60Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Ala Lys Lys Arg65 70 75 80Lys Lys Lys Asn Tyr Ser Thr Pro Lys Lys Ile Lys His Lys Lys Lys 85 90 95Lys Ile Lys Leu Ala Val Leu Lys Tyr Tyr Lys Val Asp Glu Asn Gly 100 105 110Lys Ile Ser Arg Leu Arg Arg Glu Cys Pro Ser Glu Gln Cys Gly Ala 115 120 125Gly Val Phe Met Ala Ala Met Glu Asp Arg His Tyr Cys Gly Lys Cys 130 135 140Ser Tyr Thr Leu Val Phe Asn Lys Pro Glu Glu Lys145 150 155282128PRTLygus hesperus 282Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu1 5 10 15Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp 20 25 30Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys 35 40 45Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu 50 55 60Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Val Ile Glu Pro65 70 75 80Thr Leu Arg Ile Leu Ala Gln Lys Tyr Asn Cys Asp Lys Met Ile Cys 85 90 95Arg Lys Cys Tyr Ala Arg Leu His Pro Arg Ala Thr Asn Cys Arg Lys 100 105 110Lys Lys Cys Gly His Thr Asn Asn Ile Arg Pro Lys Lys Lys Leu Lys 115 120 125283966PRTLygus hesperus 283Met Gly Met Val Val Glu Gln Pro Cys Tyr Ser Leu Ile Asn Phe Ala1 5 10 15Ala Asp Ser Glu Pro Val Ser Glu Met Gln Leu Lys Gln Asp Phe Glu 20 25 30Ser Gly Ser Thr Ala Gln Lys Val Glu Ala Leu Lys Lys Thr Ile His 35 40 45Met Ile Ser Asn Gly Glu Arg Leu Pro Gly Leu Leu Met His Ile Ile 50 55 60Arg Phe Ile Leu Pro Ser Gln Asp His Thr Ile Lys Lys Leu Leu Leu65 70 75 80Ile Phe Trp Glu Ile Val Pro Lys Thr Tyr Pro Asp Gly Lys Leu Leu 85 90 95Gln Glu Met Ile Leu Val Cys Asp Ala Tyr Arg Lys Asp Leu Gln His 100 105 110Pro Asn Glu Phe Val Arg Gly Ser Thr Leu Arg Phe Leu Cys Lys Leu 115 120 125Lys Glu Pro Glu Leu Leu Glu Pro Leu Met Pro Ala Ile Arg Ser Cys 130 135 140Leu Glu His Arg Val Ser Tyr Val Arg Arg Asn Ala Val Leu Ala Ile145 150 155 160Phe Thr Ile Tyr Lys Asn Phe Glu Phe Leu Ile Pro Asp Ala Pro Glu 165 170 175Leu Ile Ala Asn Phe Leu Asp Gly Glu Gln Asp Met Ser Cys Lys Arg 180 185 190Asn Ala Phe Leu Met Leu Leu His Ala Asp Gln Asp Arg Ala Leu Ser 195 200 205Tyr Leu Ala Ser Cys Leu Asp Gln Val Thr Ser Phe Gly Asp Ile Leu 210 215 220Gln Leu Val Ile Val Glu Leu Ile Tyr Lys Val Cys His Ala Asn Pro225 230 235 240Ser Glu Arg Ser Arg Phe Ile Arg Cys Ile Tyr Asn Leu Leu Asn Ser 245 250 255Ser Ser Pro Ala Val Arg Tyr Glu Ala Ala Gly Thr Leu Ile Thr Leu 260 265 270Ser Asn Ala Pro Thr Ala Ile Lys Ala Ala Ala Ser Cys Tyr Ile Asp 275 280 285Leu Ile Ile Lys Glu Ser Asp Asn Asn Val Lys Leu Ile Val Leu Asp 290 295 300Arg Leu Val Ala Leu Lys Asp Ile Pro Thr Tyr Glu Arg Val Leu Gln305 310 315 320Asp Leu Val Met Asp Ile Leu Arg Val Leu Ala Ser Pro Asp Met Glu 325 330 335Val Arg Lys Lys Ala Leu Asn Leu Ala Leu Asp Leu Thr Thr Ser Arg 340 345 350Cys Val Glu Glu Val Val Leu Met Leu Lys Lys Glu Val Ala Lys Thr 355 360 365His Asn Leu Ser Glu His Glu Glu Thr Gly Lys Tyr Arg Gln Leu Leu 370 375 380Val Arg Thr Leu His Ser Cys Ser Met Lys Phe Pro Asp Val Ala Ala385 390 395 400Ser Val Ile Pro Val Leu Met Glu Phe Leu Ser Asp Ser Asn Glu Leu 405 410 415Ala Ser Gln Asp Val Leu Ile Phe Val Arg Glu Ala Ile His Lys Phe 420 425 430Glu Asn Leu Arg Asn Thr Ile Ile Glu Lys Leu Leu Glu Ala Phe Pro 435 440 445Ser Ile Lys Phe Val Lys Val His Arg Ala Ala Leu Trp Ile Leu Gly 450 455 460Glu Tyr Ala Ala Ser Ile Asp Asp Val Arg Ala Val Met Lys Gln Ile465 470 475 480Lys Gln Asn Leu Gly Glu Val Pro Met Val Glu Asp Glu Met Lys Arg 485 490 495Ala Ala Gly Glu Lys Thr Glu Glu Ser Ser Glu Gln Asn Ser Gly Gly 500 505 510Ala Met Pro Ser Ser Ala Ser Lys Leu Val Thr Ser Asp Gly

Thr Tyr 515 520 525Ala Ser Gln Ser Val Phe Ser Thr Val Ser Thr Ser Lys Lys Glu Asp 530 535 540Arg Pro Pro Leu Arg Gln Tyr Leu Ile Asp Gly Asp Tyr Phe Ile Gly545 550 555 560Ser Thr Ile Ala Ser Thr Leu Val Lys Leu Ser Leu Lys Phe Asp Asn 565 570 575Leu Glu Ser Asn Thr Ala Ala Gln Asn Glu Phe Cys Asn Glu Cys Met 580 585 590Leu Ile Ile Ala Cys Thr Leu His Leu Gly Arg Ser Gly Leu Cys Thr 595 600 605Lys Asn Leu Asn Asn Asp Asp Ala Glu Arg Met Leu Phe Cys Leu Arg 610 615 620Val Leu Trp Asp Gly Ser Pro Thr Ile Glu Lys Ile Phe Thr Gln Glu625 630 635 640Cys Arg Glu Ala Leu Ala Ser Met Leu Thr Ala Gln His His Glu Glu 645 650 655Ile Ala Leu Asn Lys Ala Lys Glu Lys Thr Ala His Leu Ile His Val 660 665 670Asp Asp Pro Val Ser Phe Leu Gln Leu Ser Ser Leu Arg Asn Ser Glu 675 680 685Leu Gly Ser Glu Asn Val Phe Glu Leu Ser Leu Thr Gln Ala Leu Gly 690 695 700Gly Pro Thr Ser Gly Gly Ser Ser Asn Ser Asp Leu Phe Phe Ser Ala705 710 715 720Ser Lys Leu Asn Lys Val Thr Gln Leu Thr Gly Phe Ser Asp Pro Val 725 730 735Tyr Ala Glu Ala Tyr Val Gln Val Asn Gln Tyr Asp Ile Val Leu Asp 740 745 750Val Leu Ile Val Asn Gln Thr Ala Asp Thr Leu Gln Asn Cys Thr Leu 755 760 765Glu Leu Ala Thr Leu Gly Asp Leu Lys Leu Val Glu Lys Pro Gln Pro 770 775 780Cys Val Leu Ala Pro His Asp Phe Cys Asn Ile Lys Ala Asn Val Lys785 790 795 800Val Ala Ser Thr Glu Asn Gly Ile Ile Phe Gly Asn Ile Val Tyr Asp 805 810 815Val Ser Gly Ala Ala Ser Asp Arg Asn Val Val Val Leu Asn Asp Ile 820 825 830His Ile Asp Ile Met Asp Tyr Ile Val Pro Ala Ser Cys Ser Asp Thr 835 840 845Glu Phe Arg Gln Met Trp Ala Glu Phe Glu Trp Glu Asn Lys Val Ser 850 855 860Val Asn Thr Asn Leu Thr Asp Leu His Glu Tyr Leu Ala His Leu Val865 870 875 880Arg Ser Thr Asn Met Lys Cys Leu Thr Pro Glu Lys Ala Leu Cys Gly 885 890 895Gln Cys Gly Phe Met Ala Ala Asn Met Tyr Ala Arg Ser Ile Phe Gly 900 905 910Glu Asp Ala Leu Ala Asn Leu Ser Ile Glu Lys Pro Phe Asn Lys Pro 915 920 925Asp Ala Pro Val Thr Gly His Ile Arg Ile Arg Ala Lys Ser Gln Gly 930 935 940Met Ala Leu Ser Leu Gly Asp Lys Ile Asn Met Thr Gln Lys Arg Pro945 950 955 960Gln Lys Met Tyr Gly Ala 965284118PRTLygus hesperus 284Met Ala Ser Gln Thr Gln Gly Ile Gln Gln Leu Leu Ala Ala Glu Lys1 5 10 15Arg Ala Ala Glu Lys Val Ala Glu Ala Lys Lys Arg Lys Ala Arg Arg 20 25 30Leu Lys Gln Ala Lys Glu Glu Ala Gln Glu Glu Ile Glu Arg Tyr Lys 35 40 45Gln Asp Arg Glu Lys Gln Phe Lys Glu Phe Glu Ala Gln His Met Gly 50 55 60Ser Arg Glu Asp Val Ala Ala Arg Ile Asp Ala Asp Thr Arg Gln Arg65 70 75 80Ile Glu Glu Met Thr Lys Ala Val Asn Val Asn Lys Glu Gln Val Ile 85 90 95Gln Arg Ile Leu Glu Leu Val Tyr Asp Ile Arg Pro Glu Met His Lys 100 105 110Asn Tyr Arg Pro Thr Leu 115285198PRTLygus hesperus 285Met Ser Ser Leu Lys Leu Gln Lys Arg Leu Ala Ala Ser Val Met Arg1 5 10 15Cys Gly Lys Lys Lys Val Trp Leu Asp Pro Asn Glu Ile Asn Glu Ile 20 25 30Ala Asn Thr Asn Ser Arg Gln Asn Ile Arg Lys Leu Ile Lys Asp Gly 35 40 45Leu Ile Ile Lys Lys Pro Val Ala Val His Ser Arg Ala Arg Val Arg 50 55 60Lys Asn Thr Glu Ala Arg Arg Lys Gly Arg His Cys Gly Phe Gly Lys65 70 75 80Arg Lys Gly Thr Ala Asn Ala Arg Met Pro Val Lys Val Leu Trp Val 85 90 95Asn Arg Met Arg Val Leu Arg Arg Leu Leu Lys Lys Tyr Arg Glu Ala 100 105 110Lys Lys Ile Asp Arg Gln Met Tyr His Asp Leu Tyr Met Lys Ala Lys 115 120 125Gly Asn Val Phe Lys Asn Lys Arg Val Leu Met Asp Phe Ile His Lys 130 135 140Lys Lys Ala Glu Lys Ala Arg Ser Lys Met Leu Lys Asp Gln Ala Glu145 150 155 160Ala Arg Arg Phe Lys Val Lys Glu Ala Lys Lys Arg Arg Glu Glu Arg 165 170 175Ile Ala Thr Lys Lys Gln Glu Ile Met Gln Ala Tyr Ala Arg Glu Asp 180 185 190Glu Ala Ala Val Lys Lys 195286767PRTLygus hesperus 286Met Thr Thr Tyr Glu Glu Phe Ile Gln Gln Ser Glu Glu Arg Asp Gly1 5 10 15Ile Arg Phe Thr Trp Asn Val Trp Pro Ser Ser Arg Ile Glu Ala Thr 20 25 30Arg Leu Val Val Pro Val Gly Cys Leu Tyr Gln Pro Leu Lys Glu Arg 35 40 45Thr Asp Leu Pro Ala Ile Gln Tyr Asp Pro Val Leu Cys Thr Arg Asn 50 55 60Thr Cys Arg Ala Ile Leu Asn Pro Met Cys Gln Val Asn Tyr Arg Ala65 70 75 80Lys Leu Trp Val Cys Asn Phe Cys Phe Gln Arg Asn Pro Phe Pro Pro 85 90 95Gln Tyr Ala Ala Ile Ser Glu Gln His Gln Pro Ala Glu Leu Ile Pro 100 105 110Ser Phe Ser Thr Ile Glu Tyr Thr Ile Ser Arg Ala Gln Phe Leu Pro 115 120 125Pro Ile Phe Leu Leu Val Val Asp Thr Cys Leu Asp Asp Asp Glu Leu 130 135 140Gly Ala Leu Lys Asp Ser Leu Gln Thr Ser Leu Ser Leu Leu Pro Thr145 150 155 160Asn Ser Leu Val Gly Leu Ile Thr Phe Gly Lys Met Val Gln Val His 165 170 175Glu Leu Gly Cys Glu Gly Cys Ser Arg Ser Tyr Val Phe Arg Gly Thr 180 185 190Lys Asp Leu Thr Ser Lys Gln Val Gln Asp Met Leu Gly Ile Gly Lys 195 200 205Val Ser Ala Ser Pro Gln Gln Gln Gln Gln Arg Ala Met Gly Gly Gln 210 215 220Gln Pro Phe Pro Thr Asn Arg Phe Ile Gln Pro Ile Gln Ser Cys Asp225 230 235 240Met Ser Leu Thr Asp Leu Leu Gly Glu Met Gln Arg Asp Pro Trp Pro 245 250 255Val Gly Gln Gly Lys Arg Pro Leu Arg Ser Thr Gly Ala Ala Leu Ala 260 265 270Ile Ala Ile Gly Leu Leu Glu Cys Ser Tyr Pro Asn Thr Gly Ala Lys 275 280 285Val Met Leu Phe Leu Gly Gly Pro Cys Ser Gln Gly Pro Gly Gln Val 290 295 300Val Asn Asp Asp Leu Arg Glu Pro Ile Arg Ser His His Asp Ile Gln305 310 315 320Lys Asp Asn Ala Arg Tyr Met Lys Lys Ala Ile Lys His Tyr Asp Ser 325 330 335Leu Ala Leu Arg Ala Ala Thr Asn Gly His Ser Val Asp Ile Tyr Ser 340 345 350Cys Ala Leu Asp Gln Thr Gly Leu Ala Glu Met Lys Gln Cys Cys Asn 355 360 365Ser Thr Gly Gly His Met Val Met Gly Asp Thr Phe Asn Ser Thr Leu 370 375 380Phe Lys Gln Thr Phe Gln Arg Val Leu Ser Arg Asp Gln Lys Gly Glu385 390 395 400Phe Lys Met Ala Phe Asn Gly Val Val Glu Val Lys Thr Ser Arg Glu 405 410 415Leu Lys Val Met Gly Ala Ile Gly Pro Cys Val Ser Leu Asn Thr Lys 420 425 430Gly Pro Cys Val Ser Glu Thr Asp Ile Gly Leu Gly Gly Thr Cys Gln 435 440 445Trp Lys Phe Cys Thr Phe Asn Gln Asn Thr Thr Ala Ala Met Phe Phe 450 455 460Glu Val Val Asn Gln His Ala Ala Pro Ile Pro Gln Gly Gly Arg Gly465 470 475 480Cys Ile Gln Phe Ile Thr Gln Tyr Gln His Ala Ser Gly Gln Arg Arg 485 490 495Ile Arg Val Thr Thr Val Ala Arg Asn Trp Ala Asp Ala Thr Thr Asn 500 505 510Met His His Val Ser Ala Gly Phe Asp Gln Glu Ala Gly Ala Val Leu 515 520 525Met Ala Arg Met Val Val His Arg Ala Glu Thr Asp Asp Gly Pro Asp 530 535 540Val Met Arg Trp Ala Asp Arg Met Leu Ile Arg Leu Cys Gln Lys Phe545 550 555 560Gly Glu Tyr Asn Lys Asp Asp Pro Asn Ser Phe Arg Leu Pro Glu Asn 565 570 575Phe Ser Leu Tyr Pro Gln Phe Met Tyr His Leu Arg Arg Ser Gln Phe 580 585 590Leu Gln Val Phe Asn Asn Ser Pro Asp Glu Thr Ser Tyr Tyr Arg His 595 600 605Ile Leu Met Arg Glu Asp Leu Ser Gln Ser Leu Ile Met Ile Gln Pro 610 615 620Ile Leu Tyr Ser Tyr Ser Phe Asn Gly Pro Glu Pro Val Leu Leu Asp625 630 635 640Thr Ser Ser Ile Gln Pro Asp Arg Ile Leu Leu Met Asp Thr Phe Phe 645 650 655Gln Ile Leu Ile Phe His Gly Glu Thr Ile Ala Gln Trp Arg Ala Gln 660 665 670Arg Tyr Gln Asp Leu Pro Glu Tyr Glu Asn Phe Lys Gln Leu Leu Gln 675 680 685Ala Pro Val Asp Asp Ala Lys Glu Ile Leu His Thr Arg Phe Pro Met 690 695 700Pro Arg Tyr Ile Asp Thr Glu Gln Gly Gly Ser Gln Ala Arg Phe Leu705 710 715 720Leu Ser Lys Val Asn Pro Ser Gln Thr His Asn Asn Met Tyr Gly Tyr 725 730 735Gly Gly Glu Phe Gly Ala Pro Val Leu Thr Asp Asp Val Ser Leu Gln 740 745 750Val Phe Met Glu His Leu Lys Lys Leu Ala Val Ser Phe Thr Ala 755 760 765287938PRTLygus hesperus 287Met Pro Leu Arg Leu Asp Ile Lys Arg Lys Leu Ser Ala Arg Ser Asp1 5 10 15Arg Val Lys Cys Val Asp Leu His Pro Thr Glu Pro Trp Met Leu Ala 20 25 30Ser Leu Tyr Asn Gly Asn Val His Ile Trp Asn His Glu Thr Gln Gln 35 40 45Leu Leu Lys Ser Phe Glu Val Cys Glu Leu Pro Ile Arg Ala Ala Val 50 55 60Phe Val Pro Arg Lys Asn Trp Val Val Thr Gly Ser Asp Asp Met His65 70 75 80Val Arg Val Phe Asn Tyr Asn Thr Leu Glu Arg Val His Ser Phe Glu 85 90 95Ala His Ser Asp Tyr Leu Arg Cys Ile Ile Val His Pro Thr Gln Pro 100 105 110Tyr Ile Leu Thr Cys Ser Asp Asp Met Leu Ile Lys Leu Trp Asn Trp 115 120 125Glu Lys Asn Trp Leu Cys Gln Gln Val Phe Glu Ser His Thr His Tyr 130 135 140Val Met Gln Ile Val Leu Asn Pro Lys Asp Asn Asn Thr Phe Ala Ser145 150 155 160Ala Ser Leu Asp His Thr Leu Lys Val Trp Gln Leu Gly Ser Ala Ala 165 170 175Ala Asn Phe Thr Leu Asp Gly His Glu Lys Gly Val Asn Cys Val Asp 180 185 190Tyr Tyr His Gly Gly Asp Lys Pro Tyr Leu Ile Ser Gly Ala Asp Asp 195 200 205His Met Val Lys Ile Trp Asp Tyr Gln Asn Lys Thr Cys Val Gln Thr 210 215 220Leu Glu Gly His Ala Gln Asn Ile Thr Ala Val Cys Phe His Thr Glu225 230 235 240Leu Pro Ile Ala Ile Thr Gly Ser Glu Asp Gly Thr Val Arg Leu Trp 245 250 255His Ser Ala Thr Tyr Arg Leu Glu Ser Ser Leu Asn Tyr Gly Phe Glu 260 265 270Arg Val Trp Thr Ile Arg Cys Leu Lys Gly Ser Asn His Ile Ala Leu 275 280 285Gly Tyr Asp Glu Gly Ser Ile Met Val Lys Val Gly Arg Glu Glu Pro 290 295 300Ala Ile Ser Met Asp Val Asn Gly Glu Lys Ile Val Trp Ala Arg His305 310 315 320Ser Glu Ile Gln Gln Val Asn Leu Lys Ser Leu Met Thr Asp Glu Ser 325 330 335Glu Ile Arg Asp Gly Glu Lys Leu Pro Val Ala Ala Lys Asp Met Gly 340 345 350Pro Cys Glu Val Phe Pro Gln Ser Ile Ala His Asn Pro Asn Gly Arg 355 360 365Phe Val Val Val Cys Gly Asp Gly Glu Tyr Ile Ile Tyr Thr Ala Met 370 375 380Ala Leu Arg Asn Lys Ser Phe Gly Ser Ala Gln Glu Phe Val Trp Ala385 390 395 400Gln Asp Ser Ser Asp Tyr Ala Ile Arg Glu Gly Thr Ser Thr Val Arg 405 410 415Leu Phe Arg Gln Phe Lys Glu Arg Lys Asn Phe Lys Pro Glu Phe Gly 420 425 430Ala Glu Gly Ile Phe Gly Gly Gln Leu Leu Gly Val Arg Thr Val Thr 435 440 445Gly Leu Ser Leu Tyr Asp Trp Glu Thr Leu Glu Leu Ile Arg Ser Ile 450 455 460Asp Ile Gln Ala Lys Ala Pro Tyr Trp Ser Glu Ala Gly His Leu Leu465 470 475 480Ala Ile Val Thr Asp Asp Ser Tyr Tyr Leu Leu Lys Phe Asp Gln Ser 485 490 495Ala Ile Ser Thr Ser Thr Pro Gly Thr Asp Gly Tyr Glu Asp Ala Phe 500 505 510Glu Leu Val Gly Glu Val Asn Asp Thr Val Lys Thr Gly Leu Trp Val 515 520 525Gly Asp Cys Phe Ile Tyr Thr Asn Ala Val Cys Arg Ile Asn Tyr Tyr 530 535 540Val Gly Gly Glu Ile Val Thr Val Ala His Leu Asp Thr Thr Met Tyr545 550 555 560Leu Leu Gly Tyr Val Ala Arg Gln Asn Leu Leu Tyr Leu Cys Asp Lys 565 570 575His His Asn Ile Ile Cys Tyr Thr Leu Leu Leu Ser Val Leu Glu Tyr 580 585 590Gln Thr Ala Val Met Arg Arg Asp Phe Glu Thr Ala Asp Arg Val Leu 595 600 605Pro Thr Ile Pro Val Gln His Arg Ser Arg Val Ala His Phe Leu Glu 610 615 620Lys Gln Gly Phe Lys Arg Gln Ala Leu Ala Val Ser Thr Asp Ala Glu625 630 635 640His Lys Phe Glu Leu Ala Leu Gln Leu Ser Asp Leu Glu Ala Ala Val 645 650 655Gly Leu Ala Arg Glu Ile Gly Ser Lys Ala Lys Trp Val Gln Val Ala 660 665 670Glu Leu Ala Met Ser Glu Ala Lys Leu Gly Leu Ala Gln Met Cys Leu 675 680 685His Gln Ala Gln His Tyr Gly Gly Leu Leu Leu Leu Ser Thr Ser Ala 690 695 700Gly Asn Val Asp Met Met Glu Lys Leu Ala Glu Ser Ser Leu Ser Asp705 710 715 720Gly Lys Asn Asn Val Ser Phe Leu Thr Tyr Phe Leu Met Gly Asn Val 725 730 735Glu Lys Cys Leu Gln Ile Leu Ile Asp Thr Gly Arg Ile Pro Glu Ala 740 745 750Ala Phe Phe Ala Arg Thr Tyr Met Pro Lys Glu Val Ser Arg Val Val 755 760 765Asp Met Trp Lys Thr Leu Ser Lys Asp Lys Thr Gly Gln Ser Leu Ala 770 775 780Asp Pro Ala Gln Tyr Pro Asn Leu Phe Pro Lys His Thr Glu Ala Leu785 790 795 800Lys Ala Glu Gln Phe Met Lys Lys Glu Leu Thr Gln Arg Ile Pro Ala 805 810 815Ser Ser His Lys Asp Ile Lys Pro Asn Tyr Glu Arg Asn Ala Ile Glu 820 825 830Glu Met Lys Glu Ala Glu Ala Asn Gly Leu Phe Thr Tyr Asp Pro Pro 835 840 845Val Ala Pro Ala Ser Ile Asn Asn Leu Ile Asp Val Ser Glu Pro Ala 850 855 860Asn Arg Ser Glu Pro Ser Pro Ser Glu Ile Phe Ser Glu Ala Pro Ala865 870 875 880Val Ser Lys Met Thr Ser Asp Ala Arg Pro Leu Val Ala Pro Val Pro 885 890 895Pro Ala Ala Arg Pro Gln Lys Arg Pro Ser Ala Phe Asp Asp Asp Asp 900 905 910Leu Glu Leu Glu Ile Glu Asn Met Asn Leu Asp Asp Ile Asp Ala Ser 915 920 925Asp Leu Asn Glu Glu Asp Leu Leu Ile

Asp 930 935288220PRTLygus hesperus 288Met Ser Phe Phe Ser Lys Val Phe Gly Gly Lys Lys Asp Asp Lys Gly1 5 10 15Pro Thr Ala Ser Glu Ala Ile Gln Lys Leu Arg Glu Thr Glu Asp Met 20 25 30Leu Val Lys Lys Gln Glu Tyr Leu Glu Thr Lys Ile Glu Ala Glu Met 35 40 45Lys Ile Ile Lys Lys Asn Gly Thr Ala Asn Arg Arg Val Ser Ile Gln 50 55 60Ala Leu Lys Lys Lys Lys Arg Phe Glu Lys Gln Leu Gln Gln Ile Asp65 70 75 80Gly Thr Leu Ser Thr Ile Glu Met Gln Arg Glu Ala Leu Glu Ser Ala 85 90 95Asn Thr Ser Ser Lys Val Val Gln Thr Met Lys Leu Ala Ala Asp Thr 100 105 110Leu Lys Thr Ala His Gln His Met Asp Val Asp Gln Val His Asp Met 115 120 125Met Asp Glu Ile Ala Glu Gln His Glu Ala Ala Lys Glu Ile Ser Glu 130 135 140Ala Ile Ser Asn Pro Val Ala Phe Gly Asn Asp Ile Asp Glu Asp Glu145 150 155 160Leu Glu Arg Glu Leu Glu Glu Leu Glu Gln Gln Glu Leu Asp Arg Glu 165 170 175Leu Leu Gly Thr His Thr Pro Ala Ala Asp His Leu Pro Asp Val Pro 180 185 190Ala Thr Ile Pro Val Pro His Lys Pro Lys Gln Thr Val Ala Asp Glu 195 200 205Asp Asp Asp Leu Lys Gln Leu Gln Glu Trp Ala Thr 210 215 220

Claims

1. An interfering ribonucleic acid (RNA) molecule which comprises at least one double-stranded region, wherein said double-stranded region comprises a sense RNA strand annealed by complementary basepairing to an antisense RNA strand, wherein the interfering RNA molecule upon uptake by an insect pest species is toxic to the insect pest species, wherein the interfering RNA molecule is encoded by a nucleic acid molecule comprising: (i) a nucleotide sequence that is at least 85% identical to any of SEQ ID NOs: 1, 21, or the complement thereof; (ii) a nucleotide sequence comprising at least 21 contiguous nucleotides of any of SEQ ID NOs: 1, 21, or the complement thereof; (iii) a nucleotide sequence that is at least 21 contiguous nucleotides and encodes an amino acid sequence that is encoded by al least 21 contiguous nucleotides of any of SEQ ID NOs: 1 or 21; or (iv) a nucleotide sequence that is at least 21 contiguous nucleotides and encodes an amino acid sequence that is at least 7 contiguous amino acids and is represented in SEQ ID NO: 206.

2. The interfering RNA of claim 1, wherein the RNA comprises at least one silencing element, wherein the silencing element comprises a sequence of nucleotides which is at least partially complementary to a target nucleotide sequence within the tetraspanin 2A protein target gene.

3. The interfering RNA of claim 2, wherein the silencing element comprises a sequence of al least 21 contiguous nucleotides which is at least partially complementary to a target nucleotide sequence within the tetraspanin 2A protein target gene.

4. The interfering RNA of claim 2, wherein the silencing element is a region of double-stranded RNA comprising annealed complementary strands, one strand of which comprises a sequence of nucleotides which is al least partially complementary to a target nucleotide sequence within the tetraspanin 2A protein target gene.

5. The interfering RNA of claim 2 wherein the RNA comprises at least two silencing elements, wherein each silencing element comprises a sequence of nucleotides which is at least partially complementary to a target nucleotide sequence within a tetraspanin 2A protein target gene.

6. The interfering RNA of claim 5 wherein each of the silencing elements comprises a different sequence of nucleotides which is complementary to a different target nucleotide sequence.

7. The interfering RNA of claim 6 wherein the different target nucleotide sequences originate from a single tetraspanin 2A protein target gene.

8. The interfering RNA of claim 6 wherein the different target nucleotide sequences originate from different target genes.

9. The interfering RNA of claim 8 wherein the different target genes originate from the same insect pest species.

10. The interfering RNA of claim 8 wherein the different target genes originate from different insect pest species.

11. The interfering RNA of claim 1 wherein the insect pest species is a plant pest.

12. The interfering RNA of claim 11 wherein the plant pest is selected from the Lygus genus or the Leptinotarsa genus.

13. The interfering RNA of claim 12 wherein the plant pest is from the Lygus genus and is Lygus hesperus, or wherein the plant pest is from the Leptinotarsa genus and is Leptinotarsa decemlineata.

14. The interfering RNA of claim 1 wherein the tetraspanin 2A protein target gene is an essential pest gene such that down-regulating expression causes decreased growth, development, reproduction, or survival of the pest as compared with pest species exposed to an interfering ribonucleic acid targeting a non-essential gene or an interfering ribonucleic acid that does not down-regulate any genes within the pest species.

15. An isolated polynucleotide encoding the interfering RNA of claim 1.

16. A DNA construct comprising the polynucleotide of claim 15.

17. The DNA construct of claim 16 wherein the construct is an expression construct and wherein the polynucleotide is operably linked to at least one regulatory sequence capable of driving expression of the polynucleotide.

18. A host cell comprising an interfering RNA of claim 1, a polynucleotide encoding the interfering RNA of claim 1, or a DNA construct comprising a polynucleotide encoding the interfering RNA of claim 1.

19. The host cell of claim 18 wherein the host cell is a prokaryotic or a eukaryotic cell.